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Abstract 
 
N1- and N2-Src are neuronal specific splice variants of the ubiquitously expressed 
tyrosine kinase C-Src. They differ only by short amino acid inserts within their SH3 
domains, a region known to confer substrate specificity. Due to their highly identical 
sequence it has been difficult to attribute specific neuronal functions to each Src 
enzyme, however, many C-Src SH3 domain substrates do not bind to the N-Src SH3 
domains. The limited functional N1-Src data indicate that it is involved in neuronal 
differentiation. Furthermore, high expression levels of the N-Srcs in childhood 
neuroblastoma correlate with cases in which the tumour spontaneously differentiates 
to a harmless neuronal phenotype. In this study, I sought to explain how the amino 
acid inserts in the N-Src SH3 domains affect substrate specificity and kinase activity 
and how they might act to drive neuronal differentiation.  
 I employed a multi-disciplinary approach to investigate the functions of the 
N-Srcs. Studies in heterologous cells revealed a specific role for the N-Srcs in 
cytoskeletal rearrangement. A sensitive in vitro kinase assay was developed and this 
showed that the N-Src SH3 domain ligand preferences differ from those of C-Src. A 
subsequent phage display screen was able to identify a novel consensus sequence for 
the N1-Src SH3 domain and peptides containing this consensus motif were shown to 
be highly specific N1-Src inhibitors both in vitro and in cells. Bioinformatic analyses 
revealed the consensus sequence to be present in many neuronal proteins and 
identified a number of putative N1-Src substrates. In cultured neurons I identified a 
specific role for N1-Src acting in the L1-CAM pathway to modulate neurite 
outgrowth. 
 The data presented here provide evidence that the inserts in the SH3 domains 
of the N-Srcs confer significant differences in their substrate preferences and that the 
functions mediated by the N-Srcs are different to those of C-Src. A role for N1-Src 
has been identified in the modulation of axon outgrowth in cultured neurons and the 
putative substrates identified now provide promising targets for the further study of 
N1-Src function. Future investigations will be able to utilise the data presented here 
to elucidate how N1-Src regulates the neuronal cytoskeleton, while tools I have 
developed; including a highly specific N1-Src inhibitor will greatly aid these 
investigations.  
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1 Introduction 
 
1.1 Protein phosphorylation 
 
The opposing actions of phosphorylation and dephosphorylation are able to regulate 
a protein in almost every conceivable way. They can increase or decrease activity, 
stabilise a protein or mark it for destruction, promote or prevent movement between 
subcellular compartments and initiate or disrupt protein-protein interactions. The 
addition of a phosphate group to a protein is simple, flexible and reversible. It is now 
thought to represent the most general regulatory mechanism within the eukaryotic 
cell, its prevalence possibly driven by the ready abundance of ATP within the cell. It 
has been estimated that as many as 30% of proteins within the human genome can be 
phosphorylated, many of them at multiple sites (Cohen, 2002b). However, the ability 
of the simple incorporation of a phosphate moiety to alter so many aspects of a 
protein’s characteristics means that uncontrolled or abnormal phosphorylation is now 
recognised both as a major cause and consequence of a huge range of disease 
processes (Cohen, 2002a). 
Addition of a phosphate group to an amino acid is mediated by kinase 
enzymes while phosphatases reverse the process, by removing the phosphate. The 
human genome contains two broad classes of protein kinase; serine/theonine kinases 
and tyrosine kinases. 518 (1.7%) genes in the human genome code for protein 
kinases, 90 of these are known tyrosine kinases and an extra 43 are predicted to have 
tyrosine kinase activity (Manning et al, 2002b). For the purposes of this study the 
majority of the discussion will be focussed on the tyrosine kinases and their 
functions.  
There are two classes of tyrosine kinase. Receptor tyrosine kinases (RTKs) 
are type I transmembrane proteins with an N-terminal extracellular domain that can 
bind ligands, a single transmembrane domain, and a C-terminal cytoplasmic domain 
that includes the catalytic domain. RTKs comprise 58 of the 90 tyrosine kinases in 
the human genome (Manning et al, 2002b). Most RTKs are activated through 
binding of their extracellular domain to specific protein ligands, such as growth 
factors and cytokines. Ligand binding promotes RTK oligomerization and 
subsequent activation of the cytoplasmic catalytic domain by transphosphorylation 
of tyrosine residues in the juxtamembrane region. Transphosphorylation can also 
Chapter 1 
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result in the creation of binding sites for cellular adapters and signalling molecules, 
resulting in the transduction of extracellular signals across the plasma membrane 
(Hubbard & Till, 2000). 
Nonreceptor tyrosine kinases lack a transmembrane domain and may either 
be soluble intracellular proteins or associate with membranes via membrane 
targeting lipid modifications. Nonreceptor tyrosine kinases are also activated by 
ligand binding, commonly resulting in either a conformational change or 
oligomerisation. They mediate a wide range of cellular processes including growth, 
differation, proliferation and migration (Hubbard & Till, 2000). 
 
1.1.1 The study of protein phosphorylation 
 
Tyrosine phosphorylation was first identified within immunoprecipitates of the 
polyomavirus middle T antigen (Eckhart et al, 1979). This discovery represented a 
new form of protein phosphorylation but it initially came to be associated with the 
ability of cytoplasmic retroviral oncoproteins (v-Src, v-Abl, v-Fps) to elicit cellular 
transformation (Rodrigues & Park, 1994). The normal cellular counterparts of these 
viral proteins were rapidly identified and shown to have intrinsic tyrosine kinase 
activity. Importantly, this kinase activity was shown to function within cells, acting 
to influence a wide range of signalling processes ranging from migration and 
differentiation to wound healing and immune cell function (Pawson, 2004). 
However, the unregulated signalling resulting from tyrosine kinases has continued to 
be associated with disease processes, in particular cancer. A notable example is the 
prevalence of the Bcr-Abl fusion protein in chronic myeloid leukaemia (CML) 
(Konopka et al, 1984). Therefore, as well as continuing to understand the normal 
signalling processes of the kinases, recent work has been focussed on targeting 
kinases for therapy.  
Prior to the discovery of tyrosine phosphorylation a precedent for the 
importance of protein modification by phosphorylation had been set by seminal work 
elucidating the functions of serine/threonine kinases. The purification of the first 
kinase enzyme, cAMP dependent protein kinase (PKA) followed by the elucidation 
of its composition and structural requirements for activation began to allow analysis 
of the functional consequences of kinase signalling at a molecular level (Taylor et al, 
1990). The first crystal structure of a kinase, phosphorylase a, (Barford & Johnson, 
Chapter 1 
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1989) facilitated further understanding of how kinases function and how they are 
regulated. 
It was only when this knowledge of kinase structure was combined with the 
discoveries of cAMP, heterotrimeric G-proteins and G-protein coupled receptors that 
the outline of a canonical signal transduction pathway was put together, with 
serine/threonine phosphorylation established as a key mechanism for rapidly 
modulating protein function. These discoveries resulted in a new way of thinking 
about protein phosphorylation and established it as a major target of research to 
understand how cells respond to extracellular cues and the signalling pathways that 
elicit biological responses. The discovery of tyrosine phosphorylation provided an 
additional mechanism that the cell could utilise to regulate signal transduction. 
Modern genomic and proteomic techniques mean that we now know most, if 
not all, of the kinases within the human genome, known as the ‘kinome’ (Manning et 
al, 2002b). Large numbers of phosphorylated sites within proteins have been 
established through high throughput techniques including mass spectrometry. The 
current challenge in the field is to match kinases with their substrates in order to 
separate functions performed by different kinases within the cell. In addition, we 
need to begin to understand the mechanisms of spatio-temporal regulation of kinase-
substrate interactions and to elucidate the roles of multi-site and multi-PTM (post 
translational modification) of proteins. These complex modes of regulation may 
mean that protein modification by kinases will come to rival RNA splicing and gene 
regulation as a method of biological control (Pawson & Scott, 2005).  
 
1.1.2 The evolution of tyrosine kinase signalling 
 
Tyrosine phosphorylation appears to be a feature of eukaryotes and has been linked 
to the emergence of multicellularity. Phosphorylation in prokaryotes is dominated by 
histidine phosphorylation, a process that is very much in the minority in eurkaryotic 
cells. Prokaryotes have the more evolutionary ancient serine and threonine kinases 
but tyrosine kinases are nearly absent (Manning et al, 2002a). The prokaryotic 
tyrosine kinases that do exist do not share the same common ancestor as eukaryotic 
tyrosine kinases, which are all derived from the same initial tyrosine kinase. In fact, 
tyrosine kinases appear relatively recently in evolution, with eukaryotic-like tyrosine 
kinases absent in plants, yeast and fungi. Tyrosine kinase signalling is thought to be 
Chapter 1 
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specific to metazoans and tyrosine kinases seem to have evolved primarily to 
function as signalling enzymes allowing cell to cell communication (King et al, 
2003).  
It has been suggested that the emergence of the signalling components of 
tyrosine phosphorylation was the crucial step that allowed the rapid development of 
multicellular organisms. True tyrosine kinase signal transduction emerges about 600 
million years ago, just prior to the development of multicellularity (King et al, 2003; 
Manning et al, 2008; Pincus et al, 2008). Tyrosine kinase signalling is now known to 
be crucial for the complex cell to cell communication that is a feature of metazoan 
biology and is involved in diverse processes ranging from the regulation of 
proliferation, differentiation, adhesion, hormone responses and immune functions 
(Hunter, 2009). This diverse and complex signalling is possible due to the tripartite 
system of kinases, phosphatases and phosphotyrosine binding SH2 domains. Recent 
work sequencing the genomes of many organisms has allowed speculation about 
how the evolution of these components occurred.  
Surprisingly, it was not the tyrosine kinase domains themselves that were 
first observed during evolution. The genome of the single celled eukaryote 
Sacchromyces cerevisiae has no tyrosine kinases, one proto-SH2 domain and 3 
phosphatase domains (Pincus et al, 2008). Most fungi have no tyrosine kinase or 
SH2 domains but ~5 phosphatase domains. The S. cerevisiae proto-SH2 domain 
shares overall sequence and structural similarity with modern SH2 domains but does 
not possess phosphotyrosine binding ability. Instead, it has been shown to bind 
phosphorylated serine and theonine residues (Dengl et al, 2009).  
The appearance of protein tyrosine phosphatase (PTP) domains prior to the 
advent of tyrosine kinases may be due to the presence of dual specificity 
serine/threonine kinases that are able to phosphorylate tyrosine residues. 
Serine/threonine kinases are more ancient than tyrosine kinases, dating 
approximately from the emergence of eukaryotes. Organisms lacking tyrosine 
kinases, such as yeast, do have a small but detectable level of phosphotyrosine that 
must be present due to the action of dual specificity kinases (Schieven et al, 1986). It 
is known that some processes, such as the activation of mitogen-activated protein 
(MAP) kinases and the inhibiton of cyclin dependent kinase 1 (cdk1), require 
phosphorylation on tyrosine residues and that these phosphorylation events must 
have taken place before dedicated tyrosine kinases existed. Therefore, the evolution 
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of PTP domains that could remove these phosphotyrosine residues would provide a 
mechanism of negative regulation for these rare, but functionally important, 
phosphorylation events. In addition they would provide a way to buffer the 
occasional errant phosphorylation of a tyrosine residue. It is likely that these first 
dedicated PTPs arose from a common ancestor of the dual specificity phosphatases 
that are still found in most single celled eukaryotes (Alonso et al, 2004; Kennelly, 
2001). The catalytic domains of PTPs and dual specificity phosphatases are distinct 
from each other but evolutionarily related.  
The next portion of the tyrosine kinase signalling machinery to emerge was 
probably the SH2 domain. The slime mould Dictyostelium discoideum is a soil 
dwelling amoeba that is unicellular in the presence of abundant bacterial food but it 
is able to aggregate and form a pseudo-multicellular organism in the absence of a 
sufficient food source. It possesses the simplest SH2 domain genome complement of 
any sequenced genome and probably represents the closest living relative of the 
second stage of tyrosine kinase signalling evolution (Eichinger et al, 2005).  
The ability of Dictyostelium to aggregate is reliant on the PTP and SH2 
domains. Its genome contains 12 SH2 domains that fall into 5 classes of protein. 
Notably, the Shk proteins are kinases that contain a dual-specificity kinase domain 
followed by a SH2 domain. This domain arrangement is similar to that observed in 
Src Family Kinases (SFKs) (Moniakis et al, 2001). Dictyostelium has no dedicated 
tyrosine kinases, indicating that they probably evolved following the emergence of 
tyrosine specific SH2 domains, but there is a massive expansion of the putative dual-
specificity kinase complement in the genome to approximately 70 (Manning et al, 
2008). This shows the increased functionality of kinase signalling when it can be 
controlled and directed by SH2 domains.  
 True tyrosine kinase domains are only present in metazoans and 
choanoflagellates, the closest known single-celled relatives of metazoans (King et al, 
2008). This indicates that tyrosine kinases arose very close to the separation of 
metazoans from choanoflagellates, probably as a branch of the pre-existing 
serine/threonine kinases. Choanoflagellates and metazoans both have a full 
complement of tyrosine kinases, PTPs and SH2 domains but the proteins that they 
are contained in and the functions that they perform vary widely. This reinforces the 
opinion that the tripartite system was acquired only shortly before their divergence. 
There are some tyrosine kinases present in the genomes of bacteria (known as BYs), 
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however these are not evolutionarily related to the eukaryotic tyrosine kinases and 
have emerged separately (Lee & Jia, 2009).  
 Interestingly, all choanoflagellates and metazoans sequenced have between 
30 and 150 tyrosine kinases (Manning et al, 2008; Pincus et al, 2008). There is a 
notable absence of genomes with small numbers of tyrosine kinases. This implies 
that tyrosine kinase signalling was very important for the functions of multicellular 
organisms and resulted in their rapid expansion within the genome. The rapid 
increase in the number of tyrosine kinases also coincides with a dramatic increase in 
the numbers of SH2 and PTP domains in genomes (Pincus et al, 2008). Where 
Dictyostelium has ~10 SH2 domains and ~5 PTP domains in its genome, the 
genomes of all available metazoans and choanoflagellates have ~100 SH2 domains 
and 30-40 PTP domains per genome. As well as the increase in number, proteins 
containing SH2 and PTP domains also became more complex, with proteins 
containing SH2 or PTP domains commonly also containing 3-10 other domains (Jin 
et al, 2009). It seems that the advent of the true dedicated tyrosine kinase made the 
PTP and SH2 domains more useful in themselves, this is reflected in the large 
increase in their prevalence within the genome following the emergence of the 
tyrosine kinase domain. The tripartite system also allowed for a wider, more diverse 
range of regulatory roles mediated by tyrosine kinase signalling.   
 The emergence of tyrosine kinase signalling represented a novel mechanism 
for regulation of proteins. Therefore, it allowed for the rapid accumulation of new 
regulatory functions that, importantly, did not interfere with existing networks of 
regulation such as those mediated by the serine/threonine kinases.  
  
1.2 The Src Family Kinases 
 
Src Family Kinases (SFKs) are a group of structurally and functionally related non-
receptor tyrosine kinases (Brown & Cooper, 1996; Thomas & Brugge, 1997). Src is 
the founding member of the family and it was first identified as the transforming 
protein of the oncogenic retrovirus, Rous sarcoma virus. This viral form of the 
protein (v-Src) was soon shown to have a normal cellular counterpart, C-Src, a 
ubiquitously expressed tyrosine kinase that is highly conserved through evolution. 
Following the identification of Src, 8 other tyrosine kinases with a high degree of 
both amino acid and structural similarity have been identified in verebrates. The SFK 
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family members are Src, Fyn, Yes, Yrk, Blk, Fgr, Hck, Lck and Lyn. The expression 
patterns of the SFKs are varied with some expressed ubiquitously and some showing 
restricted expression (Thomas & Brugge, 1997). It is likely that all cells will express 
at least one SFK member, with some expressing multiple isoforms of the same 
protein. The variety in the specificity of these related kinases along with their broad 
expression patterns mean that they regulate a wide variety of biological functions 
including proliferation, cytoskeletal rearrangement, differentiation, survival, 
adhesion and migration (Thomas & Brugge, 1997).  
 
1.2.1 Structure of the SFKs 
 
The SFKs range between 52 and 62 kDa and share a conserved modular domain 
organisation composed of 6 regions: i) SH4 domain, ii) unique domain, iii) SH3 
domain, iv) SH2 domain, v) kinase domain, vi) negative regulatory C-terminal tail 
(Figure 1.2.1.1). 
Figure 1.2.1.1 Domain organisation of the SFKs.  
SFKs share a common, modular domain organisation They are N-terminally 
myristoylated and some family members are additionally palmitoylated. The SH3 
domain interacts with ligands containing the consensus motif PxxP. SH2 domains 
interact with phosphotyrosine residues. The SH3 and SH2 domains function in 
substrate selection. The kinase domain is responsible for substrate phosphorylation. 
The approximate positions of two important phosphorylation sites are indicated. 
Phosphorylation at Y416 in the kinase domain promotes the active conformation of 
the kinase and phosphorylation of Y527 in the C-terminal tail promotes the inactive 
conformation of the kinases are discussed in section 1.2.2.  
1.2.1.1 SH4 domain 
 
SFKs are generally found associated with the plasma membrane and other 
intracellular membranes (Courtneidge et al, 1980; Garber et al, 1983). Their 
signalling is reliant on this membrane association (Spencer et al, 1995), indicating 
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that they predominantly phosphorylate substrates that are also membrane associated. 
The SH4 domain is a ~15 amino acid sequence at the extreme N-terminal tail of the 
kinase that contains the sequences required for lipid modification of the kinases, 
although the 7 residues located at the extreme N-terminus are sufficient for 
myristoylation to occur (Cross et al, 1984). Myristoylation is an irreversible 
modification that occurs during translation (Buss et al, 1984). A glycine residue at 
position 2 (all residue numbering refers to the amino acid sequence of the 
prototypical chicken Src) is required as the site of myristoylation and is essential for 
the addition to occur. The residues in positions 3-7 are also important and are 
relatively conserved between the family members. Myristoylation enhances 
membrane association of the kinase and non-myristoylated Src is not membrane 
associated (David-Pfeuty et al, 1993). A small amount of myristoylated Src is, 
however, found free in the cytoplasm (Buss et al, 1984).  
 Src and Blk contain a high proportion of basic residues within their SH4 
domains (Resh, 1994). These are thought to contribute to membrane association, 
most likely by interacting with the polar headgroups of the phopholipid membrane.  
 All SFKs other than Src and Blk lack these basic residues but do have one or 
more cysteine residues within their SH4 domains. The cysteine at position 3, and 
potentially others, can be palmitoylated (Shenoy-Scaria et al, 1993). Palmitoylation 
occurs post translationally and can be dynamically regulated by a cycle of 
palmitoylation and depalmitoylation (Koegl et al, 1994; Paige et al, 1993). This 
cycle may be a mechanism to allow the re-localisation of the kinase upon 
stimulation. The addition of a palmitoyl group acts to stabilise the kinase at the 
membrane. Experiments using mutants of Hck that cannot be palmitoylated have 
shown that, while the palmitoylated protein is essentially all membrane bound, only 
about 30% of the non-palmitoylated protein is (Lock et al, 1991; Robbins et al, 
1995). 
 The processes of palmitoylation and myristoylation allow membrane 
association but also facilitate membrane clustering within domains of the plasma 
membrane. The palmitoyl modification allows certain SFKs to enter lipid rafts and to 
associate with specific signalling complexes. Therefore, these lipid modifications are 
essential for the localisation and signalling of the kinases.  
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1.2.1.2 Unique domain 
 
As the name suggests, the unique domain of the SFKs is the only domain that varies 
greatly between the members of the family. The SFK unique domains are between 
50 and 80 amino acids in length. Their roles are not entirely clear but they would be 
predicted to mediate protein-protein interactions that are specific to each member of 
the family. The unique domain is dispensable for the regulation of the kinases in 
vitro (Carrera et al, 1995). Serine and threonine phosphorylation sites have been 
identified within the Src and Lck unique domains, although the cellular 
consequences of these phosphorylation events remain unclear. 
 Src, but not other SFKs, is phosphorylated in the unique domain by Cdc2 
during M phase at Y34, Y46 and S72 (Chackalaparampil & Shalloway, 1988; 
Morgan et al, 1989; Shenoy et al, 1989). Src can also be phosphorylated within its 
unique domain in response to PKC activation in cells and is constitutively 
phosphorylated by PKA at S17 (Collett et al, 1979; Cross & Hanafusa, 1983).  
S42 and S59 in the Lck unique domain are also phosphorylated in response to 
PKC activation in cells. S42 has been shown to be an in vitro PKC site, while S59 is 
an in vitro MAPK site (Winkler et al, 1993). 
 
1.2.1.3 SH3 domain 
 
SH3 domains are small, globular non-catalytic domains, approximately 60 amino 
acids in length that are important for both intra- and intermolecular interactions of 
the kinases. The SH3 domain acts to modulate the dual roles of kinase activity 
regulation and substrate specificity determination. 
 The structure of the Src SH3 domain was first solved by Yu et al (1992) and 
this revealed that it consists of two three stranded anti-parallel β-sheets. The two 
sheets pack against each other at approximately right angles, forming a hydrophobic 
core. The ligand binding site consists of a slightly curved, hydrophobic depression 
on the SH3 domain surface with an acidic cluster at one end.  
SH3 domains bind to short, contiguous amino acid sequences that are rich in 
proline. The high proline content means that they adopt a left-handed helical 
conformation (a polyproline type II (PPII) helix) (Yu et al, 1994). Combinatorial 
peptide library and phage display studies have shown that the Src SH3 domain is 
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able to bind to two distinct classes of substrate, both with the core motif PxxP. The 
consensus sequences are RPLPPLP and φPPLPxR (where φ represents a 
hydrophobic amino acid) and are termed Class I and Class II respectively (Feng et al, 
1994; Rickles et al, 1994). Class I sequences have an arginine residue before a PxxP 
motif and Class II sequences have an arginine residue after the PxxP. They bind to 
the SH3 domain in opposite orientations (Feng et al, 1994).  
The binding affinity of these short peptides is low (Kms are typically low 
micromolar) and their sequence specificity is poor (small changes in the amino acid 
sequence has little effect on binding affinity) (Yu et al, 1994). However, phage 
display experiments using a biased peptide library with the core residues of the 
interaction fixed have revealed that the flanking residues play an important role in 
establishing specificity (Feng et al, 1995; Rickles et al, 1995). Importantly, when the 
flanking residues are considered, the binding preferences of the individual SFK 
members are different. This would allow each SFK to be able to specifically select 
its own substrates in vivo. 
The affinity of the SH3 domain for protein substrates is higher than that for 
the isolated peptide. This is partly because many Src substrates are multi-domain 
proteins, able to form contacts with both the SH2 domain and the SH3 domain. 
Additionally, some substrates, such as the p85 subunit of phosphoinosidide 3-kinase 
(PI3K), contain multiple SH3 domain binding motifs. This increases the local 
concentration of SH3 domain binding sites and results in a reduction in Km. 
The molecular basis for substrate binding to the Src SH3 domain was 
elucidated by Feng et al (1994). These solution structures showed the C-Src SH3 
domain bound to both Class I and Class II ligands and confirmed the prediction that 
the two substrates would bind to the same surface but in opposite orientations. 
Previous structures of the PI3K, Abl and Fyn SH3 domains had shown that SH3 
domain ligands adopt a PPII helix (Musacchio et al, 1994). Src SH3 domain ligands 
were also shown to bind as a PPII helix, confirming this as a general mechanism for 
interaction with SH3 domains (Yu et al, 1994). The ligand bound structure of the 
C-Src SH3 domain is essentially the same as the free structure, but ligand binding 
appears to slow the unfolding rate, stabilising the domain (Feng et al, 1994).  
The PPII helix has three residues per turn, meaning that residues i and i + 3 
within a substrate will be on the same face of the helix. Taking the Class I C-Src 
SH3 domain peptide R
1
ALPPLPRY
9
 as an example binding peptide, residues 1, 4 
Chapter 1 
21 
and 7 on one face and 3 and 6 on a second face all form contacts with the SH3 
domain surface (Feng et al, 1994). The ligand binding site contains three binding 
pockets. The first is an arginine binding pocket that binds the arginine residues in 
both Class I and Class II substrates and is commonly known as the specificity 
pocket. R1 of the Class I peptide interacts with W118 of the Src SH3 domain via a 
hydrogen bond and D99 via a salt bridge. The importance of this interaction is 
demonstrated by the fact that SH3 domains with the mutation D99N bind the Class I 
ligand with a ~40 fold decrease in affinity compared to the wild type SH3 domain 
(Feng et al, 1995). The second and third pockets are responsible for docking the 
proline residues. They are commonly referred to as dipeptide binding pockets as they 
also bind the residue immediately prior to the proline. Residues Y92, W118, P133 
and Y136 form the second binding pocket and it makes extensive hydrophobic 
contacts with L3 and P4. The methyl group of L3 also form additional contacts with 
the side chains of D117 and N135. L6 and P7 dock into a binding site formed by 
Y90 and Y136 (Yu et al, 1994). The residues that form the binding interactions are 
shown in Figure 1.2.1. 
Figure 1.2.1 Structure of the C-Src SH3 domain. 
The C-Src SH3 domain (red) bound to a Class I ligand (blue). The sidechains of the 
C-Src SH3 domain amino acids that form binding interactions with the ligand are 
shown. W118 and D99 form the first binding pocket for the arginine residue (R1). 
Y92, W118, P133, Y136, D117 and N135 form the first dipeptide binding pocket and 
contact L3 and P4. Y90 and Y136 form the second dipeptide binding pocket and 
contact L6 and P7. The n-Src loop is the location of the extra residues contained in 
N1- and N2-Src and can be seen to be adjacent to the substrate binding site. 
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An increasing number of SH3 domain binding peptides identified do not 
conform to the PxxP consensus motif originally identified. While some bind to 
surfaces entirely separate to the well characterised SH3 domain binding site, others 
bind to the same surface but utilise other contacts (Kami et al, 2002). It has become 
clear that it is not necessary for an SH3 domain binding peptide to adopt a PPII helix 
to form binding contacts. In general, atypical SH3 domain binding motifs form 
extensive contacts around the negatively charged area of the specificity pocket. This 
area consists of a shallow groove formed by the β3 and β4 strands, flanked at one 
end by parts of the β2 strand, n-Src loop and the RT loop. Many SH3 domains have 
one or more subpockets within this area that are able to contribute to the binding 
interactions. Ligands that bind in this area may or may not also utilise additional 
contacts in the dipeptide binding pockets (Saksela & Permi, 2012). Surprisingly, 
many atypical SH3 domain binding peptides bind with a higher affinity than 
substrates containing the canonical binding motifs.  
Notably, interactions with the residues of the n-Src loop often contribute to 
the binding of atypical SH3 domain ligands. In both the interactions of the Csk SH3 
domain with the PEP-3BP1 (Ghose et al, 2001) and the C-terminal SH3 domain of 
p67
phox
 with p47
phox
 (Kami et al, 2002) the ligands bind in the minus orientation via 
both canonical contracts with the dipeptide binding pockets but also additional 
interactions with an acid pocket adjacent to the specificity pocket. Both binding 
peptides adopt a helical conformation but the nature of their interaction with the SH3 
domain differs slightly. The PEP-3BP1 peptide forms a 310 helix that presents a 
hydrophobic isoleucine residue to K33 of the Csk SH3 domain, a residue contained 
within the n-Src loop. In the p67
phox
-p47
phox
 complex the 47
phox 
peptide forms a 
helix-turn-helix structure that is able to interact with residues in the β4 strand and 
n-Src loop of the p67
phox
 SH3 domain.  
Some SH3 domains are able to interact in both canonical and atypical modes. 
The Fyn SH3 domain is known to bind to classical PxxP motifs but has also been 
shown to bind to the atypical sequence RKxxYxxY in the immune cell adaptor 
SKAP55 (Kang et al, 2000). This interaction also constituted the first reported 
example of a SH3 domain interaction that was not reliant on at least one proline 
residue. Prior to this the atypical motif PxxDY (Mongioví et al, 1999) had been 
reported but it still required the proline residue in order to bind.  
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1.2.1.4 SH2 domain 
 
SH2 domains bind phosphotyrosine residues within proteins (Moran et al, 1990). 
The specificity of this interaction is achieved by individual SH2 domain recognition 
of the residues flanking the phosphotyrosine. Songyang et al (1993a) used a random 
library of phosphopeptides to identify the binding preferences of a number of SH2 
domains. SFK members Src, Fyn, Lck and Fgr all select the sequence pYEEI, while 
the SH2 domain of Abl selects pYENP and Crk selects pYDHP (Songyang & 
Cantley, 2004; Songyang et al, 1993b). 
 The molecular basis for this interaction is apparent from the structures of the 
Src and Lck SH2 domains (Eck et al, 1993; Waksman et al, 1992). Both have a deep 
hydrophobic pocket that is able to accept the isoleucine in position pY + 3. Other 
β-branched amino acids, such as valine, are also able to fit into the pocket, but 
methionine and leucine are too long. The acidic residues at positions pY + 1 and 
pY + 2 are positioned in a shallow groove on the SH2 domain surface, oriented 
towards basic residues on the otherwise neutral SH2 domain surface.  
 The residues in the binding sites of the individual SH2 domains directly 
modulate the sequences that are able to bind. Changing a residue adjacent to the 
Y + 2 binding site (Y215) to tryptophan in the Src SH2 domain, as it is in the Grb2 
SH2 domain, alters the binding preferences of the SH2 domain to pYENP. The 
binding preference of the Grb2 SH2 domain is pYQNY/Q. Therefore the Src SH2 
domain now favours asparagine in the Y + 2 position, as Grb2 does (Songyang et al, 
1993a).  
 The ability of SH2 domains to select ligands from random peptide libraries 
indicated that they would be able to bind to similar short contiguous sequences in 
their substrates. Investigation of the sequences of their substrates has shown this to 
be partially true. Focal adhesion kinase (FAK) is known to be phosphorylatted at 
Y397 and to bind to the Src SH2 domain. The sequence that the SH2 domain is 
binding to in this instance is pYAEI, which closely matches the ideal sequence of 
pYEEI (Xing et al, 1994). Some substrates do not contain such apparently ideal 
sequences. The platelet derived growth factor receptor (PDGF-R) and colony 
stimulating factor-1 (CSF-1) are phosphorylated at pYIYV and pYTFI respectively 
(Alonso et al, 1995). Both of these sequences lack the acidic residues selected by the 
SH2 domain in vitro; they do, however, both retain the long, branched amino acid at 
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position pY + 3. It is likely that, as there are more contacts from the SH2 domain 
surface to the residue at pY + 3 than to the other two residues that binding of an 
appropriate amino acid in this position is able to compensate for the lack of acidic 
amino acids. In addition the tyrosine residue at position pY + 2 in the PDGF binding 
sequence is itself phosphorylated and this phosphorylation increases the acidity of 
the local peptide sequence and enhances the interaction. Therefore, there can be 
multiple layers of modulation that influence the affinity of the interaction.  
 It is also common that longer range interactions are also involved when the 
phosphorylation of a protein is considered as opposed to that of a peptide. In general, 
the binding affinity of SH2 domains to phosphoproteins is lower than that to the 
phosphopeptides derived from them. In the case of the SFKs, it is known that 
substrates are themselves commonly modular and able to interact with both the SH2 
domain and the SH3 domain. Therefore, in vivo substrates may not require the ideal 
binding motif to be able to bind to the SH2 domain. 
 In addition to phosphotyrosine binding, certain SH2 domains also seem to be 
able to interact with phospholipids (Zhao et al, 1993). Association with 
phospholipids of the plasma membrane would be able to aid membrane association. 
However, it remains to be shown how the balance between substrate binding and 
phospholipid binding is achieved in vivo and how the balance between the two is 
regulated.  
 
1.2.1.5 The kinase domain 
 
The Src kinase domain is broadly conserved across all SFK members and other 
tyrosine kinases. It is both necessary and sufficient for kinase activity. It also plays a 
major role in the determination of substrate specificity. If the kinase domain of the 
v-ErbB kinase, a heterologous tyrosine kinase oncoprotein, is replaced with the 
kinase domain of Src then the substrate preferences of the resulting kinase become 
more similar to those of C-Src (Chang et al, 1995). 
 Studies using combinatorial peptide libraries have shown that the substrate 
preferences of the two kinases are indeed different with Src preferring 
EEEIYG/EEFD and EGF-R (the normal cellular counterpart of v-ErbB) preferring 
EEEEYFEφ (where φ represents a hydrophobic amino acid) (Songyang et al, 1995a). 
Importantly, this study also showed that the substrate preferences of the individual 
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members of the SFKs also differ, with the Lck kinase domain selecting 
XEXIYGVφφ (where φ represents a hydrophobic amino acid) (Songyang et al, 
1995b). It has also been noted that the kinase domain substrate preferences resemble 
the SH2 domain preferences of the kinases. The Src SH2 domain binds to substrates 
containing pYEEI. This means that the SH2 domain is able to dock onto tyrosine 
residues phosphorylated by the kinase domain, allowing further phosphorylation of 
the substrate by the kinase domain. This is a process known as processive 
phosphorylation (Mayer et al, 1995).  
 The first structure of a tyrosine kinase elucidated was that of the insulin 
receptor kinase (InsR kinase) (Hubbard et al, 1994). This allowed for the comparison 
of a tyrosine kinase structure with the serine/threonine kinase PKA. The specificity 
of the InsR kinase for tyrosine over serine or threonine was shown to be caused by 
the proximity of a loop that is conserved between all tyrosine kinases to the substrate 
binding site. In Src this loop is FP
425
IKWTA. The proline residue within this 
sequence binds to the phenyl ring of the substrate tyrosine, aiding its binding. This 
would not be beneficial for the binding of either serine or threonine.  
 A major site of autophosphorylation for Src occurs in the kinase domain at 
Y416 (Smart et al, 1981). There has been a large amount of debate about whether 
this phosphorylation occurs intra- or intermolecularly. Initial studies found that the 
phosphorylation occurred entirely or mostly intramolecularly (Feder & Bishop, 
1990; Sugimoto et al, 1985). Subsequent experiments have shown that 
autophosphorylation of catalytically inactive kinases can occur and therefore 
phosphorylation must be able to proceed in trans (Cooper & MacAuley, 1988). It 
remains unclear whether other kinases are able to contribute to phosphorylation at 
this site. The phosphorylation event at Y416 is important for regulation of the kinase 
conformation and activity and will be discussed further in section 1.2.2.  
 
1.2.1.6 The C-terminal tail 
 
All vertebrate SFKs have a C-terminal extension of 15-17 residues following their 
kinase domains. This region contains a tyrosine residue (Y527 in chicken Src) 
contained within a conserved sequence at a constant position. This C-terminal 
phosphorylation site has been shown to be a major site of phosphorylation within the 
cell and in resting fibroblasts, both Src and Lck are quantitatively phosphorylated at 
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this site (Cooper et al, 1986; Kussick & Cooper, 1992; Marth et al, 1988). The cycle 
of phosphorylation and dephosphorylation of this C-terminal site is involved in the 
regulation of the activity and conformation of the SFKs, the mechanism by which 
this is achieved is discussed further in section 1.2.2. 
 
1.2.2 Regulation of the Src Family Kinases 
 
The first crystal structure of full length C-Src was obtained in 1997 by Xu et al 
(1997) and it revealed the nature of the intramolecular associations that regulate Src 
kinase activity. It was already known that a highly conserved tyrosine residue 
(Y527) in the C-terminal tail region interacts with the phosphotyrosine binding site 
in the SH2 domain and this was confirmed by the crystal structure. In addition, 
another unexpected association was observed. The linker between the SH2 domain 
and the kinase domain is able to adopt a polyproline type II (PPII) helix, despite 
containing only one proline residue, and bind to the SH3 domain.  
The SH2:tail association is facilitated by a regulatory kinase known as Csk 
(C-terminal Src kinase) and the closely related kinase CSK-homologous kinase 
(Chk) that phosphorylate the highly conserved tail residue Y527 (Nada et al, 1991; 
Okada et al, 1991). Knockout studies suggest that Csk is a master regulator of SFK 
activity; the Csk knockout is embryonic lethal and biochemical analysis showed a 
substantial overall increase in SFK activity in the embryo (Imamoto & Soriano, 
1993; Nada et al, 1993).  
When the tail residue is phosphorylated it is able to interact with the 
phosphotyrosine binding SH2 domain, forcing the kinase into an inactive 
conformation. The importance of this interaction in the regulation of kinase activity 
becomes apparent when the product of the transforming retroviral oncogene v-src is 
considered. The primary structural difference between v-Src and C-Src protein is a 
deleted tail region in v-Src. As a result, v-Src is constitutively active, its kinase 
activity is unregulated and it has a transforming phenotype when transfected into 
cells. Mutation of the single residue Y527F in C-Src was subsequently shown to 
recreate the constitutive activity of v-Src (Briggs & Smithgall, 1999). 
When the SH2:tail and SH3:linker intramolecular interactions are in place, 
the kinase activity of C-Src is downregulated. The crystal structure revealed that, in 
this conformation, the activation loop in the kinase domain adopts a partially helical 
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conformation which results in the autophosphorylation site (Y416) pointing inwards. 
In contrast, the crystal structure of the activated kinase shows that the activation loop 
is re-orientated to a position more compatible with ATP and substrate binding. In 
this conformation Y416 becomes surface exposed, allowing autophosphorylation 
which acts to stabilise the open (active) conformation (Xu et al, 1997). 
Figure 1.2.2.1 SFK activation scheme 
SFKs can be activated by the displacement of the intramolecular interactions that 
serve to constrain the kinase activity in the absence of a substrate. Substrate 
binding can displace either the SH3:linker interaction or the SH2:tail interaction. It 
remains unclear whether displacement of one intramolecular interaction acts to 
destabilise the second interaction and produces a fully open and active kinase or if it 
can result in two distinct partially activated forms of the kinase that phosphorylate 
different subsets of substrates. 
Mutation of the residues involved in the SH2:tail and SH3:linker interactions 
result in an increase in the kinase activity of the SFKs. This led to the hypothesis that 
interaction of the SH2 and SH3 domains with their high affinity substrates could 
have the same effect in vivo. Numerous studies have shown that disruption of either 
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SH2:tail or SH3:linker interactions, either by mutation, interaction with other 
proteins, or tail dephosphorylation, is sufficient to induce SFK activation in vitro but 
the minimal component for activation in vivo is still a matter of much debate. It has 
been suggested that disruption of the SH3 association alone may result in transient 
kinase activation, substrate phosphorylation and release, followed by a return of the 
kinase to its inactive state (Pellicena and Miller, 2002). 
One of the best studied examples of kinase activation resulting from SH3 
domain displacement is the association between the Hck SH3 domain and Nef, a 
HIV accessory factor that is involved in AIDS progression (Lee et al, 1995; Saksela 
et al, 1995). Nef binds to the Hck SH3 domain by the sequence PQVPXR (Saksela et 
al, 1995). This sequence is able to form a PPII helix that contacts the Hck SH3 
domain surface (Grzesiek et al, 1996). Nef binding to full length Hck results in an 
increase in kinase activity that has been demonstrated in vitro (Moarefi et al, 1997; 
Trible et al, 2006) and in cell based assays (Briggs & Smithgall, 1999; Lerner & 
Smithgall, 2002). Mutagenesis of the PxxP motif in Nef prevents this association and 
in turn prevents the increase in kinase activity (Choi & Smithgall, 2004).  
SH3 domain release is also shown to result in an increase in kinase activity 
when binding to p130Cas (Burnham et al, 2000; Pellicena & Miller, 2001), the 
progesterone receptor (Boonyaratanakornkit et al, 2001) and Stat3 (Schreiner et al, 
2002), among others. This supports the theory that SH3 domain displacement primes 
the kinase for activation.  
SFK activation by SH2 domain displacement has also been shown to occur in 
vivo. SFK activation by growth factor receptor tyrosine kinases involves the 
displacement of the SH2 domain from the SH2:tail interaction and onto the 
phosphorylated residues of the activated, autophosphorylated receptor. This is able to 
activate the kinase to phosphorylate the receptor, initiating a signalling cascade 
(Parsons & Parsons, 1997).  
 The presence of two distinct regulatory interactions within the kinase 
molecule means that there are a number of structural possibilities upon activation. If 
the displacement of either SH2:tail or SH3:linker interactions is sufficient to 
independently induce kinase activity, there would be more than one active 
conformation. This raises the possibility of the existence of distinct active states with 
distinct signalling properties. Alternatively, the disruption of one intramolecular 
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association may serve to destabilise the second leading to only one, fully open, 
active state. 
Molecular dynamics experiments using Hck kinase support the second 
hypothesis, indicating that the movements of the SH2 and SH3 domains are highly 
correlated in the inactive state (Young et al, 2001). However, there is some 
compelling evidence that, in vivo, alternate mechanisms of activation are possible. 
Rat-2 fibroblasts transfected with either Hck Y527F (SH2 activated) or Hck bound to 
a SH3 ligand (SH3 activated) have been analysed for phosphotyrosine content by 2D 
electrophoresis followed by detection using an antiphosphotyrosine antibody (Engen 
et al, 2008). Multiple unique phosphotyrosine containing spots were observed in 
each case, supporting the idea that Hck substrate selection can be influenced by the 
mechanism of activation. If this can be demonstrated to be true for other SFK 
members and to occur under physiologically relevant signalling conditions, it would 
provide evidence that there are distinct mechanisms of activations and that the mode 
of activation can impact upon the substrates phosphorylated and the downstream 
signalling events that occur.  
 A more recent C-Src crystal structure (Cowan-Jacob et al, 2005) appears to 
support the idea that a similar mechanism of alternate activation could also be true of 
C-Src. The structure was obtained using unphosphorylated C-Src and, as a result, the 
tail is released from the SH2 domain. The activation loop of the kinase domain can 
be seen to adopt a conformation similar to that observed in active kinase domains. 
Despite this, the linker remains bound to the SH3 domain but the SH2:SH3:linker 
complex is rotated approximately 130
o
 compared to its position in the downregulated 
kinase structure. The biological relevance and kinase activity of this structure have 
not been determined and further investigation is needed.  
 There is mounting evidence that suggests the SFKs can adopt multiple active 
conformations in vivo. This conformational plasticity may go some way to 
explaining how the SFKs are able to function in such a diverse range of cellular 
processes.  
 
1.3 Functions of SFKs 
 
SFKs play diverse roles in many different cellular processes; including cytoskeletal 
rearrangement, differentiation, adhesion, migration, survival and immune function 
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(Thomas & Brugge, 1997) and function in all mammalian tissues. For the purposes 
of this study only the neuronal roles of SFKs are considered in detail. 
 
1.3.1 SFKs in development 
 
SFK signalling is crucial for a wide range of functions in neuronal development 
including neural tube formation, axonal growth and guidance, myelination and 
synapse stability. These functions are primarily mediated by Src, Fyn, Yes and Lyn; 
the major SFKs expressed in neurons. Src, Fyn and Yes are all broadly expressed 
throughout the central nervous system (CNS) (Maness, 1992) while Lyn expression 
is more restricted (Chen et al, 1996). The expression of Src and Fyn appears to be 
developmentally regulated, while the expression of Yes remains relatively 
unchanged throughout development (Inomata et al, 1994). Src and Fyn expression 
first occurs in neuroectodermal cells during neural fold formation at the onset of 
neuronal differentiation (Maness et al, 1986). Both Src and Fyn are enriched in the 
growth cone, or growing tip, of neurons and expression of both declines, although 
remains detectable, during neuronal maturation (Bixby & Jhabvala, 1993; Wiestler & 
Walter, 1988). However, there are differences in the expression patterns of Src and 
Fyn. Fyn expression is more highly enriched in axons than that of Src, and following 
sciatic nerve transection injury, Src expression is upregulated while Fyn expression 
remains constant (Zhao et al, 2003). This indicates that, despite being highly related, 
they mediate specific and individual roles within the neuron. 
Surprisingly, the single knockout mice of Src and Yes have no detectable 
neurological deficits (Lowell & Soriano, 1996), although it is possible that 
reassessment using modern techniques for assessment of neuronal function may 
reveal more subtle phenotypes. In support of this, mice that are lacking Fyn will 
upregulate Src activity, presumably as a mechanism to compensate for the loss of 
Fyn activity (Grant et al, 1995; Stein et al, 1994). 
The single knockout of Fyn does have some mild cognitive impairment, 
characterised by a reduction in long term potentiation (LTP), an activity dependent 
signalling cascade associated with the capacity to learn and form memories (Grant et 
al, 1992). Fyn
-/-
 mice also show an associated defect in a test of the conversion of 
short term to long term memory. These phenotypes are thought to be due to mild 
morphological abnormalities observed in the hippocampus. The granule cell layer of 
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the dentate gyrus and the pyramidial cell layer of the CA3 region in the hippocampus 
have approximately 25% more neurons than wild type mice, indicating a role for Fyn 
in the regulation of neuronal differentiation and proliferation, possibly by 
influencing the extent of cell death. The brains of mice lacking Fyn have reduced 
global levels of tyrosine phosphorylation and phosphorylation of the SFK substrate 
FAK is reduced. FAK is also known to be a substrate of Src so it would be surprising 
if the effects of Fyn knockout were mediated through FAK as it would be thought 
that compensation through Src phosphorylation could occur.  
Fyn
-/-
 mice with a different strain background were shown to have a 
neurological defect in that the neonates fail to suckle (Yagi et al, 1993). This has 
been partially attributed to the 40-50% decrease in the amount of myelination 
observed in these mice (Sperber et al, 2001). Therefore, it seems that Fyn also plays 
a role in the myelination of neurons. Fyn is expressed in oligodendrocytes, the cells 
responsible for myelination, but the mechanistic requirement for Fyn in myelination 
remains to be elucidated. It is interesting that the two different Fyn
-/-
 lines showed 
different phenotypes and therefore important that further investigation is carried out 
to rule out effects due to the strain background. It is possible that the production of a 
Src
-/-
 mouse in a different strain background would reveal a phenotype. 
Elucidation of SFK function from knockout studies is complicated by their 
high degree of functional redundancy and ability to compensate. A good indication 
that there is functional redundancy between the kinases is that the double knockout 
of Src and Fyn has a much more severe phenotype and the triple knockout of Src, 
Fyn and Yes is embryonic lethal (Stein et al, 1994).  
 Src, Yes and Fyn are all expressed in the growth cone, the growing tip of the 
developing neuron (Maness, 1992), but the functions of Src and its roles in 
mediating axon guidance are the most well studied. Src signalling is required 
downstream of axon guidance receptors and cell adhesion molecules including L1 
and NCAM. Neurons taken from Src
-/-
 mice are unable to extend on a substrate of 
L1-CAM but show wild type growth on laminin (Ignelzi et al, 1994). Conversely, 
neurons taken from Fyn
-/-
 mice are unable to grow on a substrate of NCAM, while 
growth is normal on both L1-CAM and laminin (Beggs et al, 1994). These results 
indicate that both Src and Fyn play a role in the processes of neurite outgrowth, with 
Src signalling downstream of L1-CAM and Fyn signalling downstream of NCAM. 
These results indicate that, despite some amount of functional redundancy, the 
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individual isoforms of the SFKs are able to mediate individual functions within 
neurons. The subtle phenotypes were not observed in neuronal slices taken from 
single knockout mice as, in the intact brain, the neurons would be migrating through 
regions containing both L1-CAM and NCAM.  
Inhibition of Src results in an increase of laminin mediated outgrowth in 
chick sensory neurons and application of tyrosine kinase inhibitors are able to 
promote neurite outgrowth in culture (Hoffman-Kim et al, 2002). In addition, 
application of the extracellular domains of L1-CAM or NCAM results in a decrease 
in tyrosine phosphorylation mediated by endogenous SFKs in the growth cone 
(Atashi et al, 1992). These data are in contrast with the previous neurite outgrowth 
studies that demonstrated a requirement for SFK signalling in neuronal outgrowth. 
This is probably because the SFKs play specialised roles in the processes of neuronal 
outgrowth and may be able to play opposing roles depending on the developmental 
stage. The differing effects could be achieved through the tight regulation of kinase 
activity and localisation.  
In addition to roles in regulating neurite outgrowth as a response to L1-CAM 
signalling, Src is also involved in the internalisation and recycling of L1 between the 
plasma membrane and the endosomes (Schaefer et al, 2002). Therefore, Src 
signalling is able to influence neurite growth as a result of L1-CAM by at least two 
different mechanisms. The molecular basis for the role of Src in L1-CAM signalling 
will be discussed further in section 1.6. 
Studies in Drosophila melanogaster have also provided evidence for a role of 
the SFKs in neuronal development. Overexpression of Drosophila Src in embryos is 
lethal and specific inhibition in the neuronal precursors of the developing eye results 
in a block of neuronal specification and differentiation (Kussick et al, 1993; 
Takahashi et al, 1996). This result would imply that Src kinase activity plays a 
positive role in the specification and differentiation of neurons.  
 SFK signalling has also been implicated in growth cone guidance signalling 
originating from a large number of pathways including responses to netrin, brain 
derived neurotrophic factor (BDNF), ephrin A and semaphorin 3A (Sema3A). The 
molecular basis for these responses will be discussed further in section 1.5. 
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1.3.2 SFKs in the mature brain 
 
Synaptic transmission is the mechanism by which neurons in the CNS communicate. 
This communication occurs at specialised intercellular connections between the 
presynaptic nerve terminals and postsynaptic targets, called synapses. In the 
mammalian CNS, signalling at synapses is primarily chemically mediated and can be 
segregated broadly into two classes; excitatory and inhibitory. Transmission at 
excitatory synapses increases the likelihood that an action potential will be produced 
in the postsynaptic neuron and that the signal will be potentiated. This occurs 
through membrane depolarisation in the postsynaptic neuron. Conversely, 
transmission at an inhibitory synapse reduces the likelihood of an action potential 
being produced by eliciting membrane hyperpolarisation. Both excitatory and 
inhibitory synaptic transmissions are mediated by binding of neurotransmitters 
released from the presynaptic neuron to transmembrane receptors on the postsynaptic 
neuron. Normal CNS function is based on a balance between excitatory and 
inhibitory synaptic transmission and abnormality in this can result in neurological or 
psychiatric disease (Cline, 2005).  
 Signalling at excitatory synapses is predominantly mediated by glutamate 
released from the presynaptic cell by calcium dependent exocytosis of synaptic 
vesicles and binding to ionotrophic glutamate receptors in the postsynaptic cell 
membrane. There are three pharmacologically and molecularly defined classes of 
ionotrophic glutamate receptors, named according to their preferred agonists; the 
N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazole-3-proprionic 
acid (AMPA) and kainate receptors (Dingledine et al, 1999). 
 Glutamatergic synaptic transmission is dynamically controlled and highly 
plastic. This plasticity is essential for key physiological processes, but can also lead 
to disease states. Changes in the function, or number, of postsynaptic glutamate 
receptors is associated with the control of learning and memory (Bliss & 
Collingridge, 1993) but also chronic pain, epilepsy and neurodegeneration. 
Phosphorylation has emerged as a key regulatory process in the functions of 
glutamate receptors (Köles et al, 2001; Soderling & Derkach, 2000; Swope et al, 
1999), with tyrosine phosphorylation, predominantly carried out by SFKs, crucial for 
the regulation of NMDA-R function and number (Ali & Salter, 2001; Salter & Kalia, 
2004).  
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The neuronal functions of SFKs were originally thought to be limited to 
proliferation and differentiation. However, the discovery of SFKs in post-mitotic, 
differentiated neurons (Cooke & Perlmutter, 1989; Cotton & Brugge, 1983; Sudol & 
Hanafusa, 1986; Zhao et al, 1990) suggested a role beyond development, in the 
mature brain. In support of this, mice lacking Fyn or Lyn have behavioural 
abnormalities (Grant et al, 1992; Umemori et al, 2003). This suggests a role for the 
SFKs in the molecular processes of neuronal plasticity which often presents as a 
defect in learning and memory or behaviour in mouse models. The molecular 
mechanisms underlying these effects and the specific kinases and substrates involved 
are only recently beginning to be understood.  
A major role of SFKs in the developed CNS is now thought to be the 
regulation of ion channels. The first ion channel identified as being regulated by 
SFKs was the NMDA-R (Wang & Salter, 1994). Subsequently potassium channels 
(Fadool et al, 1997), calcium channels (Cataldi et al, 1996), γ-aminobutyric acid type 
A (GABAA) receptors (Moss et al, 1995) and nicotinic acetylcholine receptors 
(Wang et al, 2004) have all been shown to be regulated by SFK phosphorylation.  
Native NMDA-Rs are multiprotein complexes, with the NMDA receptor 
subunits at their core and physical associations with numerous scaffold proteins, 
adaptor proteins and signalling enzymes (Husi et al, 2000). NMDA-R activation 
requires binding of both glutamate and the co-agonist glycine to sites in the 
extracellular domain. Once activated the channel becomes permeable to K
+, 
Na
+
 and 
Ca
2+
. As an additional mechanism of regulation, the current passing through the 
channels can be mediated by a balance between phosphorylation and 
dephosphorylation.  
Inhibition of endogenous tyrosine kinase activity or upregulation of 
phosphatase activity results in a reduction in NMDA-R mediated currents. 
Conversely, inhibition of phosphatase activity or increase of tyrosine kinase activity 
results in an enhancement of NMDA-R mediated current (Wang & Salter, 1994; 
Wang et al, 1996). Therefore, it was concluded that NMDA-Rs are regulated by the 
opposing actions of phosphorylation and dephosphorylation. 
 Both Src and Fyn are able to potentiate currents through recombinantly 
expressed NMDA-Rs in HEK cells (Köhr & Seeburg, 1996) or Xenopus oocytes 
(Chen & Leonard, 1996). Single channel recordings of NMDA-Rs showed that 
increasing tyrosine phosphorylation and inhibition of phosphatases results in an 
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increase in the gating properties of the channels with no change in the single channel 
conductance (Wang et al, 1996).  
SFKs were first implicated in the regulation of NMDA-Rs because the SFK 
activating peptide (pYEEI), which works by binding to the SH2 domain of the SFKs, 
is able to increase the activity of NMDA-R mediated currents in both cultured 
neurons (Yu et al, 1997) and hippocampal slices (Lu et al, 1998). Src (Huang et al, 
2001), Fyn (Suzuki & Okumura-Noji, 1995), Lck, Lyn and Yes (Kalia & Salter, 
2003) are all found within the post-synaptic density (PSD) in the postsynaptic cell 
and Src (Yu et al, 1997), Fyn (Yaka et al, 2002), Lyn and Yes (Kalia & Salter, 2003) 
are all present within the NMDA-R complex. Therefore, there are multiple SFK 
family members located in the correct position to be able to regulate NMDA-R 
function. Src itself was implicated because application of both the inhibitory 
antibody (α-src1) (Roche et al, 1995) and the inhibitory peptide (Src40-58) (Yu et al, 
1997), that are able to inhibit Src selectively over the other SFK family members, 
results in a reduction in NMDA-R mediated currents. This reduction occurs through 
a reduction in channel gating, the same effect observed when the SFKs were 
inhibited non-specifically. The peptide Src40-58 binds to the corresponding residues 
within the unique domain of Src. It has therefore been hypothesised that Src may be 
interacting directly with the NMDA-R via its unique domain and that application of 
the peptide prevents this interaction.  
 Direct SFK phosphorylation of neurotransmitter receptors is beginning to be 
established as the method by which SFKs may regulate synaptic transmission. 
NMDA-Rs are tetramers that consist of two NR1 subunits and two modulatory 
subunits (either NR2A-D or NR3A-D). Both Src and Fyn phosphorylate residues in 
the tails of NR2A and NR2B (Nakazawa et al, 2001; Yang & Leonard, 2001). Site 
directed mutagenesis studies have identified specific tyrosine residues that are 
phosphorylated by Src or Fyn when the NMDA-R subunits and the kinases are 
co-expressed in heterologous cells (Cheung & Gurd, 2001). The phosphorylation 
events have been demonstrated to have functional consequences and mutation of the 
residues required results in learning deficits (Nakazawa et al, 2006).  
 Src is also enriched in pre-synaptic vesicles (Linstedt et al, 1992) and has 
well characterised pre-synaptic targets including the synaptic vesicle proteins 
dynamin, synapsin (Foster-Barber & Bishop, 1998) and synaptophysin (reviewed by 
(Evans & Cousin, 2005)). The pre-synaptic association between Src and synapsin is 
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the best characterised and results in the regulation of synaptic vesicle trafficking 
(Messa et al, 2010). 
 
1.4 Neuronal Src kinases 
 
C-Src kinase has two splice variants expressed solely in neuronal tissue (Brugge et 
al, 1985; Pyper & Bolen, 1989; Pyper & Bolen, 1990). These have been termed N1- 
and N2-Src and contain short inserts within their SH3 domains, of 6 and 17 amino 
acids respectively (Martinez et al, 1987; Pyper & Bolen, 1990). The splicing event 
occurs between exons 3 and 4 of the C-Src mRNA. The N2-Src protein is a product 
of expression of both the N1 and N2 exons; expression of the N2 exon alone has 
never been observed. The reason for this remains unclear because expression of exon 
3 and exon N2 would not result in an alteration of the reading frame (Black, 1992). 
Expression of the neuronal Src isoforms is suppressed in non-neuronal cells by 
binding of the polypyrimidine tract binding protein (PTB) to the intron sequence 
upstream of the N1 exon (Chan & Black, 1997; Chou et al, 2000). Neuronal Src 
expression is also under positive control in neuronal cells, with a sequence in the 
intron downstream of the N1 exon acting as a splice enhancer (Modafferi & Black, 
1997). 
The presence of alternative splicing of the C-Src gene product to produce 
neuron specific isoforms appears to be a feature of ‘higher’ animals, and is 
conserved in mammals, birds, reptiles and teleost fish (Raulf et al, 1989; Yang et al, 
1989). It was later demonstrated that frogs have a neuron specific splice variant of C-
Src but it has only a 5 amino acid insert in the SH3 domain rather than the 6 amino 
acids seen in other organisms. The charge of the amino acids contained within the 
insert is retained and it is therefore predicted to carry out similar functions to the 
kinases with a 6 amino acid insert (Collett & Steele, 1992; Collett & Steele, 1993). 
There is no N2-Src equivalent in frogs. In contrast to the comparatively late 
emergence of the N1-Src gene product, C-Src appears for the first time in the most 
primitive of multicellular organisms, the sponges (Barnekow & Schartl, 1984; Ottilie 
et al, 1992). This has led to the suggestion that the neuronal Src kinases may 
function in advanced brain functions including the molecular mechanisms 
underlying learning and memory. However, the in vivo substrates of the neuronal 
Srcs largely remain to be identified 
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Figure 1.4.1 The N-Src kinases contain SH3 domain inserts.  
The only structural difference between C-Src and the N-Src kinases is the presence 
of short SH3 domain inserts in the neuronal isoforms. The amino acid sequences of 
the insets are indicated. As previously indicated in Figure 1.2.1.1 the SH3 and SH2 
domains are involved in substrate selection while the kinase domain is responsible 
for substrate phosphorylation. The important regulatory phosphorylation sites Y416 
and Y527 are indicated and their significance discussed in section 1.2.2. 
The SH3 domain inserts are within the n-Src loop, directly adjacent to the 
substrate binding site. Due to the critical role played by the SH3 domain in substrate 
recognition, it would be predicted that their binding to known C-Src ligands would 
be altered (Yu et al, 1992). Indeed, all studies that have looked specifically at N-Src 
binding have shown that it is either reduced or abolished, as compared to C-Src. The 
N1-Src SH3 domain does not interact with FAK or the neuron specific isoform 
FAK
+
 (Messina et al, 2003), dynamin or synapsin (Foster-Barber & Bishop, 1998), 
Tau (Reynolds et al, 2008) 3BP1 (Cicchetti et al, 1992) and shows reduced 
interaction with Sam68 (Finan Kellie, 1996). In fact, the N1-Src SH3 domain has 
been shown to interact with far fewer substrates than the C-Src SH3 domain in 
resting 3T3 cells (Weng et al, 1993).  
Some putative N1-Src SH3 domain binding partners have been identified. 
The Ena/VASP-like protein (EVL), a PKA substrate shown to play a role in the 
regulation of actin dynamics, has been demonstrated to bind the N1-Src SH3 
domain, while binding to the C-Src SH3 domain is minimal (Lambrechts et al, 
2000). Currently, the functional implications of this interaction, and whether EVL is 
a substrate of the N1-Src kinase domain remains to be determined. 
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A yeast two-hybrid experiment performed in 1997 in the laboratory of Eric 
Kandel using the N1-Src SH3 domain as bait produced a single positively reacting 
fusion product (Santoro et al, 1997). The protein they isolated was shown to interact 
strongly with N1-Src but not C-Src, Fyn or Abl (a non-receptor tyrosine kinase 
belonging to a different family). Western blot analysis confirmed that the protein 
identified was expressed specifically in the brain, with no expression observed in any 
other tissue tested. Sequence analysis of the protein identified led Santoro et al to 
identify it as a novel cAMP and voltage-gated potassium channel.  
 It is now known that the protein identified by the Kandel lab is a 
hyperpolarization-activated and cyclic nucleotide gated (HCN) channel, HCN1. 
HCN channels are expressed both in the heart and the brain and are unique in that 
they are activated by membrane hyperpolarization rather than depolarization. A 
number of important neuronal functions are thought to be in part regulated by the 
currents produced by HCN channels. These are reviewed by Wahl-Schott and Biel 
(2009) and include maintenance of membrane potential, dendritic integration, 
constraint of LTP, motor learning and synaptic transmission. 
 The interaction of N1-Src with HCN1 has not been confirmed beyond the 
initial yeast two-hybrid interaction, although regulation of HCN channels by 
phosphorylation is not unprecedented. HCN2 has been shown to interact with the 
C-Src SH3 domain in yeast two-hybrid and GST pulldown experiments; the resulting 
phosphorylation both enhances the activation kinetics of the channel and regulates its 
trafficking (Zong et al, 2005). Regulation of HCN channel current by 
phosphorylation has been demonstrated under physiological conditions in the rat 
heart (Arinsburg et al, 2006) as well as neurons (Zong et al, 2005). This supports the 
idea that the HCN channels are indeed under phosphorylation control in vivo and that 
members of the SFKs are responsible. In addition, HCN channels contain extensive 
proline rich domains which are attractive potential SH3 domain ligands.  
A second, biased, yeast two-hybrid experiment has identified another 
possible N1-Src substrate. Miyagi et al (2002) demonstrated that the SH3 domain of 
N1-Src can bind to Delphilin. Delphilin is a PDZ domain containing protein that 
interacts with the orphan glutamate receptor GluRδ2 (Miyagi et al, 2002). There is 
currently no biological role assigned to GluRδ2 and although its binding to Delphilin 
is under phosphorylation control, this phosphorylation is thought to be carried out by 
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PKA. Sequence analysis of Delphilin reveals that it does contain a proline rich 
region with a number of PxxP motifs that could potentially bind to an SH3 domain. 
In addition to differing substrate specificities, the expression patterns and 
subcellular localisation of the neuronal Src kinases may differ from those of C-Src. 
C-Src and N1-Src are both enriched in axons and dendrites compared to the cell 
soma (Sugrue et al, 1990). N1-Src activity first occurs slightly later than that of 
C-Src but N1-Src activity increases sharply at E12 and remains substantially higher 
than C-Src into the adult mouse (Wiestler & Walter, 1988). It is generally agreed that 
both C- and N1-Src are present in the growth cones of developing neurons (Brugge 
et al, 1985; Maness et al, 1990), but it has been reported that N1-Src may be 
preferentially recruited to lipid rafts (Mukherjee et al, 2003). Lipid raft localisation 
of Src would not be expected because it is normally the dual lipid modified SFKs 
(not Src or Blk) that are found in lipid rafts. 
The presence of the additional residues within the N-Src SH3 domain has 
also been shown to result in an increase in the tyrosine kinase activity of the proteins. 
This increased activity has been repeatedly reported in association with the neuronal 
kinases (Brugge et al, 1985; Levy & Brugge, 1989), but there do seem to be some 
instances in which the activities of C- and N-Src do not differ greatly (Yang & 
Walter, 1988); implying that the activity of the N-Srcs can be regulated. Highly 
active SFKs, such as v-Src, are known to illicit cellular transformation while their 
normal cellular counterparts are not transforming (Kmiecik & Shalloway, 1987). The 
transforming potential of N1-Src was found to be intermediate between the 
non-transforming C-Src and the highly transforming v-Src (Levy & Brugge, 1989). 
Mutational analysis of the C-Src SH3 domain has revealed the importance of 
the n-Src loop in the regulation of the kinases. Mutation of a residue within the n-Src 
loop (D117N) results in an increase in kinase activity (Brábek et al, 2002). This 
increase in activity has been interpreted as a reduction in the ability of the SH3 
domain to form the SH3:linker intramolecular association that normally constrains 
the activity of the kinase. The presence of an insert in the n-Src loop is thought to 
decrease the folding rate but not affect the overall structure of SH3 domains on a 
large scale (Grantcharova et al, 2000). 
 Existing studies into the functions of the N-Src kinases point to roles in 
neuronal development. Kotani et al (2007) showed that overexpression of a 
constitutively active form of N1-Src specifically in the Purkinje cells of mice 
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resulted in aberrant neurite outgrowth and cell body mislocalisation, while 
overexpression of constitutively active C-Src had little effect. The aberrant 
outgrowth was shown to be restricted to the dendrites, with axons appearing 
morphologically normal. Overexpression of C- and N1-Src in the developing 
Xenopus retina were also shown to differentially impair neurite outgrowth (Worley 
et al, 1997). In this case, it is the axons that are primarily affected, with the axons of 
C-Src overexpressing ventral forebrain neurons shorter than the control and N1-Src 
overexpressing neurons longer. Conversely, in the neurons of the optic pathway, 
overexpression of constitutively active N1-Src acted to inhibit axonogenesis. Work 
by Schmidt et al (1992) has also identified a role for N1-Src in the inhibition of 
neuronal differentiation. It is not yet clear why the overexpression has differing 
effects in the two neuronal types but it is possible that the kinase may be interacting 
with different substrates in the various neuronal cell types investigated. 
 There are currently no known potential N2-Src substrates. However, there is 
a known association between N2-Src expression levels and prognosis for the cancer 
neuroblastoma. Neuroblastoma is a childhood cancer of neural crest derivation and is 
the most common solid tumour diagnosed in children. The tumour cells of 
neuroblastoma are arrested at various stages during their differentiation and the 
grade of differentiation is related to the clinical course and prognosis (Rudolph et al, 
1997). In general, a more differentiated tumour is considered to be less aggressive. 
Neuroblastomas are divided into stages 1 to 4 and 4s according to the International 
Neuroblastoma Staging System (Brodeur et al, 1988). An intriguing property of 
stage 4s tumours is their ability to spontaneously differentiate to mature 
non-proliferative cells resembling ganglion cells (Evans et al, 1980). The age of the 
patient is known to be an important factor in this phenomenon. Infants (under 1 year) 
are commonly diagnosed with stage 4s disease and an associated good prognosis, 
whereas older children frequently have a more aggressive form of the cancer. 
Interestingly, infant stage 4s tumours appear by histology to be poorly differentiated 
but the occurrence of spontaneous remission into histologically differentiated cells 
means that they do possess the ability to differentiate over time (Evans et al, 1980).  
 Neuronal Src has been shown to be expressed in neuroblastoma and 
retinoblastoma tumours but not in Askin tumours or esthesioneuroblastoma, which 
are also derived from neuronal tissue (Bjelfman et al, 1990a). The neuronal Srcs are 
not expressed in non-neuronal derived tumours. Importantly, low stage and stage 4s 
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infant neuroblastomas have high levels of N2-Src expression, indicating that N2-Src 
expression is an indicator of the capacity of a tumour to differentiate. In contrast 
neuroblastomas expressing only C-Src or C- and N1-Src are more often malignant; 
this type of tumour is typical in older children (Bjelfman et al, 1990a; Matsunaga et 
al, 1993). In general, tumours that are expressing more N2-Src than C-Src are less 
aggressive than the converse situation and have a good prognosis.  
 N2-Src has therefore been considered to be a potential marker both for the 
identification of neuroblastoma as opposed to other neuronal derived tumours and a 
prognostic marker of the severity of the disease and a predictor of a tumour’s 
capacity to spontaneously differentiate.  
  
1.5 Neuronal development mediated by guidance cues 
 
The complex array of information processing carried out by the brain relies on an 
intricate network of connections forming between neurons. In the adult human 
approximately 1 trillion neurons make on average 1000 connections and the precise 
patterning of these interactions is essential for normal neuronal function. 
Connections between neurons form during neuronal development when each 
developing neuron produces an axon. At the growing tip of this axon is a structure 
called the growth cone that is responsible for the guidance of the axon to the correct 
location. The growth of a new axon in vivo appears to occur in a directed manner 
with few errors and it was therefore assumed that axon grow in direct response to 
guidance cues.  
 Over a century ago Ramon y Cajal proposed that axon guidance may be 
mediated by chemoattraction. This model was refined in the 1940s by Roger 
Sperry’s chemoaffinity hypothesis (Sperry, 1963). Cell culture experiments have 
since confirmed that neurons will grow towards their target cells, indicating the 
presence of diffusible chemoattractive substances. The converse is also true, with 
axons shown to grow away from cells that they would not make contacts with in 
vivo. In addition to the long range actions of chemoattraction and chemorepulsion, 
axon growth has also been shown to be regulated by short range contact-mediated 
mechanisms involving non-diffusable cell surface or ECM molecules. It is known 
that axon growth in culture requires a substrate for growth that is both adhesive and 
allows growth, as not all neurons are able to grow on all adhesive substrates. Contact 
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repulsion is also observed in culture. These processes are reviewed by Tessier-
Lavigne and Goodman (1996). 
Figure 1.5.1 The principles of guidance molecule regulation of axon growth. 
There are multiple signalling pathways capable of regulating axon guidance, 
meaning that a growing axon can be guided, probably simultaneously, by multiple 
guidance cues. The growth of an axon can be directed away from one area by 
chemorepulsion while attracted towards another by chemoattraction.  
Developing neurons can respond to multiple signals to modulate the extent 
and direction of their growth. These broadly fall into two classes; attractive and 
repulsive and can be either diffusible or contact mediated.contact-mediated attractive 
and repulsive cues can allow the fine tuning of directionality. Many of the molecules 
that mediate these guidance cues and their cell surface receptors have been 
established have commonly been shown to be modulated by phosphorylation, 
specifically SFK phosphorylation. The major signalling pathways and the roles of 
SFK mediated phosphorylation are outlined below.  
 
1.5.1 Eph family of ephrin receptors 
 
The Eph family are a family of RTKs that bind to and are activated by the 
extracellular domain of their ligands, ephrins, which are tethered to neighbouring 
cells. EphA signalling results in the regulation of neurite outgrowth by linking to the 
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actin and microtubule cytoskeleton (Weinl et al, 2003). These signalling events are 
mediated through a large number of pathways including MAP kinase, PI3K, 
p190rhoGAP/rasGAP and SFK signalling (Kullander & Klein, 2002). EphA 
activation results in a repulsive response, mediated by growth cone collapse. 
 SFKs bind to the juxtamembrane region of the activated EphA receptor via 
two conserved and phosphorylated tyrosine residues (Zisch et al, 1998). This results 
in the activation of EphA kinase activity and allows it to phosphorylate substrate 
proteins. Inhibition of SFKs though chemical means or by overexpression of the 
regulatory kinase Csk results in the abolition of EphA mediated repulsion (Wong et 
al, 2004). The main protein targets of the SFK were shown by IP to be ephexin and 
cortactin (Knöll & Drescher, 2004). Ephexin is a RhoGEF that is activated by 
phosphorylation and signals to RhoA, Rac and Cdc42 in order to regulate 
cytoskeletal dynamics. Ephexin signalling activates RhoA, a negative regulator of 
neurite outgrowth.  
Cortactin is an actin binding protein that plays a key role in de novo actin 
polymerisation (Weed & Parsons, 2001). It is known to localise to growth cones (Du 
et al, 1998) and to interact with EphA receptors (in muscle cells) (Lai et al, 2001). 
SFK phosphorylation is known to be Src dependent (Thomas et al, 1995) and to 
decrease the activity of cortactin (Huang et al, 1997), resulting in a decrease in the 
amount of neurite outgrowth. The SFK member responsible remains to be elucidated 
but it is known that while Src, Yes and Fyn all bind to Eph A, Src does so with the 
highest affinity (Zisch et al, 1998).  
 In addition to the phosphorylation of downstream signalling molecules, the 
SFKs are also able to directly phosphorylate EphA receptors. This was demonstrated 
by overexpression of Fyn and EphA in SYF cells, cells that lack essentially all 
tyrosine kinase activity (Klinghoffer et al, 1999). It is predicted that this 
phosphorylation would act to create binding sites for other EphA interacting 
partners.  
  
1.5.2 Trk family of neurotrophin receptors 
 
The Trk proteins are also a family of RTKs and act as receptors for members of the 
neurotrophin family. Seminal work by Rita Levi-Montalcini identified nerve growth 
factor (NGF) several decades prior to the discovery of Trk receptors (see Levi-
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Montalcini, 1987 for review). Trk receptors are now known to be highly expressed 
throughout the CNS and their expression is developmentally regulated, a property 
that first indicated that they may play a role in the regulation of neurite outgrowth 
(Ringstedt et al, 1993). Trk proteins are involved in a large range of neuronal 
processes including the regulation of proliferation, survival, axonal and dendritic 
growth and remodelling, association with and remodelling of the cytoskeleton and 
synapse formation, function and plasticity (Huang & Reichardt, 2001). There are 
three main Trk receptors; TrkA, B and C that can be generally considered to be 
activated by the neurotrophins NGF, BDNF or NT3 or NT4 respectively, however 
alternative splicing adds to the complexity of their signalling (Huang & Reichardt, 
2001).  
Classically, Trk receptor activation results in the activation of the MAP 
kinase signalling pathway, resulting in gene transcription by CREB and the 
promotion of neurite outgrowth. There is also evidence that Trk receptors can be 
activated by at least two G-protein coupled receptors; the adenosineA2a and PAC-1 
receptors (Lee & Chao, 2001; Lee et al, 2002). Activation by this mechanism has 
different kinetics to classical activation and acts over hours rather than minutes. This 
form of activation is dependent on both intracellular calcium and SFKs but not on 
PKA or PKC. The SFK member required and how it acts remains to be elucidated. 
 Src itself is also directly implicated in mediating Trk signalling. Classical Trk 
signalling results in Ras activation and activated Ras can induce the sequential 
activation of RalGDS (guanine nucleotide disassociation stimulator), Ral and C-Src 
(Ouwens et al, 2002). Activated C-Src is then able to mediate effects on neuronal 
outgrowth through phosphorylation of proteins that play a role in cytoskeletal 
dynamics.  
In addition to signalling downstream of Trk activation, C-Src can be directly 
recruited to the Trk signalling complex. Activated Trk becomes phosphorylated at 
Y490, resulting in the recruitment of the FGF receptor substrate-2 (Frs2). Frs2 is 
then itself phosphorylated, creating a binding site for a number of adaptor proteins 
and signalling molecules, including C-Src (Yan et al, 2002). Recruitment of C-Src to 
this position has been suggested to increase neurite outgrowth in a manner distinct to 
the MAP kinase signalling pathway because activation of C-Src is able to increase 
neurite outgrowth without affecting the kinetics of MAPK signalling in PC12 cells 
(Marshall, 1995).  
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1.5.3 Netrin receptors and netrin 
 
Netrins act to promote neurite outgrowth and pathfinding through binding to netrin 
receptors. Netrin and netrin receptors are highly conserved in invertebrates and 
vertebrates (Serafini et al, 1994) and therefore a large number of the studies into 
their functions have been carried out in Caenorhabditis elegans, a genetically 
tractable organism. Netrin1 is the prototypical member of the netrin family in 
vertebrates and its homolog in C. elegans is UNC6. The netrin receptors are UNC40 
and UNC5 in C. elegans and their mammalian homologues are DCC (deleted in 
colorectal cancer), neogenin and UNC5A-D. DCC/UNC40 are thought to mediate 
both attractive and repulsive forces while UNC5 solely mediates repulsive forces. 
Vertebrate netrin signalling is thought to act predominantly though phospholipase C 
(PLC), PI3K, MAP kinases and the small GTPases Cdc42 and Rac in order to 
mediate neurite outgrowth (Moore et al, 2007).  Netrin binding to netrin 
receptors is known to induce phosphorylation of FAK, a cytoplasmic tyrosine kinase 
with documented roles in a wide range of processes including adhesion, spreading, 
migration, survival, cell cycle progression and proliferation (Serafini et al, 1994). 
The phosphorylation of FAK is required for netrin mediated neurite outgrowth (Liu 
et al, 2004). The activity of SFKs is required for netrin induced FAK 
phosphorylation and chemical inhibition of SFKs results in reduced neurite 
outgrowth (Li et al, 2004). Therefore, SFK activity is required to mediate the neurite 
outgrowth effects of netrin signalling. It is thought that SFK signalling activates a 
signalling cascade through RhoGTPases resulting in the regulation of actin 
polymerisation and cytoskeletal dynamics. 
 
1.5.4 Semaphorins 
 
Semaphorins are a large family of cell surface and secreted guidance proteins that 
are defined by a Sema domain of approximately 420 residues, at their N-termini. 
Semaphorins signal through large, multimeric receptor complexes and their primary 
receptors are thought to be plexins. Semaphorin class 3 proteins are vertebrate 
Semaphorins that are secreted and bind to vertebrate PlexinA proteins in a receptor 
complex that also contains neuropilin (Nakamura et al, 2000). 
Chapter 1 
46 
As previously described for netrin signalling, an activation and association 
between FAK and SFKs is also required for Semaphorin3B (Sema3B) signalling 
(Falk et al, 2005). Interestingly, in this case FAK/SFKs are only required for 
attractive signalling and not repulsive, even though both can be mediated by Sema3B 
binding. In the attractive condition, Sema3B binding results in the recruitment of Src 
to membrane associated FAK. Fyn only becomes phosphorylated and associates with 
FAK under attractive conditions. Notably, the application of a SFK inhibitor not 
only abolished the attractive response of axons to Sema3B but converted it to a 
repulsive response.  
More recently, evidence has emerged that Src/FAK signalling may be 
involved in repulsive signalling pathways mediated by the semaphorin Sema3A 
(Bechara et al, 2008; Chacón et al, 2010). 
   
1.5.5 Slit and Robo 
 
Slits are secreted proteins that bind to their receptor Robo (Roundabout) and act to 
modulate axon guidance (Brose et al, 1999). There is currently no known 
requirement for tyrosine phosphorylation or SFK signalling in the modulation of 
Slit/Robo signalling.  
 
1.6 Cell adhesion molecules in neuronal development 
 
At all stages during their development, growing neurons are able to respond to 
extracellular cues to regulate their development. Signalling resulting from cell 
adhesion molecules is required at the early stages of development for neurite 
induction, proliferation and migration and later in development is involved in growth 
cone guidance to postsynaptic targets and synapse formation. Cell adhesion 
molecules are expressed throughout development in the mammalian nervous system 
and their general role is to mediate both homophilic or heterophilic interactions with 
neighbouring cells and with the extracellular matrix (Walsh & Doherty, 1997). These 
interactions initiate signalling cascades that ultimately either positively or negatively 
regulated neurite outgrowth. In this way the extension length and position of the 
growing neuron is heavily influenced by the signalling arising from the interactions 
of neuronal recognition molecules. With relevance to the findings presented in 
Chapter 1 
47 
Chapter 5, further discussion of cell adhesion molecules will focus on the functions 
of the L1 family of cell adhesion molecules belonging to the Ig superfamily. 
 
1.6.1 L1-CAM family 
 
L1-CAM is the founding member of the L1 family of cell adhesion molecules. The 
family consists of L1, CHL1 (close homolog of L1), NrCAM and neurofascin. L1 
family members share a conserved domain organisation with a large extracellular 
portion and a short C-terminal cytoplasmic tail. The extracellular portion consists of 
6 Ig domains and 4-5 fibronectin type III (FnIII) domains. It is the site of interaction 
for a wide range of ligands including integrins, components of the ECM and 
homophilic interactions with other L1 molecules. The intracellular portion links to 
the actin cytoskeleton and acts to relay extracellular messages across the plasma 
membrane and initiate intracellular signalling cascades (Walsh & Doherty, 1997). 
The structural similarity of the L1-CAM family members results in partial functional 
overlap (Sakurai et al, 2001). 
 L1-CAM signalling plays important roles throughout neuronal development 
and is implicated in migration, growth, pathfinding, synapse formation and plasticity 
(Crossin & Krushel, 2000). From early embryonic development (E9.5) L1-CAM is 
found expressed on the cell bodies of migrating neurons and later in development is 
strongly expressed on growing axons (Kallunki et al, 1997). This then declines to 
more moderate levels postnatally. L1-CAM knockout mice have errors in axon 
guidance (Cohen et al, 1998) and defects in LTP (Bliss et al, 2000); indicating a role 
for L1-CAM in both the developing and mature brain.  
 The importance of L1-CAM mediated signalling in neuronal function is 
indicated by the large number of mutations in the L1-CAM gene that have been 
associated with impaired cognitive ability. The L1-CAM mutations have been 
grouped together into the syndrome CRASH, characterised by corpus callosum 
hypoplasia, retardation, adducted thumbs, spasticity and hydrocephalus (Yamasaki et 
al, 1997). A similar phenotype is also observed in mice lacking the L1-CAM protein 
(Demyanenko et al, 1999).  
 L1-CAM is known to act as a potent regulator of axonal growth and 
branching in experiments where is it employed as a substrate or overexpressed. The 
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mechanism of this is thought to involve the linkage between L1-CAM and the 
cytoskeleton, mediated by ankyrins and ezrin-radixin-moesin (ERM) proteins.  
 
1.6.1.1 L1-CAM and ankyrins 
 
Ankyrin B (ANK2) and ankyrin G (ANK3) are both known to bind to the 
cytoplasmic tail of L1-CAM and to provide a link to the actin cytoskeleton. This 
association is thought to act to stabilise L1-CAM expression at the plasma 
membrane. Homophilic binding of L1-CAM is known to result in the recruitment of 
ankyrins and this binding is then mediated by a MAP kinase dependent pathway 
(Malhotra et al, 1998).  
The conserved sequence FIGQY in the cytoplasmic tail is phosphorylated as 
a result of ERK activation (Whittard et al, 2006). The tyrosine kinase that carries out 
the phosphorylation remains to be elucidated but does not appear to be Src. 
Phosphorylation at this residue prevents the L1-CAM interaction with ankyrin and 
results in the promotion of neurite outgrowth (Gil et al, 2003). Transgenic mice 
carrying a mutation at the residue required for phosphorylation (Y1229H) have 
altered morphology of retinal axons and abnormal interstitial branching (branching 
that occurs along an established axon rather than at the growth cone) (Buhusi et al, 
2008). They also have impaired elongation and branching of interneurons (Guan & 
Maness, 2010).  
The interaction with ankyrin G is quite well established to promote stationary 
behaviour (Gil et al, 2003). However, the role of ankyrin B remains less clear. 
Neurons of mice lacking ankyrin B display hypoplasia of axonal tracts and also 
reduced steady state levels of L1-CAM expression (Scotland et al, 1998). This would 
indicate that ankyrin B mediates similar functions to ankyrin G in stabilising L1-
CAM. Ankyrin B is also shown to co-localise with L1-CAM in developing axons 
while ankyrin B does not. Furthermore, the L1-CAM interaction with ankyrin B has 
been demonstrated to be involved in neurite formation but not elongation (Boiko et 
al, 2007). These results are somewhat contradictory to the findings of Gil et al (2003) 
and Cheng et al (2005) and the roles of ankyrin B interaction with L1-CAM remain 
controversial.  
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1.6.1.2 L1-CAM and ERM proteins 
 
The ERM proteins are known to function to link the actin cytoskeleton to various 
transmembrane proteins, including L1-CAM (Dickson et al, 2002). There are two 
ezrin binding sites in the cytosplasmic tail of L1-CAM, one of which is located in 
the neuron specific sequence YRSLE (Cheng et al, 2005a; Sakurai et al, 2008). The 
interaction with ezrin is known to be involved in the modulation of neurite 
outgrowth and branching. Overexpression of a dominant negative form of ezrin 
results in an increase in the amount of branching of neurons grown on a substrate of 
L1-CAM (Dickson et al, 2002). This indicates that ezrin interaction normally 
functions to negatively regulate outgrowth. Mutation of the ezrin binding sites in the 
cytoplasmic tail of L1-CAM results in a decrease in the amount of branching 
observed (Cheng et al, 2005a). The reason for these contradictory results for the 
function of ezrin-L1-CAM interaction remains unclear.  
 The YRSLE motif also forms the binding site for the µ2 subunit of the AP2 
adapter complex. Binding of both ezrin and AP2 is abolished by phosphorylation at 
this tyrosine residue (Sakurai et al, 2008; Schaefer et al, 2002). Therefore, in 
addition to modulating the interaction with ezrin, phosphorylation at this site is also 
able to regulate the trafficking of L1-CAM to and from the plasma membrane. It is 
thought that ezrin and AP2 are within different membrane domains within the cell 
and that competitive binding does not occur (Kamiguchi & Lemmon, 2000; 
Kamiguchi & Yoshihara, 2001). Phosphorylation at this residue could therefore 
allow for two distinct mechanisms of regulation of L1-CAM signalling.  
 
1.6.1.3 Interplay between L1-CAM and other guidance pathways 
 
In addition to direct linkage to the cytoskeleton, classical activation of L1-CAM 
through homophilic binding results in the activation of FAK in a SFK dependent 
manner and subsequent activation of the MAPK pathway resulting in neurite 
outgrowth (Schafer & Frotscher, 2012). This mechanism of signal transduction has 
previously been introduced in relation to netrin and semaphorin signalling and will 
be discussed further in section 1.7. L1 homophilic binding is also known to result in 
the transient activation of Src, which in turn initiates the sequential activation of 
phosphoinositide 3-kinase (PI3K), the Vav2 guanine nucleotide exchange factor 
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(GEF), Rac1 and PAK1, again resulting in MEK1/2 and ERK1/2 activation (Schafer 
& Frotscher, 2012). Therefore, L1-CAM signalling can proceed by at least two 
different signalling pathways that converge on the MAP kinase pathway to modulate 
outgrowth. 
 L1-CAM can also signal through heterophilic interactions with other 
guidance cue receptors, including the fibroblast growth factor receptor (FGF-R) 
(Saffell et al, 1997). This interaction ultimately results in neurite outgrowth in a 
calcium dependent manner (Doherty et al, 2000). L1-CAM and the netrin receptor 
DCC have been shown to co-localise in response to the application of Netrin, resulting 
in an increase in axon growth (Antoine-Bertrand et al, 2011) and L1-CAM expression in 
growth cones has been demonstrated to increase in response to neurotrophin stimulation 
(Marsick et al, 2012). Both of these responses are thought to be mediated through the 
L1-ezrin interaction. A requirement for L1-CAM is also known in Sema3A mediated 
growth cone collapse, a signalling pathway that mediated negative effects on neurite 
outgrowth (Castellani et al, 2000; Castellani et al, 2004).  
L1-CAM signalling in conjunction with integrins to promote cell migration 
and neurite extension is also an established mechanism of heterophilic interaction. 
Clustering of L1-CAM molecules in the cell membrane promotes adhesion to the 
extracellular matrix through certain members of the integrin family and acts to 
potentiate mobility and migration (Felding-Habermann et al, 1997). The mechanism 
of this action is unclear. In some cases a conserved RGD motif in the 6
th
 Ig domain 
of L1-CAM is required (Thelen et al, 2002) but it can also occur through non-RGD 
binding integrins. In this case the interaction is possibly mediated by a dibasic motif 
in the 3
rd
 Fn III domain (Silletti et al, 2000). Therefore, it is unclear whether there is 
a direct interaction between the L1-CAM extracellular domain and the integrins or 
whether intermediate binding partners facilitate the interactions.  
Signalling through β1 integrins can act through Src, PI3K, Rac1 and PAK1, 
just as L1-CAM signalling does (Ridley et al, 2003). Therefore it can be assumed 
either that L1-CAM is able to signal directly through its association with integrins or 
that the two pathways converge at an early point and mediate the same effects. It is 
known that L1-CAM can associate with RanBPM, an adaptor protein that couples 
integrins and growth factor receptors to the Ras/ERK pathway (Cheng et al, 2005b). 
This interaction provides a possible mechanism by which the L1-CAM and integrin 
signalling pathways could converge.  
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1.7 Src/FAK activation – a general mechanism for the modulation 
of neurite outgrowth 
 
In addition to the numerous guidance cue specific SFK mediated signalling 
pathways, an association between SFKs and FAK has been shown to play an 
important role in the signalling resulting from netrins, semaphorins, ephrins (in 
prostatic carcinoma cells) (Parri et al, 2007), cell adhesion molecules and integrins, 
as described above. Therefore it seems that SFK activation and signalling represents 
a general mechanism used by cells to respond to guidance cues. The signalling 
cascades activated and how the integration of the numerous inputs is achieved 
remains unclear. 
Figure 1.7.1 The Src/FAK complex acts through many distinct pathways to 
modulate neurite outgrowth. 
The interaction of Src with FAK forms an active complex that is able to feed into 
many signalling pathways that act to both positively and negatively modulate neurite 
outgrowth. The activation of this complex is known to occur as a result of activation 
by many guidance cue and cell adhesion mediated interactions at the plasma 
membrane. The downstream signalling events of the Src/FAK complex occur 
predominantly through the modulation of the activities of the small GTPase Rac, 
Ras and Rho. 
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Extracellular guidance cues and adhesion molecules interact with their 
binding partners at the plasma membrane through homophilic and heterophilic 
intertactions, triggering signalling cascades in the growth cone. In order to respond 
appropriately to these cues a cell must be able to integrate them and to produce a 
co-ordinated response. This led to the hypothesis of a master regulator of guidance 
cue signalling. FAK is a cytoplasmic kinase that interacts with a complex network of 
adaptors and signalling molecules via multiple phosphorylation sites. Importantly, it 
is known to regulate the responses to both attractive and repulsive guidance cues in 
response to a wide range of guidance cues, outlined above.  
FAK signalling is able to link external signals to multiple intracellular 
pathways and to control cell shape and motility through modulation of the 
cytoskeleton. This link to the cytoskeleton is crucial to elicit the cells response to 
guidance cues and FAK has come to be regarded as a hub for integration of guidance 
cue signalling (Chacon & Fazzari, 2011).  
 The mechanisms by which FAK signalling is able to result in cytoskeletal 
rearrangement are not quite well established and have been shown to be reliant on 
the signalling of SFKs. The autophosphorylation of FAK is known to be an early 
event in its signalling and this creates a binding site for the SH2 domain of Src 
(Schaller et al, 1994). Src binding to this residue results in Src activation and the 
creation of a dual activated Src-FAK signalling complex. Src phosphorylates FAK at 
Y576 and Y577, residues within the FAK activation loop (Calalb et al, 1995). This 
results in the stabilisation of the active conformation of FAK and the perpetuation of 
FAK signalling. Src is also able to phosphorylate FAK at multiple other residues 
resulting in the creation of binding sites for other proteins (Chacon & Fazzari, 2011). 
Src phosphorylation of FAK at Y861 results in the SH3 domain mediated 
recruitment of p130Cas to FAK (Lim et al, 2004). p130Cas is subsequently 
phosphorylated by the Src-FAK complex which results in the recruitment of the 
adaptor protein Crk via its SH2 domain (Brábek et al, 2004; Cho & Klemke, 2002). 
This results in an increase in Rac activity and a correlated increase in motility and 
neurite outgrowth. 
 By a mechanism similar to the p130Cas mediated neurite outgrowth, the Src-
FAK complex also phosphorylates paxillin, which again results in Crk binding (Petit 
et al, 2000; Turner, 2000) and an increase in motility (Subauste et al, 2004).  
Chapter 1 
53 
 Src phosphorylation of FAK at Y925 creates a binding site for the Grb2 SH2 
domain. This stimulates Ras activity and signalling through the ERK1/2 and MAP 
kinase pathways. It is known that one consequence of this is the ERK2 mediated 
phosphorylation of myosin light chain kinase that results in growth cone collapse 
and contraction (Chen et al, 2002). However, as previously described, ERK1/2 
activation also results in gene transcription of factors that promote neurite outgrowth. 
How the balance between these similar pathways is achieved is unknown.  
 FAK signalling commonly acts through modulating the activity of small 
GTPases including Ras and the Rho family Rho, Rac and Cdc42. This can occur 
downstream as a result of recruitment of signalling proteins including p130Cas, 
paxillin and Grb2 as discussed above but FAK can also mediate direct effects on 
Ras/Rho signalling through modulation of their guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs) (Tomar & Schlaepfer, 2009). GEFs 
and GAPs positively and negatively regulate Ras/Rho activities respectively.  
 FAK activation results in the binding and sequestering of p120RasGAP, 
reducing its association with active Ras and resulting in Ras activation (Hecker et al, 
2004). The consequence of this is an increase in neurite outgrowth. 
 In FAK
-/-
 cells RhoA activity is elevated (Ren et al, 2000), indicating that 
FAK normally has an inhibitory effect on RhoA signalling. In support of this, 
integrin signalling is known to promote neurite outgrowth by reducing RhoA activity 
via Src-FAK mediated phosphorylation of p190RhoGAP (Arthur et al, 2000; Sieg et 
al, 2000). This phosphorylation event increases the GAP activity and results in an 
inhibition of Rho A, resulting in a positive effect on neurite outgrowth. In contrast, 
FAK can also act through p190RhoGEF to activate Rho A (Lim et al, 2008; Zhai et 
al, 2003), which results in a stabilisation of the actin cytoskeleton and the inhibition 
of outgrowth.  
 FAK also acts through Cdc42 to modulate cell motility. FAK binds to and 
phosphorylates the Cdc42 effector N-WASP after it has been activated by Cdc42 
(Wu et al, 2004). N-WASP acts to regulate the cytoskeleton through activation of the 
Arp2/3 complex. FAK phosphorylation of N-WASP results in an activation of the 
Arp2/3 complex and an increase in neurite outgrowth (Zhang et al, 2005).  
 FAK can be seen to feed into a large number of signalling pathways. 
Stimulation by different input mechanisms is able to fine tune the FAK response so 
that it can mediate the diverse responses of attraction and repulsion. It remains to be 
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elucidated how different inputs are able to activate FAK by different mechanisms 
and whether any of the pathways predominate in the cell. However, the role played 
by the SFKs is crucial to the actions of FAK and therefore the cellular response to 
guidance cues.  
 
1.8 Hypothesis 
 
The work presented in this thesis aimed to address the hypothesis that, due to their 
altered SH3 domains, the substrate preferences of the neuronal Src kinases are 
different to those of C-Src. It was also predicted that their altered substrate 
specificities would tailor the activities of the neuronal Srcs to brain specific 
functions.  
In order to investigate the substrate preferences of the kinases an in vitro 
kinase assay was developed. This assay was able to assess phosphorylation of short 
GST-tagged peptides and to reveal differences in substrate preferences due to the 
altered SH3 domains. The technique of phage display was subsequently used to 
identify a novel SH3 binding motif for the N1-Src SH3 domain.  
The functional roles of the neuronal Src kinases were assessed by 
transfection of the individual kinase isoforms into both fibroblasts and cultured 
neurons. The morphology of these cells was then analysed to reveal roles for the 
neuronal Srcs in the control of cell morphology. Finally, a role for N1-Src in the 
L1-CAM signalling pathway was identified by measuring the outgrowth of neurons 
grown on a substrate of L1-CAM. 
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2 Materials and Methods 
 
2.1 Materials 
 
Oligonucleotides were ordered from Eurogentec (Seraing, Belgium). Ligase and 
ligase buffer were purchased from Promega (Fitchburg, WI). The enzymes BamHI, 
EcoRI, SalI, NotI and BglII were purchased from NEB (Ipswich, MA). Mini prep 
kits were ordered from Machery-Nagal (Düren, Germany) and midi-prep kits and gel 
extraction kits were ordered from Qiagen (Venlo, Netherlands). Taq polymerase was 
a kind gift from Dr Daniel Ungar, University of York. The plasmid pGEX-6P-1 was 
from GE Healthcare (Waukesha, WI), pFLAG-N1 was made in house by Dr Gareth 
Evans by replacing GFP in pEGFP-N1 with the FLAG tag sequence and pmCer-C1 
was a gift from Dr Rory Duncan (Herriot Watt University) (Rizzo et al, 2004). 
Glutathione-Sepharose, Ni
2+
-Sepharose and Protein G-Sepharose beads and peptides 
were purchased from GenScript (Piscataway, NJ). PreScission Protease was 
purchased from the Technology Facility in the Department of Biology, University of 
York. Protein ladders were purchased from BioRad (Hercules, CA). PVDF 
(Immobilon-P) was purchased from Millipore (Billerica, MA). The primary 
antibodies used for Western Blotting, immunocytochemistry and 
immunoprecipitation were α-PY20 from BD Bioscience (San Diego, CA), α-GFP 
serum; a kind gift from Dr Paul Pryor, University of York, α-FLAG (M2) from 
Sigma (St. Louis, MO), α-pY416 and α-pY527 from Cell Signalling Technology 
(Boston, MA) and α-N1-Src; custom made by GenScript (Piscataway, NJ). 
Secondary antibodies for Western Blotting were purchased from Sigma (St. Louis, 
MO). Secondary antibodies used for immunocytochemistry were α-mouse Alexa 
Fluor-564 and α-rabbit Alexa Fluor-488 and purchased from Molecular Probes, 
Invitrogen (Paisley, UK). The ECL used was Immobilon Western, purchased from 
Millipore (Billerica, MA). The phage display kit used was the Ph.D.-12 kit and was 
purchased from NEB (Ipswich, MA). Culture media (MEM and DMEM) and EBSS 
were purchased from GIBCO, Invitrogen (Paisley, UK). EcoTransfect was purchased 
from Oz Biosciences (Marseille, France) and the calcium phosphate transfection kit 
purchased from Promega (Fitchburg, WI). Recombinant L1-CAM extracellular 
domain was purchased from R&D Systems (Minneapolis, MN). All other materials 
were purchased from Sigma (St. Louis, MO).  
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2.2 Molecular biology protocols 
 
2.2.1 Agarose gel electrophoresis 
 
DNA separation was carried out using agarose gel electrophosesis. Agarose 
concentrations between 0.7 and 2% were used depending on the size of the DNA 
plasmid or fragment to be analysed. The appropriate amount of agarose was added to 
1x TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA) and dissolved using a 
microwave. 3 µl SYBRSafe was added to allow visualisation of DNA. The mixture 
was poured into a gel tray and allowed to set. Samples loaded onto agarose gels were 
diluted in 5X Orange G buffer (0.5% Orange G, 25% glycerol).  
 
2.2.2 Preparation of competent cells 
 
Competent Escherichia coli (E. coli) cells were either purchased (Stratagene) or 
produced in the lab using the CaCl2 method. For in-house production, 10 ml LB was 
inoculated with a small amount of competent cells and grown overnight with an 
appropriate antibiotic. The overnight culture was diluted into 150 ml fresh LB to an 
OD600 ~0.1 and grown at 37°C, shaking 200 rpm until the OD600 reached ~0.9. At 
this point the culture was immediately chilled in an ice bath. The culture was 
centrifuged at 5000 rpm, for 10 minutes at 4°C to pellet the cells. The supernatant 
was decanted, the pellet placed on ice and then resuspended in 100 ml ice cold 100 
mM MgCl2. The cells were pelleted and resuspended in 10 ml 100 mM CaCl2. The 
solution was incubated on ice for 60 – 90 minutes with occasional agitation. The 
cells were spun down, drained and resuspended in 9.5 ml 85 mM CaCl2, 15% 
glycerol. The cell suspension was distributed into 200 µl aliquots in sterile 
eppendorfs and snap frozen in liquid nitrogen. Competent cells were stored at -80°C.  
 
2.2.3 Bacterial transformation 
 
DNA plasmids were transformed into competent E.coli strain XL-10 for all cloning 
steps and strain BL-21 for protein expression. 5 μl of a ligation mix or 50 ng of a 
purified plasmid was added to 50 µl competent E. coli and incubated on ice for 15-
30 minutes. Heat shock was carried out for 45 seconds at 42°C. The mixture was 
returned to ice for 2 minutes and, following addition of 400 µl pre-warmed LB 
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media (10 g tryptone, 10 g NaCl, 5 g yeast extract per litre), incubated at 37°C, 
shaking at 200 rpm for 1 hour. 100 µl was then plated onto an agar plate containing 
an appropriate antibiotic and incubated at 37°C overnight.  
 
2.2.4 Plasmid purification 
 
Plasmid DNA was purified from transformed E. coli cultures, cultures inoculated 
with a single colony from an agar plate or a scraping from a pre-existing glycerol 
stock using commercially available kits. For culture volumes of 5 - 10 ml a mini 
prep kit was used (Machery-Nagal) and for volumes of 100 - 200 ml a midi prep kit 
was used (Qiagen). Purified plasmids were eluted in 10 mM Tris, pH 8.5 and stored 
at -20°C. DNA quantification was carried out by analysis of absorbance at A260 using 
a spectrophotometer.  
 
2.2.5 DNA ligation  
 
Ligation of annealed oligonucleotides into digested plasmids was carried out using a 
3:1 molar ratio of insert to vector. Standard ligations used 100 ng plasmid DNA and 
were carried out in a volume of 10 µl using 1 µl of DNA ligase. Ligation reactions 
were carried out overnight at 4°C or for 3 hours at room temperature. 
 
2.2.6 DNA Sequencing 
 
DNA sequencing was carried out in the Technology Facility at the University of 
York, Department of Biology. ~100 ng of a DNA plasmid was submitted and 
sequencing was carried out using 3.2 µM of an appropriate primer. Primers were 
either selected from the list of available primers or supplied along with the DNA. 
Analysis of the sequence obtained was carried out using Sequence Scanner 1.0.  
 
2.2.7 Cloning 
 
Plasmids were prepared for use in in vitro kinase assays and cell based assays by the 
inclusion of short (~50 bp) sequences. Appropriate oligonucleotide sequences were 
synthesised by Eurogentec and annealed in an annealing buffer (50 mM HEPES, pH 
7.4, 100mM NaCl) by heating to 95°C followed by stepped cooling to 4°C in 1 hour 
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in a PCR machine. Annealed oligonucleotides were inserted into DNA plasmids as 
described in sections 1.2.7.1 and 1.2.7.2. 
 
2.2.7.1 pGEX-6P-1 plasmid generation 
 
The plasmid containing the ideal Src substrate (Y) was generated by insertion of the 
relevant nucleotide sequence (Table 1.2.7.1.1) using the enzymes BamHI and EcoRI. 
All subsequent oligonucleotides were inserted into the ‘Y’ plasmid using the 
enzymes SalI and NotI (Figure 2.2.7.1.1). The oligonucleotides used were designed 
to retain the enzyme sites following insertion and therefore a 5 amino acid linker was 
retained between the ideal Src substrate and the SH3 domain binding motifs. The 
linker had the sequence Glu Phe Pro Gly Arg and consisted of the region of the 
pGEX-6P-1 multiple cloning site (MCS) between EcoRI and SalI as shown in Figure 
2.2.7.1.1. The enzymes that were used for the cloning were chosen because they 
allowed the disruption of the Class II PXXP motif contained within the pGEX-6P-1 
MCS. 
 
Figure 2.2.7.1.1. Cloning strategy for GST-tagged peptide generation. 
To produce the GST-tagged peptides for use in in vitro kinase assays relevant 
oligonucleotides were inserted into the pGEX-GP-1 plasmid. The ideal Src substrate 
(Y) was inserted into the pGEX-6P-1 multiple cloning site (MCS) using the enzymes 
BamHI and EcoRI. The SH3 domain binding motifs were inserted using the 
enzymes SalI and NotI. The oligonucleotides were designed to retain the enzyme 
sites and therefore the resulting plasmids retained a 5 amino acid linker between 
the ideal Src substrate and the SH3 domain binding motif. 
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~1 µg pGEX-6P-1 was digested in NEB Buffer EcoRI + BSA (BamHI, 
EcoRI double digest) or Buffer 3 + BSA (SalI, NotI double digest) for 1 hour at 
37°C. The DNA was separated using a 0.7% agarose gel and the digested plasmid 
extracted using a commercial gel extraction kit (Qiagen). Appropriate annealed 
oligonucleotides were ligated into the digested plasmids as described in section 
1.2.5. The products of the ligation reactions were transformed into competent E. coli 
strain XL-10 (Section 1.2.3). Clones containing the insert were identified by PCR 
screen using the primers 5’GGGCTGGCAAGCCACGTTTGGTG and 
5’CCGGGAGCTGCATGTGTCAGAGG. The cloning of the YL plasmid was 
carried out by Kathryn Hogan, under my supervision. Positive clones were isolated 
using a mini-prep kit (Machery-Nagal). The identity of the insert confirmed by DNA 
sequencing using the 5’GGGCTGGCAAGCCACGTTTGGTG. 
 
2.2.7.2 pmCer plasmid generation 
 
PD1 and PD1-P5A were inserted into the pmCer-C1 plasmid using the enzymes 
BglII and EcoRI. ~1 μg pmCer-C1 was digested in NEB buffer EcoRI + BSA for 1 
hour at 37°C. All subsequent steps were carried out as for pGEX-6P-1 plasmid 
generation. PCR screens were carried out the primers 
5’CATGGTCTTGCTGGAGTTCGTG and 5’GAAATTTGTGATGCTATTGC. 
DNA sequencing was carried out using the primer 
5’CATGGTCTTGCTGGAGTTCGTG. 
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Table 2.2.7.1.1 Oligonucleotide sequences inserted into pGEX-6P-1 for use in 
in vitro kinase assays.  
Oligonucleotides were annealed and then ligated into digested pGEX-6P-1. For 
plasmid ‘Y’, oligonucelotides were inserted using the enzyme sites BamHI and 
EcoRI. All other oligonucelotides were inserted into the ‘Y’ plasmid using the 
enzyme sites SalI and NotI.  
Name Primers 
Y 
Sense AATTCGGTGGCGGTGCAGAAGAGGAAATTTACGGTGAATTTGG 
Anti TCGAACAAATTCACCGTAAATTTCCTCTTCTGCACCGCCACCG 
YA 
Sense TCGACTCGGTGGCGGTGTGAGCCTGGCGCGTCGTGCGCTGGCAGCTCTGGCGTAAGC 
Anti GGCCGCTTACGCCAGAGCTGCCAGCGCACGACGCGCCAGGCTCACACCGCCACCGAG 
YP1 
Sense TCGACTCGTGAGCCTGGCGCGTCGTCCGCTGCCGCCGCTGCCGTAAGC 
Anti GGCCGCTTACGGCAGCGGCAGCGGACGCGCCAGGCTCACGAG 
YP2 
Sense TCGACTCGGTGGCGGTGCGCCGCCGCTGCCGCCGCGTAACCGTCCGCGTCTGTAAGC 
Anti GGCCGCTTACTGACGCGGACGGTTACGCGGCGGCAGCGGCGGCGCACCGCCACCGAG 
YL 
Sense TCGACTCGGTGGCGGTGCGTCCAAGCCTCAGACCCAGGGCCTGGCCAAGGATGCGGC 
Anti GGCCGCCGCATCCTTGGCCAGGCCCTGGGTCTGAGGCTTGGACGCACCGCCACCGAG 
PD1 
Sense TCGACTCGGTGGCGGTGCGTGGCATCGCATGCCGGCGTATACCGCGAAATATCCGGC 
Anti GGCCGCCGGATATTTCGCGGTATACGCCGGCATGCGATGCCAGCCACCGCCACCGAG 
PD2 
Sense TCGACTCGGTGGCGGTGCCGGCCATTGGCATAGCCCGCATAAACTGACCCGCAACGC 
Anti GGCCGCGTTGCGGGTCAGTTTATGCGGGCTATGCCAATGGCCCGCACCGCCACCGAG 
PD3 
Sense TCGACTCGGTGGCGGTGCCAAGAACCCGACCAGCACGCCGGCGATGTATGCGAACGC 
Anti GGCCGCGTTCGCATACATCGCCGGCGTGCTGGTCGGGTTCTTCGCACCGCCACCGAG 
PD4 
Sense TCGACTCGGTGGCGGTGCCGGCCATCGCAACCGCGCGAACACCAGCAAGAACCCGGC 
Anti GGCCGCCGGGTTCTTGCTGGAGTTCGCGCGGTTGCGATGGCCCGCACCGCCACCGAG 
PD5 
Sense TCGACTCGGTGGCGGTGCCAAACCGCCGCAGCATACCAGCGCGCCGTATCTGCCGGC 
Anti GGCCGCCGGCAGATACGGCGCGCTGGTATGCTGCGGCGGTTTCGCACCGCCACCGAG 
PD6 
Sense TCGACTCGGTGGCGGTGCCTGGCATCGCATGCCGATGCATACCGCGAAACCGCTGGC 
Anti GGCCGCCAGCGGTTTCGCGGTATGCATCGGCATGCGATGCCACGCACCGCCACCGAG 
PD1- 
R3A 
Sense TCGACTCGGTGGCGGTGGCTGGCATGCGATGCCGGCGTATACCGCGAAATATCCGGC 
Anti GGCCGCCGGATATTTCGCGGTATACGCCGGCATCGCATGCCAGCCACCGCCACCGAG 
PD1- 
P5A 
Sense TCGACTCGGTGGCGGTGGCTGGCATCGCATGGCAGCGTATACCGCGAAATATCCGGC 
Anti GGCCGCCGGATATTTCGCGGTATACGCTGCCATGCGATGCCAGCCACCGCCACCGAG 
PD1- 
T8A 
Sense TCGACTCGGTGGCGGTGGCTGGCATCGCATGCCGGCGTATGCTGCGAAATATCCGGC 
Anti GGCCGCCGGATATTTCGCAGCATACGCCGGCATGCGATGCCAGCCACCGCCACCGAG 
PD1- 
T8V 
Sense TCGACTCGGTGGCGGTGGCTGGCATCGCATGCCGGCGTATGACGCGAAATATCCGGC 
Anti GGCCGCCGGATATTTCGCGTCATACGCCGGCATGCGATGCCAGCCACCGCCACCGAG 
PD1- 
K10A 
Sense TCGACTCGGTGGCGGTGGCTGGCATCGCATGCCGGCGTATACCGCGGCGTATCCGGC 
Anti GGCCGCCGGATACGCCGCGGTATACGCCGGCATGCGATGCCAGCCACCGCCACCGAG 
 
Table 2.2.7.2.1 Oligonucleotide sequences inserted into pmCer-C1 for use in 
cell based assays.  
Oligonucleotides were annealed and then ligated into digested pmCer using the 
enzyme sites BglII and EcoRI.  
Name Primers 
PD1 
WT 
Sense GATCTGGCGGTGGCTGGCATCGCATGCCGGCGTATACCGCGAAATATCCGTAGTCG 
Anti AATTCGACTACGGATATTTCGCGGTATACGCCGGCATGCGATGCCAGCCACCGCCA 
PD1- 
P5A 
Sense GATCTGGCGGTGGCTGGCATCGCATGGCAGCGTATACCGCGAAATATCCGTAGTCG 
Anti AATTCGACTACGGATATTTCGCGGTATACGCTGCCATGCGATGCCAGCCACCGCCA 
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2.3 Protein expression and purification 
 
2.3.1 Protein expression 
 
10 ml of LB media containing an appropriate antibiotic was inoculated with either a 
single colony from an agar plate or a scraping taken from a pre-existing glycerol 
stock containing the relevant plasmid. This culture was incubated at 37°C, shaking at 
200 rpm, overnight. The overnight culture was transferred to 1 l LB media 
containing an appropriate antibiotic and grown at 37°C, shaking at 200 rpm, until the 
OD600 reached ~0.8. Protein expression was then induced by the addition of 
isopropyl-β-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The 
recombinant protein was expressed for 3-4 hours at 37°C or overnight at 18°C. The 
low temperature condition was only used for expression of active Src kinases. Cells 
were pelleted (4,500 rpm, 10 minutes, 4°C) and the pellets frozen overnight (-80°C). 
Bacterial pellets were defrosted on ice and resuspended in PBS plus PMSF (final 
concentration 1 mM) and lysozyme (13.3 mg/l of culture). The suspension was 
incubated on ice for 30 minutes. DTT (final concentration 5 mM) and Triton-X-100 
(1.5 % w/v) were added and the suspension sonicated at 10kHz on ice for a total of 
5 minutes 30 seconds (30 seconds on, 30 seconds off). The lysate was clarified 
(12,000 rpm, 30 minutes, 4°C). The clarified lysate was transferred to a clean tube 
and purified using affinity bead capture (section 2.3.2). 
 The extent of protein expression was assessed by separating ‘uninduced’ and 
‘induced’ samples on an SDS-PAGE gel.  
 
2.3.2 Purification of GST-tagged proteins 
 
Protein expression was carried out as in section 2.3.1. Glutathione-Sepharose beads 
(GenScript) (1 ml per litre of culture) were washed x3 in PBS, added to the clarified 
lysate and the tube incubated, rotating end-over-end at 4°C, for approximately 
4 hours. The beads were pelleted (5,000 rpm, 5 minutes, 4°C) and washed x5 in 
PBS, x1 in 1.2 M NaCl in PBS and x2 in PBS. The beads were then resuspended to a 
50% slurry in PBS and stored at 4°C overnight.  
 GST-fusion proteins were eluted from glutathione-sepharose beads using an 
excess of glutathione. Glutathione elution buffer (100 mM Tris, pH 8.0, 
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20 mM glutathione, 100 mM NaCl) was added to an equal volume of beads and 
rotated end-over-end at room temperature for 20 minutes. The beads were then 
pelleted and the supernatant collected. Fresh glutathione elution buffer was added 
and the process repeated until 4 elutions had been collected. The protein content of 
these elutions was analysed by Bradford assay and the purity of the protein by 
SDS-PAGE (section 2.4.1). The protein preparation was considered to be pure if it 
contained a single band of the correct molecular weight on a Coomassie stained 
SDS-PAGE gel. If all fractions were of a high concentration and pure then they were 
combined and the final concentration determined using Bradford assay. For use in in 
vitro kinase assays the proteins were dialysed into 100 mM Tris, pH 7.5 using a 
Slide-A-Lyzer cassette (Thermo Scientific). 
 
2.3.3 Preparation of active Src kinases  
 
Src kinases were expressed as GST-tagged fusion proteins and purified as described 
in sections 2.3.1 and 2.3.2. Src proteins were expressed as a fusion to the 
phosphatase PTP1B. A PreScission Protease site was engineered between PTP1B 
and Src and therefore active Src was obtained by treatment with PreScission 
Protease3C. 5 μl PreScission Protease3C (7 mg/ml) (Department of Biology, 
Technology Facility) was added to 500 μl Src bound glutathione-sepharose beads in 
500 μl PreScission Protease buffer (50 mM Tris, 100 mM NaCl, 1 mM EDTA, 1 
mM DTT, pH 8.0) and incubated, rotating end-over-end at 4°C, overnight. The beads 
were pelleted, the supernatant recovered and immediately diluted in an equal volume 
of kinase storage buffer (KSB) (50 mM Tris, 10 mM NaCl, 0.05 mM EDTA, 
1 mM DTT, 10% glycerol, 1 mg/ml BSA, 0.05% NP-40, pH 7.5). The solution was 
immediately aliquotted and stored at -80°C. The amount of kinase present and its 
purity was assessed by SDS-PAGE of a sample taken prior to the addition of KSB. 
The kinase preparation was considered to be pure if it contained a single band of the 
correct molecular weight on a Coomassie stained SDS-PAGE gel. A kinase assay 
with the control substrate (YA) was used to test the activity of the kinases and to 
normalise C-, N1- and N2-Src activity. 
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2.4 Protein based methods 
 
2.4.1 SDS-PAGE 
 
Protein separation was carried out by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) using a Bio-Rad mini Protean Tetra gel electrophoresis kit. Resolving 
gel composition; 375 mM Tris pH 8.8, 0.1 % SDS, 0.05% APS, 0.01% TEMED with 
an appropriate acrylamide concentration depending on the size of the protein to be 
examined. Stacking gel composition; 125 mM Tris, pH 6.8, 0.1% SDS, 
4% acrylamide, 0.05% APS, 0.01% TEMED. Protein samples were diluted in 
2x Laemmli loading buffer and boiled for 5 minutes prior to loading. Gels were run 
at 120 V for approximately 20 minutes until the dye front passed through the staking 
gel and then at 160 V until the dye front reached the bottom of the gel. Running 
buffer composition; 25 mM Tris, 192 mM glycine, 0.1% SDS. A ladder of protein 
standards was used (BioRad). Gels were either stained in Coomassie 
(0.3% Coomassie Brilliant Blue R, 55% methanol, 9% acetic acid) followed by 
destaining in 14% acetic acid, 7% methanol or transferred to PVDF for 
immunoblotting (Section 1.4.2).  
 
2.4.2 Transfer to PVDF and Western Blotting 
 
SDS-PAGE gels were transferred to PVDF using the BioRad transfer system. 
Transfer was carried out at 66 V for 1 hour or at 20 V overnight. Following transfer 
membranes were blocked in either 5% Marvel or 3% BSA in PBS (1.4.2.1). Primary 
antibodies were used as indicated in Table 1.4.2.1 for approximately 2 hours at room 
temperature or overnight at 4°C. Following the application of primary antibody, 
membranes were washed x3 (5 minutes each) in PBS. Secondary antibodies used 
were conjugated to HRP and were used as indicated in Table 1.4.2.1 for 
approximately 1 hour at room temperature. Following the secondary antibody 
application, membranes were washed x3 (10 minutes each) in PBS. ECL reagents 
were either made in the lab (Solution A: 0.1 M Tris, 450 µg/ml luminol, pH 8.5. 
Solution B: 0.1 M Tris, 0.06% H2O2, pH 8.5) or purchased and detection was carried 
out using photographic film (Fisher). 
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Table 2.4.2.1 Antibodies used for Western Blotting.  
Conditions used for blocking, primary antibody and secondary antibody application 
to PVDF membranes. 
 
Primary antibody Secondary antibody 
Ab Block Conc. Buffer Ab Conc. Buffer 
PY20 
3 % BSA in 
PBS 
1:1000 PBS 
α-mouse 
HRP 
1:500 PBS 
pY416 
3 % Marvel 
in PBS 
1:1000 
PBS, 0.1%  
Tween-20, 5% BSA 
α-rabbit 
HRP 
1:500 
PBS + 0.1 % 
Tween20 
pY527 
3 % Marvel 
in PBS 
1:1000 
PBS, 0.1%  
Tween-20, 5% BSA 
α-rabbit 
HRP 
1:500 
PBS + 0.1 % 
Tween20 
FLAG 
(M2) 
5% Marvel 
in PBS 
1:1000 
PBS + 0.1 % 
Tween20 
α-mouse 
HRP 
1:500 
PBS + 0.1 % 
Tween20 
GFP 
5% Marvel 
in PBS 
1:500 
PBS + 0.1 % 
Tween20 
α-rabbit 
HRP 
1:500 
PBS + 0.1 % 
Tween20 
N1-Src 
5% Marvel 
in PBS 
As 
indicated 
PBS + 0.1 % 
Tween20 
α-rabbit 
HRP 
1:500 
PBS + 0.1 % 
Tween20 
 
 
2.4.3 In vitro kinase assays 
 
In vitro kinase assays were carried out in 100 mM Tris, 10 mM MgCl2, pH 7.5. The 
reaction was carried out at 30°C and initiated by the addition of 0.5 mM ATP final 
concentration. Kinase assays to obtain kinetics were carried out using a kinase 
concentration of 5 nM and a duration of 90 minutes. Substrate concentrations were 
altered as indicated in the text. In kinase assays where the kinase concentration was 
varied, a substrate concentration of 25 µM and a duration of 90 minutes was used. 
The kinase concentration was varied as indicated in the text. For timecourse 
experiments the kinase concentration was 5 nM and the substrate concentration 
25 µM. Samples were taken at timepoints as indicated in the text. Assays were halted 
by transfer to ice and immediate addition of 2x Laemmli buffer (Sigma). 10% of the 
assay mix was loaded onto a 15% SDS-PAGE gel followed by transfer to PVDF for 
analysis of substrate phosphotyrosine content by Western Blot. All experiments were 
carried out 3 times. 
 For peptide titration experiments a kinase concentration of 5 nM and a 
substrate concentration of 25 µM was used. The substrate used was YA. Free 
peptides of PD1-WT (CWHRMPAYTAKYP) and PD1-P5A 
(CWHRMAAYTAKYP) were synthesised commercially. Individual kinase assays 
Chapter 2 
 
65 
containing increasing peptide concentrations were set up. The peptide concentrations 
used were 1, 5, 10, 25, 50, 75 and 100 µM. Assays were carried out at 30°C for 90 
minutes before analysis as previously described.  
 For analysis of kinetics identical substrate concentrations phosphorylated by 
all 3 kinases were loaded onto the same blot. A standard sample was included on all 
blots. Densitometry of the blots was analysed using ImageJ and normalisation to the 
standard sample used to reproduce the entire curve. Densitometry of stained 
Coomassie gels was used to normalise protein levels. Phosphorylation by each of the 
kinases was therefore directly comparable. The highest value obtained by 
densitometry analysis was set to 1 and all other values scaled accordingly. The 
kinetics of the phosphorylation reaction were then calculated using SigmaPlot 
according to the laws of Michaelis-Menton kinetics. The densitometry data from the 
3 independent experiments was used to calculate the Km. 
 
2.4.4 Immunoprecipitation 
 
75 cm
2
 flasks containing a confluent layer of COS7 cells (approximately 3 x 10
6
 
cells) transfected with the appropriate plasmids (see section 1.5.2) were lysed in ice 
cold lysis buffer (20 mM Tris, pH 7, 1 mM EDTA, 1 mM EGTA, 10 mM 
sodium-β-glycerophosphate, 1 mM sodium-orthovanadate, 5% w/v glycerol, 
270 mM sucrose, 1 mM benzaminidine, 0.1% β-mercaptoethanol, 10 μg/ml 
leupeptin) 48 hours following transfection. Lysates were centrifuged (13,000 rpm, 
1 minute, 4°C) to pellet debris. Clarified lysates were then pre-cleared using 50 μl 
(settled volume) washed Protein-G-sepharose beads. 1 mg cell lysate, the appropriate 
antibody (2 µg α-FLAG or 4 µl α-GFP containing serum) and 30 μg washed 
Protein-G-sepharose beads were made up to a total volume of 1 ml and incubated at 
4°C, rotating end-over-end, for at least 4 hours or overnight. Beads were washed x3 
in ice cold lysis buffer. Bound proteins were eluted in 50 μl 2x Laemmli buffer and 
analysed by SDS-PAGE.  
 
2.4.5 Phage display 
 
Phage display experiments were carried out using the Ph.D.™-12 Phage Display 
Peptide Library Kit according to the manufacturer’s instructions. 25 µl (settled 
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volume) glutathione-sepharose beads were washed x1 in 1ml TBS (50 mM Tris, 
150 mM NaCl, pH 7.5) + 0.1% Tween20 (TBST). Beads were pelleted, the 
supernatant carefully removed and then resuspended in 1 ml blocking buffer (0.1 
M NaHCO3, 5 mg/ml BSA, 0.02% NaN3, pH 8.6) and incubated for 60 minutes at 
4°C, rotating end-over-end. During the incubation a 100-fold representation of the 
phage library (2 x 10
11
 plaque forming units (pfu)) was incubated with 1 µM final 
concentration of GST-N1-Src SH3 domain in 200 µl total volume TBST. Following 
blocking, the beads were washed x4 in 1 ml TBST. The GST-N1-Src-SH3 solution 
was then transferred into the tube with the washed beads and incubated at room 
temperature for 15 minutes, rotating end-over-end. The beads were pelleted, the 
supernatant removed and the beads washed x10 in TBST. Bound phage were eluted 
in 1 ml of Glycine Elution Buffer (0.2 M Glycine-HCl, pH 2.2, 1 mg/ml BSA) with a 
10 minute incubation at room temperature, rotating end-over-end. The beads were 
pelleted and the supernatant transferred to a clean eppendorf. The eluate was 
neutralised with 150 μl of 1 M Tris, pH 9.1.  
A small amount of the eluate was titreed as described in section 1.4.5.1. The 
remaining eluate was amplified by addition to 20 ml E. coli strain ER2738 at early 
log phase (OD600 0.01–0.05) and incubation at 37°C, shaking at 200 rpm for 
4.5 hours. Amplification was carried out either on the same day as phage binding or 
the next day following overnight incubation of the eluate at 4°C. Following 
amplification the culture was pelleted by spinning at 12,000 g for 10 minutes at 4°C. 
The supernatant was then transferred to a clean tube and spun again. The top 80% of 
the supernatant was transferred to a fresh tube and 1/6 of the volume of 20% PEG, 
2.5 M NaCl added. The phage were allowed to precipitate at 4°C either for 2 hours 
or overnight. The PEG precipitation was spun at 12,000 g for 15 minutes at 4°C and 
the supernatant removed. The pellet was resuspended in 1 ml TBS, the solution 
transferred to a clean eppendorf and spun at 13,000 rpm for 5 minutes at 4°C to 
pellet residual cells. The supernatant was transferred to a clean eppendorf and 
reprecipitated with 1/6 volume of 20% PEG, 2.5 M NaCl for 60 minutes on ice. The 
solution was spun at 13,000 rpm for 10 minutes at 4°C. The supernatant was 
removed, the tube respun briefly and any remaining supernatant removed. The pellet 
was resuspended in 200 µl TBS, spun at 13,000 rpm to remove any remaining 
insoluble material and transferred to a clean tube. This is the amplified eluate. A 
small amount of the amplified eluate was titreed as described in section 1.4.5.1.  
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 Some of the remaining amplified eluate was used for a subsequent round of 
panning. From round 2 onwards the Tween20 concentration in all washing steps was 
increased to 0.5%. A negative selection step was introduced to remove phage bound 
directly to the beads. 25 µl beads (settled volume) were washed and blocked as 
previously described. The amplified eluate containing the phage library was diluted 
in 200 µl TBST as previously but the GST-N1-Src-SH3 domain was excluded. The 
correct volume of amplified eluate was calculated from the results of the titreing so 
that it contained 2 x 10
11 
phage (see section 1.4.5.1). The phage solution was added 
to the washed beads and incubated for 15 minutes at room temperature, rotating end-
over-end. The beads were pelleted, the supernatant carefully removed and added to 
GST-N1-Src SH3 domain to produce a final target concentration of 1 µM. Panning 
steps were then continued as previously described. A total of 5 rounds of panning 
were performed.  
 
2.4.5.1 Phage titreing  
 
10 ml LB was inoculated with E. coli strain ER2738 either from a glycerol stock 
scrape or a single colony from an LB-Agar plate and grown until mid-log phase 
(OD600 ~ 0.5). Unamplified phage were serially diluted 10
1 – 104 and amplified 
phage diluted 10
8
 – 1011 in 1 ml final volumes. When the ER2738 culture reached 
mid-log phase, 200 µl aliquots were dispensed into sterile eppendorfs, one for each 
phage dilution required. 10 µl of each phage dilution was added to a tube, vortexed 
briefly and incubated at room temperature for up to 5 minutes. The infected cells 
were added, one aliquot at a time, to 3 ml aliquots of TopAgar (10 g Tryptone, 
5 g yeast extract, 5 g NaCl, 7 g Agar per litre), vortexed briefly and poured 
immediately onto a prewarmed LB/IPTG/Xgal plate. The plates were allowed to cool 
at room temperature until the TopAgar had set and then inverted and incubated 
overnight at 37°C. The next morning, blue plaques were counted. The phage plasmid 
(M13) contains the β-galactosidase gene, so growth on IPTG containing plates meant 
phage plasmid containing plaques were coloured blue. White plaques were present 
due to contaminating wild type phage and were not counted. 
 Plates from unamplified phage titreing were used for sequencing (see section 
1.9.2). Plates from amplified phage titreing were used to calculate the eluate volume 
needed to add to the next round of panning. The number of blue plaques on the 
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plates were counted. On plates with approximately 100 plaques, the number of 
plaques was multiplied by the dilution factor to calculate the number of pfu per 
10 µl. This number was then used to calculate the volume that contained the 2 x 10
11
 
phage needed for the next round of panning.  
 
2.4.5.2 Preparation of phage clones for sequencing 
 
Phage plasmids were sequenced from round 3 onwards. An overnight culture of 
E. coli ER2738 was diluted 1:100. 1 ml of diluted culture was dispensed into 15 ml 
falcon tubes, one for each clone to be sequenced. Individual blue plaques were 
picked from unamplified titre plates with approximately 100 plaques using sterile 
pipette tips and the tips dropped into the diluted culture. The tubes were incubated at 
37°C, shaking 200 rpm for 4.5 hours. The cultures were transferred to eppendorfs 
and spun at 13,000 rpm for 30 seconds at 4°C. 500 µl of the supernatant was 
transferred to a fresh eppendorf tube. 200 μl of 20% PEG, 2.5 M NaCl was added, 
inverted to mix and incubated for 10 - 20 minutes at room temperature. The solution 
was spun at 13,000 rpm for 10 minutes at 4°C and the supernatant discarded. The 
pellet (not always visible) was resuspended Iodide Buffer (10 mM Tris, 
1 mM EDTA, 4M NaI, pH 8.0), 250 µl ethanol added and incubated for 
10 - 20 minutes at room temperature. The solution was spun at 13,000 rpm for 
10 minutes at 4°C and the supernatant discarded. The pellet was washed with 0.5 ml 
70% ice-cold ethanol, re-spun, the supernatant was removed and the pellet allowed 
to air dry. The pellet was then resuspended in 30 µl TE buffer (10 mM Tris, 1 
mM EDTA, pH 8.0). Prior to sequencing, the presence of an insert was confirmed by 
PCR. Primers either side of the peptide insert site were designed (Forward: 
5’
ACCGATACAATTAAAGGCTC and Reverse: 
5’
CCCTCATAGTTAGCGTAACG). A band of 259 bp represented the presence of 
the 12-mer inserts and a band of 214 bp represented an empty phage plasmid. Clones 
shown to contain the 12-mer peptide insert were sequenced in the Technology 
Facility at the University of York using the primer 
5’
CCCTCATAGTTAGCGTAACG as suggested by NEB. 
 
2.5 Cell culture methods 
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2.5.1 Culture of cell lines 
 
COS7 cells were maintained in culture in 25 cm2 or 75 cm2 flasks. The culture medium 
was DMEM with pyruvate, high glucose and glutamine, 10 % FCS, 100 units/ml 
penicillin and 0.1 mg/ml streptomycin. Cells were passaged and split 1:3 as they 
reached confluency, approximately 3x per week. Cells were detached from the 
culture flask with 1 ml pre-warmed trypsin/EDTA. The action of trypsin was halted 
by the addition of culture medium. Cells were spun at 1000 rpm for 5 minutes. The 
supernatant was discarded and cells resuspended in 1 ml culture medium. If required 
for plating, cells would be counted using a haemocytometer and plated at a density 
of 3 x 10
4
 cells per 13 mm coverslip in a 24 well plate. Coverslips were sterilised in 
an oven prior to use. Cells were maintained at 37°C in a humidified atmosphere of 5 % 
CO2 and 95% air. 
 
2.5.2 Transient transfection of cell lines 
 
Cells were plated as described in section 1.5.1. The following day cells were 
transfected using EcoTransfect (Oz Biosciences) according to the manufacturer’s 
instructions. Single transfections were carried out using 1 µg plasmid DNA and 2 µl 
EcoTransfect each in 50 µl DMEM. Double transfections were carried out using 
1 µg of each plasmid and 4 µl EcoTransfect, both in 50 µl DMEM. The two 
solutions were mixed and incubated at room temperature for 15 minutes before 
pipetting into a well of a 24 well plate containing 500 µl media. The plate was then 
returned to the incubator. For transfection of more than one well volumes and 
amounts were scaled accordingly. For all Western Blotting and 
immunocytochemistry experiments COS7 cells were transfected for 48 hours. For 
immunoprecipitation experiments, 1 x 10
6
 cells were added to a 75 cm
2
 flask and 
co-transfected the following day with 7.5 µg of each plasmid and 30 μl 
EcoTransfect, each in 300 µl DMEM. 
 COS7 cells transfections were carried out using the following constructs. C-, 
N1- and N2-Src constructs were contained in the pFLAG-N1 vector and visualised 
using an α-FLAG antibody. The cloning of the FLAG tagged Src constructs was 
carried out by Kathi Mahal under the supervision of Dr Chris Dunning in the Evans 
lab. PD1 and PD1-P5A constructs were contained within the pmCer-C1 vector and 
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visualised using an α-GFP antibody. Details of the cloning carried out to produce 
PD1 and PD1-P5A constructs are found in section 2.2.7.2 See section 2.5.6 for 
details of antibody application.  
 
2.5.3 Preparation of CGN neurons 
 
Preparation of cerebellar granule neurons were carried out essentially as described 
previously (Tan et al, 2003). P7 Wistar rat pups were killed using a single lethal 
pentobarbital injection. Cerebellar were dissected and placed in filter sterilized 
solution B (100 mM PBS, 0.3 % BSA, 10 mM glucose, 0.38 % MgSO4.7H2O. The 
cerebellar were finely chopped using a razor blade and the diced tissue then 
incubated in trypsin (4 mg/ml) in solution B at 37°C for 15 - 20 minutes with 
agitation every 5 minutes. The action of trypsin was halted by the addition of 
solution W (solution B plus 0.5 mg soybean trypsin inhibitor and 500 units DNAase 
I). The tissue solution was spun at 1000 g for 1 minute and the supernatant 
discarded. The pellet was resuspended in solution C, a 6x concentrated solution W, 
and the cells mechanically dispersed by triturating through flamed glass pipettes of 
decreasing bore size. The resulting single cell suspension was centrifuged through 
4 % BSA in EBSS to remove debris. The pellet was resuspended in MEM culture 
medium (MEM without Ca
2+ 
and Mg
2+
, 25 mM KCl, 10 % FCS, 30 mM glucose, 
1 mM glutamine, 25 mM NaHCO3, 100 units/ml penicillin, and 0.1 mg/ml 
streptomycin).  
 Cell yield was calculated using a haemocytometer and the cells plated onto 
poly-D-lysine coated 13 mm coverslips. Coverslips were prepared by first soaking in 
ethanol for ~2 hours, sterilising in an oven for at least 3 hours and then incubating in 
sterile poly-D-lysine (15 mg/l) for 2 hours at room temperature. Coverslips were 
allowed to air dry, placed into the wells of a 24 well plate and allowed to dry 
completely overnight at 37°C. Cells were plated at a density of 2.5 x 10
5
 cells per 
coverslip and transfected 24 hours following plating (section 1.5.5), following 
transfection cells were grown in MEM culture medium plus 10 µM final 
concentration arabinofuranosyl cytidine (AraC) (+ media) for 24 hours before fixing 
for morphological analysis. Cells were maintained at 37°C in a humidified 
atmosphere of 5 % CO2 and 95% air.  
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2.5.4 Preparation of hippocampal neurons 
 
Preparation of hippocampal neurons was carried out by Dr Sangeeta Chawla 
(University of York). Hippocampal neurons were prepared from newborn Wistar rats 
as described previously (Belfield et al, 2006), and cultured in Neurobasal medium 
(Invitrogen) containing 2% B27 (Invitrogen), 5% foetal calf serum (PAA Lab, 
Pasching, Austria), 1 mM L-glutamine, 35 mM glucose, 100 units/ml penicillin, and 
0.1 mg/ml streptomycin (Invitrogen).  
 
2.5.5 Transfection of neuronal cultures 
 
Neuronal cultures were transfected using a calcium phosphate transfection kit 
(Promega) according to the manufacturer’s instructions. The culture medium was 
removed, replaced with 500 µl prewarmed MEM and incubated for 30 minutes at 
37°C. Meanwhile, 0.5 µg plasmid DNA was mixed with 12.5 µl 2.5M CaCl2 and 
made up to 100 µl with ddH2O. 100 µl HBS (HEPES buffered saline) was added to a 
second tube and the DNA mix added dropwise while vortexing. The mixture was 
incubated for 30 minutes in the dark, then added to the cells and incubated for 
45 minutes. The media was removed and the cells washed twice with prewarmed 
MEM before the media was replaced with + media. Unless otherwise stated, all 
neuronal transfections were carried out for 24 hours before the cells were fixed for 
morphological analysis.  
 
2.5.6 Immunocytochemistry 
 
Transfected cells were cultured in 24 well plates containing 13 mm coverslips as 
described in sections 2.5.1 and 2.5.2. The culture media was removed and cells 
washed x3 in PBS. Cells were fixed in 4% paraformaldehyde (PFA) or 4% PFA, 4 
% sucrose for 20 minutes at room temperature and then washed x3 in PBS. Cells 
were permeabilised and blocked in 0.1% Triton-X-100, 1% BSA in PBS for 30 
minutes at room temperature. Primary antibodies were applied in 1% BSA in PBS 
for approximately 2 hours at room temperature. α-FLAG (M2) (mouse) was used at 
1:1000 and α-GFP serum (rabbit) (to detect CFP transfected cells) was used at 1:500. 
Cells were washed x3 in PBS. Secondary antibodies were applied at 1:500 in 
1% BSA in PBS for approximately 1 hour in the dark. Secondary antibodies used 
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were α-mouse Alexa Fluor-568 and α-rabbit Alexa Fluor-488. Cells were washed x3 
in PBS and x1 in dH20. Coverslips were removed from wells, allowed to dry and 
mounted onto microscope slides using Mowial (0.2 M Tris, pH 8.5, 12 % 
w/v Mowial, 33.3 % w/v glycerol). 
 Images were acquired using a 40x objective on the Nikon TE 200 
epifluorescence inverted microscope using a RoleraXR CCD (QImaging) camera 
controlled by SimplePCI Software (Hamamatsu). 
 
2.5.7 L1-CAM neurite outgrowth assay 
 
Coverslips were prepared as described in section 1.5.3. Prior to cell plating, a 10 µl 
spot containing L1-CAM extracellular domain at 25 µg/ml and fluorescein 
isothiocyanate (FITC) at 1 mg/ml was pipetted onto the centre of a poly-D-lysine 
coated coverslip. The spot was allowed to air dry for approximately 1 hour or until 
completely dry. CGNs were plated as described in section 1.5.3, transfected as 
described in section 1.5.5 and fixed for morphological analysis (section 1.5.8) 
24 hours after transfection. 
 The constructs transfected into neuronal cultures were the same as those 
transfected into COS7 cells and are detailed in section 2.5.2. 
 
2.5.8 Morphological analysis using ImageJ 
 
Image analysis was carried out using ImageJ. To measure cell area, the outline of a 
cell was traced using the freehand tool and the area of the shape was calculated. A 
calibration image was used to allow calculation in µm
2
. The NeuronJ plugin 
(Meijering et al, 2004) was used for the calculation of neurites in both COS7 cells 
and neurons. Neurites were traced using the ‘add tracings’ tool.  
For neurons, the neurite was categorised according to whether it was an axon, 
a dendrite or a branch based on morphology. An axon is a process originating from 
the cell body and measuring over 50 µm for CGNs and over 300 μm for 
hippocampal neurons. The measured parameter ‘axon length’ refers to the length of 
the primary axon originating from the cell body and does not include the length of 
branches or dendrites. A branch is a neurite that does not originate from the cell 
soma and instead originates from an axon or dendrite, branches must measure more 
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than 10 μm. Dendrites are defined as processes longer than 10 μm and less than 
40 µm originating from the cell soma, typically from the opposite pole to the axon. 
For hippocampal neurons the parameter ‘total neurite length’ refers to the total 
length of all axons, branches and dendrites measured. The traced neurites were 
measured using a calibration image to set the scale for calculation. Data for each cell 
were compiled in Microsoft Excel and averaged for statistical analysis.  
 
2.6 Bioinformatics 
 
Bioinformatic analysis was carried out using web based bioinformatic programmes. 
All data collected was collated using Microsoft Excel.  
 
2.6.1 Scansite 
 
A position site scoring matrix (PSSM) was constructed for the binding preferences 
of the N1-Src SH3 domain (experimental data obtained in this study) and the C-Src 
SH3 domain (Sparks et al, 1996) according to the directions of (Obenauer et al, 
2003). A score was assigned to each amino acid representing the probability of 
finding it in each position of the consensus motif. Scores were in the range of 0 to 
21. A score of 0 meant a residue was excluded from that position and a score of 21 
meant that a residue must be found in a certain position. Scores of 1 – 20 represented 
an increasing likelihood of finding an amino acid in a position. Within the matrix, 
the residue at position 0 was fixed (given a score of 21) and residues varied 7 
residues either side of it. In this study the proline residue in N1-Src SH3 domain 
consensus and the first P of PxxP in the C-Src SH3 domain consensus were chosen 
as the fixed residues. As the peptides used in the phage display experiments were 
12-mers, there were 4 residues in the PSSM (positions -7 to -4) for which there were 
no input data. For these positions a score of 1, representing neither a positive or 
negative preference, was selected.  
 The PSSM was used to carry out a database search of proteins in the human 
genome containing the input motif. User defined input motifs are carried out with a 
medium degree of stringency by default and return protein hits in the top 5% of those 
examined.  
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 Scansite output orders protein hits according to how well they fit the 
consensus motif and identifies them by their UNIPROT ID as well as their full name.  
 
2.6.2 DAVID 
 
Protein hits from Scansite analysis were entered into the DAVID database (Huang et 
al, 2009b) as UNIPROT IDs. DAVID analysis was carried out using 
GOTERM_BP_ALL as the Gene Ontology term (where BP stands for Biological 
Process). The Functional Annotational Clustering tool was then used to identify the 
biological processes that were enriched i.e. present more than would be expected 
based on their prevalence in the genome. An enrichment factor cut off of 1.5 was 
enforced (Huang et al, 2009b). Proteins within enriched clusters were exported from 
DAVID identified by UNIPROT IDs. 
 
2.6.3 GPS 
 
GPS (Xue et al, 2008) requires that input sequences are in FASTA format. 
UNIPROT IDs were converted to Accession numbers using the DAVID ID 
conversion tool (Huang et al, 2008a). The Accession numbers were entered into 
NCBI using the batch entry function to obtain FASTA sequences for all proteins. 
GPS analysis was carried out using high stringency criteria, producing a maximum 
false positive rate of 4% (Xue et al, 2008). GPS was used to predict phosphorylation 
sites for all available tyrosine kinases. The output was transferred to Microsoft Excel 
and individual proteins were assessed for both predicted tyrosine phosphorylation 
and predicted SFK phosphorylation. Subsequently, all proteins predicted to be SFK 
phosphorylated were entered into GPS and prediction of phosphorylation by 
individual SFK members carried out. These were analysed individually in Microsoft 
Excel.  
 
2.6.4 PhosphoSite 
 
UNIPROT IDs of proteins predicted to be Src phosphorylated were entered into the 
PhosphoSite database (Hornbeck et al, 2004). Residues with evidence of tyrosine 
phosphorylation were collated in Microsoft Word and compared to sites predicted to 
be phosphorylated by GPS. Proteins were included in the final list of putative N1-Src 
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substrates if there was evidence in the PhosphoSite database for phosphorylation at 
the same site as was predicted by GPS. 
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3 In vitro characterisation of N-Src activity and substrate 
specificity.  
 
3.1 Introduction 
 
3.1.1 Methods for assessing tyrosine kinase activity 
 
The activity of a tyrosine kinase can be investigated either by assessing the 
activation state of the kinase itself or by monitoring the phosphorylation of a 
substrate. These experiments can be carried out either in cell based or in vitro assays 
and multiple methods of both forms have been developed to investigate the functions 
of SFKs.  
 Early experiments using a total Src antibody identified Src localised to 
endosomes and the trans-Golgi network using specific markers and was also present 
diffuse in the cytoplasm (Kaplan et al, 1992). In contrast, constitutively active Src 
was primarily localised to focal adhesions at the plasma membrane, but again had 
some diffuse cytoplasmic staining (Kaplan et al, 1994). These studies gave no 
information, however, about the activation state of the kinase enzymes in these 
different locations. Subsequent studies used overexpression of GFP-Src co-stained 
with an antibody against active, autophosphorylated Src (pY416) and this revealed 
that inactive Src is predominantly localised in the perinuclear area while active Src is 
found predominantly at the plasma membrane (Sandilands et al, 2004). Cytoplasmic 
Src is predominantly inactive with some active puncta (Sandilands et al, 2004). 
These puncta are thought to be active Src attached to the membrane of vesicles being 
trafficked to the plasma membrane (Sandilands et al, 2007). Cell based studies of 
SFK activity therefore revealed that tyrosine kinase signalling is regulated by the 
activity state of the kinase enzymes themselves but also by their subcellular 
localisation. 
 It is more challenging to measure substrate phosphorylation attributed to 
specific kinases in cell based assays. Cells express multiple kinases and proteins are 
often phosphorylated on more than one site. The opposing action of phosphatases 
also makes kinetic analysis of substrates in cells difficult. Therefore, a number of in 
vitro methods have been developed to closely monitor substrate phosphorylation by 
individual kinases.  
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 The identification of Src substrates allowed monitoring of substrate 
phosphorylation in vitro and therefore assessment of the effect of Src manipulation. 
Enolase is phosphorylated at a single residue by SFKs both in cells and in vitro 
(Cooper et al, 1984). This made it a useful tool for the study of Src function as many 
Src substrates are phosphorylated at multiple sites, making the assessment of kinetics 
less simple. Phosphorylation of enolase was used to confirm that the kinase activity 
of v-Src is higher than that of C-Src (Courtneidge, 1985), as a model substrate to 
assess Src activity (Golden et al, 1986) and has been used multiple times since.  
The mapping of the specific residues phosphorylated by tyrosine kinases in 
substrate proteins allowed the development of peptide assays that could specifically 
monitor the phosphate incorporated into a particular residue. Work by Bruce Kemp 
was crucial in developing these methods and assessed phosphorylation of peptides 
derived from chicken egg white lysozyme to determine the importance of primary 
sequence in phosphorylation by the serine/threonine kinase PKA (Kemp et al, 1976; 
Kemp et al, 1977). Subsequently, Casnellie et al (1982) used the amino acid 
sequence surrounding Y416, the site of Src autophosphorylation, to carry out the 
first assessment of peptide phosphorylation by Src. The main drawback to these 
methods was that the kinases used were derived from crude cell lysates as methods 
to recombinantly express kinases had not yet been developed.  
 The development of methods for the recombinant expression of kinases 
allowed more in-depth analysis of phosphorylation events. Expression of kinases in 
standard bacterial expression systems is toxic because bacterial genomes do not 
contain eukaryotic-like tyrosine kinases. Expression of tyrosine kinases in these 
systems therefore causes aberrant phosphorylation and activation of signalling 
pathways. A number of methods have now been developed to allow the expression 
and purification of active SFKs and these all involve a method to restrict the kinase 
activity during expression. Caspers et al (1994) overexpressed bacterial chaperones 
to enable the preparation of soluble Csk, Fyn and Lck from E. coli. Sicheri et al 
(1997) used Spodoptera fruguperda (Sf9) cells that were co-infected with 
baculoviruses expressing Hck and Csk to obtain pure, active Hck. Csk constitutively 
phosphorylates Y527 in the SFK C-terminal tail, promoting an inactive 
conformation. Wang et al (2006) created a vector that expresses Src as a fusion 
protein with maltose binding protein (MBP) and the phosphatase PTP1B. The 
phosphatase can dephosphorylate Src at Y416, promoting the inactive state of the 
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kinase, and can also dephosphorylate any aberrant bacterial protein phosphorylation 
that does occur. A thrombin cleavage site between PTP1B and Src allowed 
purification of isolated, active Src. A similar method has been employed in the 
Evans lab, with the cloning carried out by Dr Chris Dunning. A vector was created 
that expresses Src as a fusion protein with GST and PTP1B (Figure 3.5.1 A). A 
PreScission Protease site was engineered between PTP1B and Src and the resulting 
active Src protein retains a His-tag. The constructs used are Δ80 truncations and lack 
the first 80 residues of the Src sequence; the unique domain. This region is primarily 
involved in regulating the subcellular localisation of the kinases and is not required 
for kinase activity. Recently, Marin et al (2010) obtained active N1-Src kinase using 
low temperature expression alone. It is not clear how this was achieved as many 
other groups have reported the low temperature bacterial expression of SFKs to be 
toxic.  
 The elucidation of the consensus sequences for the domains of Src allowed 
detailed kinetic analysis of phosphorylation events mediated by pure preparations of 
kinases. Songyang et al (1995a) identified AEEEIYGEF as the consensus motif for 
the Src kinase domain. This sequence has now been used multiple times to assess 
substrate phosphorylation by Src both in cells (Graness et al, 2000) and in vitro. The 
versatility of peptide systems allowed the investigation of how the intramolecular 
associations of SFKs influence substrate specificity and kinase activity. Pellicena et 
al (1998) used peptide substrates to assess how the phosphorylation of an ideal 
substrate was affected by the additional ability of the substrate to bind to the SH2 
domain. They found a 10-fold increase in substrate phosphorylation when SH2 
domain binding could occur. Subsequent work from the same lab (Scott & Miller, 
2000) showed that the presence of a SH3 domain binding motif resulted in a 3-fold 
decrease in the Km of phosphorylation of the ideal substrate. 
 These studies all used isolated peptides and monitored the incorporation of 
phosphate using 
32
P. Peptides were either separated from free 
32
P by HPLC followed 
by scintillation counting or by dotting onto phosphocellulose paper followed by 
autoradiogram analysis. The use of GST-tagged peptides (Kim et al, 1999) allows 
their resolution by SDS-PAGE before 
32
P detection by autoradiogram.  
 To avoid the use of 
32
P other groups have developed spectrophotometric 
techniques. The advantage of this is that the phosphate incorporation can be 
monitored continuously. Barker et al (1995) developed a spectrophotometric assay 
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based on the conversion of NADH to NAD
+
 and the corresponding change in 
absorbance. Development of a similar assay was attempted in the course of this study 
but was demonstrated to be prone to artefactual results and was not sensitive enough 
to detect the changes in substrate affinities required.  
 Another alternative to the use of 
32
P is to assess phosphate incorporation 
using a phosphotyrosine antibody and detection using Western Blotting. The 
development and characterisation of an assay based on this technique will be 
described in this chapter.  
  
3.2 Aims 
 
The substrate preferences and functions of the neuronal Src kinases are currently 
poorly understood. We hypothesise that their substrate preferences, and therefore 
their functions, will differ to those of C-Src due to the inserts contained within their 
SH3 domains, a domain known to influence both substrate specificity and activity. 
To enable the investigation of these highly related kinases, a sensitive in vitro kinase 
assay has been developed. In parallel studies, the morphology and subcellular 
localisation of Src overexpressing cells was analysed. 
 
3.3 Overexpression of neuronal kinases induces large scale 
morphological alterations 
 
Compared to the large amount of research that has been carried out into the functions 
of C-Src, little is known about the functions of the neuronal Src kinases. There are 
technical difficulties in studying individual SFK members in cells. Most of the 
available inhibitors are competitive ATP analogues and the high degree of structural 
similarity in SFK members means that they act with low specificity (Bain et al, 
2007). As the kinase domains of C-, N1- and N2-Src are identical, kinase inhibitors 
that target the kinase domain cannot be used to study the functions of individual 
isoforms in cell based assays. Primary investigations into the functions of the N-Src 
kinases were therefore carried out in heterologous cells to allow greater control over 
the isoform being investigated. The cell line chosen for the overexpression 
experiments was COS7 cells, a fibroblast cell line that endogenously expresses 
C-Src but not the neuronal Src isoforms. 
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Figure 3.3.1 N-Src overexpression induces neuronal morphology in 
heterologous cells. 
C-, N1- and N2-Src FLAG tagged constructs were overexpressed in COS7 cells for 
48 hours. Control cells were transfected with CFP for visualisation. For control cells 
CFP signal is shown in green, for all Src constructs FLAG signal is shown in green 
Representative epifluorescent images. Scale bar = 10 μm. n=3 experiments, 20 
fields of view, containing an average of 60 cells imaged per condition per 
experiment.   
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Figure 3.3.2 N-Src transfection results in reduced cell body size and 
production of neurites 
C-, N1- and N2-Src FLAG tagged constructs were overexpressed in COS7 cells for 
48 hours. Control cells were transfected with CFP for visualisation. Transfected cells 
were analysed for cell body area (A), process length (B) and neurite number (C) 
using ImageJ. n=3 experiments, 20 fields of view, containing an average of 60 cells 
analysed per condition per experiment. Error bars show SEM. Statistical analysis 
carried out using ANOVA and post hoc Tukey test. * p<0.05, ** p<0.01, *** p<0.001, 
all conditions are compared to control (CFP transfected) cells. 
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Figure 3.3.3 COS7 cells transfected with N1- or N2-Src show perinuclear localisation. 
N1- and N2-Src FLAG tagged constructs were overexpressed in COS7 cells for 48 hours. Representative epifluorescent images shown. 
Transfected cells identified by FLAG staining (green). Nuclei identified by DAPI staining (bliue). Scale bar = 10 μm. 
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C-, N1- and N2-Src sequences were all inserted into a FLAG tagged vector for 
mammalian expression. The cloning of the Src constructs was carried out in the 
Evans lab by Kathi Mahal under the supervision of Dr Chris Dunning. As the 
extreme C-terminus of the Src sequence is involved in an intramolecular association 
with the SH2 domain, the FLAG tag was separated from the Src sequence by a 
GSGS linker. This prevents the tag from interfering with the regulation of the kinase. 
Tagging at the N-terminus was not possible as the extreme N-terminus is involved in 
membrane localisation and is required for targeting of the kinases. FLAG-tagged Src 
constructs have been produced previously and shown not to alter the subcellular 
localisation of Src (Schmitt & Stork, 2002). Other groups have added alternative tags 
including HA (Miller et al, 2000) and GFP (Qi et al, 2006; Sandilands et al, 2004) to 
the C-terminus of Src with no effect on kinase location or activity. Therefore, the 
addition of a FLAG tag is not predicted to alter the properties of the kinases in this 
study. 
 The Src constructs were transfected into COS7 cells and the kinases 
expressed for 48 hours before fixing and staining for morphological analysis. 
Control cells were transfected with CFP to allow visualisation of individual cells for 
quantification. The most striking effect of N-Src overexpression in heterologous 
cells was on their morphology. Overexpression of both N1- and N2-Src resulted in 
striking changes in cell morphology (Figure 3.3.1 A). COS7 cells are normally large, 
rounded cells but N-Src overexpression resulted in a dramatic contraction of the cell 
body, with N-Src transfected cells approximately 60% smaller than control cells 
(Figure 3.3.1 B) N-Src overexpression also resulted in the production of fine 
‘neurite-like’ processes (3.3.1 C and D). The difference between the morphology of 
N-Src transfected cells and control cells was highly statistically significant (Figure 
3.3.1) 
In contrast, overexpression of C-Src had little effect on overall cell 
morphology. Quantification of the transfected cells revealed that C-Src transfected 
cells were approximately 15-20% larger than control cells (Figure 3.3.1 B) and had 
slightly longer neurites (Figure 3.3.1 C) than control cells but the overall appearance 
of the cells was not substantially altered. Even cells overexpressing very high levels 
of C-Src (Figure 3.3.1 A right hand panel) did not show any gross morphological 
phenotype.  
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For initial examination of morphology, all fine protrusions originating from 
the cell body were measured as processes (Figure 3.3.1 C). Control and C-Src 
transfected cells had an average process length of approximately 15 µm. Fibroblastic 
filopodia are typically approximately 10 µm long (Mallavarapu & Mitchison, 1999) 
and therefore the majority of these processes are probably filopodia. Therefore, for 
subsequent analyses, ‘neurites’ were defined as processes more than 15 µm in 
length. Figure 3.3.1 D shows that these abnormally long protrusions are much more 
common in N1- and N2-Src transfected cells than they are in either control or C-Src 
transfected cells.  
N2-Src overexpressing cells were, on average approximately 100 µm
2
 larger 
than N1-Src transfected cells (Figure 3.3.1 B) but this increase is not statistically 
significant. This is probably a result of the variability of the morphology of 
transfected cells but indicated that N2-Src overexpression does not cause as great a 
cell retraction as N1-Src overexpression. N2-Src overexpression also results in cells 
with more and longer neurites, although again this was not significant (Figure 3.3.1 
C and D). Therefore, although both N1- and N2- Src overexpression induces 
neuronal morphology, there are some subtle differences in the morphology of N1- 
and N2-Src transfected cells. This implies that, while both seem to be involved in 
processes regulating cell morphology, they mediate slightly different functions.  
In addition to morphological differences, analysis of transfected cells also revealed 
interesting insights into the subcellular localisation of the kinases. The subcellular 
localisation of C-Src is well characterised (Kaplan et al, 1994; Kaplan et al, 1992) 
and is in agreement with the localisation observed in this study (Figure 3.3.2). Under 
basal conditions C-Src adopts a generally diffuse localisation with more intense 
staining of the perinuclear area. This is known to relocate to intense plasma 
membrane staining following C-Src activation (Sandilands et al, 2004) and this 
relocalisation has been demonstrated within the Evans lab (K. Mahal personal 
communication), indicating that the Src constructs used here are physiologically 
active.  
The subcellular localisation of the N-Srcs has not been previously reported 
and is hindered here by the small cell body size of N-Src transfected cells. The 
majority of N-Src transfected cells do seem to have staining adjacent to the nucleus 
but as there is so little cytoplasm surrounding the nucleus it is difficult to assess 
whether this is true perinuclear localisation. Assessment of the localisation of N-Srcs 
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is also hindered by the long exposure times needed to visualise the weakly stained 
processes. Examples of Src overexpressing cells more clearly showing perinuclear 
localisation are shown in Figure 3.3.2. In these cells, perinuclear staining can clearly 
be seen but correlative experiments using specific markers are required for further 
comparisons to C-Src to the made.  
 While C- and N1-Src staining is generally diffuse, closer analysis of N2-Src 
overexpressing cells revealed a much more punctate localisation throughout the 
cytoplasm (Figure 3.3.2). This is unusual for a SFK and indicates that N2-Src is 
localised to membrane microdomains or present in large amounts on trafficking 
vesicles. There is some evidence that N-Srcs are able to enter lipid rafts (Mukherjee 
et al, 2003) but the significance of this in relation to their signalling remains 
unknown. 
 Taken together, the results of the individual overexpression experiments 
provide important insights into the roles of the N-Src kinases and provide strong 
evidence that they differ functionally from C-Src. These data also provide evidence 
that the functions and possibly subcellular localisations of N1- and N2-Src are not 
identical. The fact that these striking alterations in cell morphology are observed in 
non-neuronal heterologous cells indicates that not all of the cellular substrates of N1- 
and N2-Src are neuronal specific.  
 
3.4 Increased basal kinase activity levels in the neuronal kinases 
 
Morphological analysis has revealed that the N-Src kinases are able to induce a 
striking alteration of COS7 cell morphology. This could be due to the substrate 
preferences of the neuronal Srcs being different to those of C-Src but it could also be 
attributed to the increased level of basal kinase activity that has been repeatedly 
reported for the N-Src kinases (Brugge et al, 1985; Levy & Brugge, 1989). In order 
to assess the activation state of the kinases and enable comparison between the 
isoforms, transfected COS7 cell lysates were analysed by Western blot. There are a 
number of phosphospecific antibodies available that are used to assess the activation 
state of the kinases. Phosphorylation of a residue within the kinase domain (Y416) 
stabilises the active state of the kinase. Therefore, phosphorylation at Y416 is 
associated with an active state of the kinase. Phosphorylation of the C-terminal tail  
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Figure 3.4.1 N-Srcs have higher levels of Y416 phosphorylation than C-Src. 
C-, N1- and N2-Src FLAG tagged constructs were transfected into COS7 cells and 
lysed 48 hours following transfection. Transfected COS7 cell lysates were analysed 
for total phosphotyrosine content (PY20), active Src (pY416) and inactive Src 
(pY527). Equal expression levels shown by FLAG signal and equal loading shown 
by PKAc loading control.  
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residue Y527 enables the formation of the SH2:tail intramolecular association and is 
associated with the inactive form of the kinase.  
 Blotting using antibodies specific for these residues revealed that the intrinsic 
kinase activities of N1- and N2-Src are much higher than that of C-Src. This 
experiment was carried out under basal conditions; under these conditions no pY416 
signal was observed for C-Src but a pY527 signal was detected. This indicates that 
the majority of the kinase in the cell is in a closed, inactive conformation. 
Constitutive phosphorylation of C-Src at Y527 in resting fibroblasts has been 
reported previously (Chackalaparampil & Shalloway, 1988). In contrast, strong 
immunoreactivity was seen at Y416 for N1- and N2-Src, whereas no pY527 signal 
was observed. Taken together, these results show that the neuronal Srcs have a much 
higher basal level of autophosphorylation than C-Src, inferring a higher basal level 
of kinase activity.  
 It is interesting, however, that the high kinase activity of the N-Srcs does not 
result in high levels of substrate phosphorylation. Blotting for total phosphotyrosine 
content of the cells revealed that the main phosphorylated protein within the cells are 
the neuronal Srcs themselves (Figure 3.4.1 - PY20 blot). This is probably detection 
of the phosphorylated pY416 residue. If the high basal kinase activity of the N-Srcs 
resulted in unregulated substrate phosphorylation, it would be expected that the 
substrates phosphorylated would be detected by the phosphotyrosine antibody. The 
absence of this indicates that the signalling of the N-Srcs is regulated despite their 
high constitutive kinase activity and raises the question of how this is achieved.  
These data from heterologous cells raise important questions about the 
functions of the N-Src kinases. Firstly, how do the SH3 domain inserts of N1- and 
N2-Src exert their impact on kinase activity and what is the result on substrate 
phosphorylation? Secondly, what substrates are the N-Srcs able to interact with and 
does this result in the regulation of cytoskeletal rearrangement? The first question 
will be addressed using in vitro biochemical techniques presented in Chapters 3 and 
4. The functional aspects of N-Src signalling and their impact on cytoskeletal 
remodelling in neurons will be addressed in Chapter 5. 
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3.5 Design of an in vitro assay for kinase activity 
 
Experiments in heterologous cells have provided useful insights into the potential 
functions of the N-Src kinases but, as there are limited tools available to manipulate 
specific Src isoforms in cell based assays, more detailed analysis into the substrate 
preferences of the kinases was carried out using in vitro techniques. To facilitate 
these investigations it was necessary to design an in vitro kinase assay that was 
capable of detecting differences in the substrate preferences of the kinases.  
 The in vitro method chosen for these investigations was the use of 
GST-tagged peptides. The peptides were designed to contain a tyrosine residue that 
could be phosphorylated by the kinase domain and also sequences designed to test 
the SH3 domain binding of the kinases. Appropriate oligonucelotides were 
commercially synthesised (Eurogentec) and cloned into a GST-expression vector. 
The kinase domain is identical for all three splice variants and therefore any 
differences in phosphorylation observed will be due to differences in the binding 
ability of the SH3 domain. The basis of this assay is depicted in Figure 3.5.1 B. 
Detection of the extent of phosphorylation of the tyrosine was carried out using an α-
phosphotyrosine antibody (PY20) and detection by Western Blotting.  
 The peptide containing the tyrosine residue able to be phosphorylated by the 
kinase domain consisted of the sequence AEEEIYGEF. This was defined as the 
consensus sequence for recognition by the Src kinase domain by Songyang et al 
(1995a). This sequence is present in all of the GST-peptides produced and is referred 
to as ‘Y’ in the GST-peptide naming convention.  
A linker of 5 amino acids was present between the Y peptide and the peptides 
inserted to assess binding to the SH3 domain due to the nature of the cloning carried 
out (see Materials and Methods, section 2.2.7.1 for details). This meant that there 
was a linker of 13 amino acids between the phosphorylatable tyrosine residue and 
the first amino acid known to play a structural role in the contact of the C-Src SH3 
domain. This is the same as the linker separating kinase and SH3 domain interacting 
elements in a study of Hck phosphorylation (Scott & Miller, 2000), who calculated 
that it was sufficient to allow simultaneous interaction of both contacts with the 
kinase.  
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 The SH3 domain binding peptides introduced into the assay were based on 
the known binding preferences of the SH3 domain of C-Src as the preferences of the 
N-Src SH3 domains were not known. Two classes of ligand are known to bind to the  
 
Figure 3.5.1 Schematic representation of the kinases and substrates used in 
the in vitro kinase assay.  
A) Recombinant Src was expressed as fusion protein with GST and PTP1B. 
Isolated His-tagged Src is obtained by PreScission protease cleavage. B) The in 
vitro kinase assay. GST-peptide substrates contain a tyrosine residue that can be 
phoshorylated by the Src kinase domain. Sequences inserted at the position of 
PxxP assess the changes in phosphorylation induced by SH3 domain binding. C) 
The GST-peptide substrates. All substrates contain the phosphorylatable tyrosine 
residue; ‘Y’ in the GST-peptide naming convention, contained within a sequence 
known to bind well to the Src kinase domain. YP1 and YP2 represent the Class I 
and Class II C-Src SH3 domain binding sequences. YA is a control sequence that 
cannot bind to the SH3 domain. YL contains the amino acid sequence found in the 
linker region between the SH2 domain and the kinase domain of the Src kinases. 
This sequence is known to bind to the SH3 domain of C-Src, forming an 
intramolecular association that promotes the inactive conformation of the kinase. 
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C-Src SH3 domain, both with the core consensus motif PxxP. These are termed 
Class I and Class II based on the presence of a positively charged arginine (R) 
residue before or after the PxxP motif respectively. The sequence of the Class I 
peptide used was VSLARRPLPPLP and the Class II peptide was PPLPPRNRPRL as 
defined by Rickles et al (1995). An additional 4 residue glycine (G) linker was added 
prior to the Class II sequence to ensure that the first residue involved in binding the 
SH3 domain was situated an equal distance away from the phosphorylatable tyrosine 
residue for both the Class I and Class II peptides. The GST-peptides containing both 
the kinase recognition sequence (Y) and the Class I or Class II SH3 domain binding 
motifs were termed YP1 and YP2 respectively. To provide a control peptide, alanine 
substitutions of all residues involved in SH3 domain binding in the Class I peptide 
were made. This control was necessary as it mimicked the steric properties of a 
peptide not able to bind the SH3 domain. The control peptide was termed YA. The 
peptides are depicted schematically in Figure 3.5.1 C. 
 The ultimate aim for the in vitro kinase assay was to allow it to be used to 
assess the kinetics of phosphorylation of the three substrate peptides by each of the 
kinases. As the binding preferences of the C-Src SH3 domain were known they 
could be used to assess the sensitivity and accuracy of the assay. Once the validity of 
the assay had been confirmed it could then be used to assess the binding preferences 
of the N-Srcs and discover whether they differ to the preferences of C-Src. Before 
these experiments could be carried out the assay needed to be optimised so that the 
incorporation of phosphate was linear with respect to both time and kinase 
concentration. When the incorporation of phosphate is linear the reaction will 
proceed according to the laws of Michaelis-Menton kinetics. Varying the substrate 
concentration around the approximate Km would then allow the elucidation of an 
accurate Km and Vmax for the phosphorylation of each substrate by each of the 
kinases. 
 The control experiments to establish concentrations where phosphate 
incorporation was linear were all carried out by assessing the phosphorylation of YA 
by C-Src. Varying the kinase concentration resulted in a concentration dependant 
increase in phosphorylation (Figure 3.5.2 A). Densitometry analysis showed that this 
increase was linear at lower concentrations and saturated at higher concentrations 
(Figure 3.5.2 B). Based on these data a kinase concentration of 5 nM was chosen for 
subsequent investigations.  
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Figure 3.5.2 Characterisation of the in vitro kinase assay.  
All kinase assays were carried out at 30 °C, initiated by the addition of ATP and 
halted by transfer to ice and immediate addition of Laemmli buffer. A) Optimisation 
of kinase concentration for use in the in vitro kinase assay. C-Src kinase 
concentration varied as indicated. YA substrate (25 μM) phosphorylation assessed 
after 90 minutes. B) Densitometry analysis of kinase concentration optimisation, n=3 
experiments. C) Timecourse of YA phosphorylation. C-Src concentration 5 nM, YA 
concentration 25 μM, samples taken at the timepoints indicated. D) Densitometry 
analysis of timecourse experiment, n=3 experiments. E) Comparison of YA and YP1 
phosphorylation by C-Src. C-Src concentration 5 nM, samples taken after 90 
minutes. Substrate concentrations varied as indicated F) Densitometry analysis of 
substrate comparison, n = 3 experiments. Phosphotyrosine detected using the 
antibody PY20. All densitometry analysis carried out in Image J. All error bars show 
+/- SEM.  
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A timecourse experiment revealed that, using a kinase concentration of 5 nM, 
phosphorylation occurs linearly between approximately 75 and 150 minutes. A long 
lag phase is observed before any phosphorylation can be detected. The phosphate 
incorporation saturates at later timepoints (Figure 3.5.2 C and D). A timepoint for all 
subsequent experiments of 90 minutes was selected based on these data. 
 In order for the in vitro assay to be able to report on substrate specificity it 
needed to be able to distinguish between the phosphorylation of substrates that can 
bind the SH3 domain and those that cannot. It is known that the C-Src SH3 domain 
binds to the YP1 sequence but not to the control YA. Therefore, it would be 
predicted that phosphorylation of YP1 would be enhanced over that of YA. To 
assess this, the substrate concentration was varied while the kinase concentration and 
duration of the experiment were fixed at 5 nM and 90 minutes as previously 
described. Figure 3.5.2 E and F show that the assay is able to clearly distinguish 
between the phosphorylation of the two substrates. Phosphorylation of YP1 can be 
detected at approximately a 30-fold lower substrate concentration for YP1 than for 
YA (Figure 3.5.2 E), although both saturate at approximately the same point (Figure 
3.5.2 F). Therefore the in vitro kinase assay was able to report on the SH3 domain 
binding ability of the kinases to GST-peptide substrates and was suitable for use to 
assess the binding preferences of the neuronal kinases.  
 
3.6 The N-Src SH3 domain has a different ligand specificity to C-
Src 
 
It is known that the neuronal Src kinases do not bind to the majority of C-Src ligands 
that have been tested. It is also known that the N-Srcs have a higher level of basal 
kinase activity than C-Src (Figure 3.4.1). However, the substrate preferences of the 
neuronal kinases and how their substrate phosphorylation is affected by the increased 
constitutive activity were not known. The development of the sensitive in vitro 
kinase assay allowed the investigation of N-Src substrate preferences. 
 Increased basal kinase activity is commonly a trait of oncogenic mutation of 
kinases and results in unregulated and aberrant substrate phosphorylation. If this 
were true of the neuronal Src kinases, it would be predicted that SH3 domain 
docking would not be required for substrate recognition and that phosphorylation of 
the control peptide, YA, would be increased over C-Src. Figure 3.6.1 shows that,  
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Figure 3.6.1 N-Srcs do not show increased phosphorylation of a control 
substrate.  
Phosphorylation of the control substrate YA by C-, N1- and N2-Src was assessed. 
YA concentration varied as indicated, kinase concentration 5 nM, timepoint 90 
minutes. A) Analysis of phosphorylation by western blot. Detection using the 
phosphotyrosine antibody PY20. B) Densitometry analysis of YA phosphorylation 
carried out using ImageJ. Equivalent substrate concentrations were loaded onto the 
same blot and normalised using a standard to allow direct comparison between the 
three kinases. See materials and methods for more details. C) Analysis of the rate 
of reaction, computed by SigmaPlot 
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surprisingly, N1-Src and N2-Src phosphorylation of YA occurs with the same 
kinetics as for C-Src. The densitometry data obtained from the phosphotyrosine blots 
was used to calculate the kinetics of the phosphorylation, according to Michaelis-
Menton parameters. This analysis was carried out using SigmaPlot and the binding 
curve produced fitted well to the model for single site saturation. This would be 
predicted as the phosphorylation of a single tyrosine residue was being monitored. 
The calculated Km for the phosphorylation of YA by all three kinases was 
approximately 30 µM (Figure 3.6.2 E). This correlates well with the known Km of 
the AEEEIYGEF peptide for the kinase domain of 33 µM (Songyang et al, 1995a). 
The Vmax of the phosphorylation reactions was also calculated and, although it is not 
possible to calculate the rate of the reaction in terms of the absolute rate of phosphate 
incorporation, this showed that the Vmax of all three phosphorylation reactions was 
equivalent (Figure 3.6.1 C). These data indicated that an appropriate SH3 domain 
interaction is required for N-Src substrate recognition as it is for C-Src.  
 In order to assess whether the SH3 domain substrate preferences of the 
N-Srcs differ from those of C-Src, phosphorylation of YP1 and YP2 was 
investigated. This revealed that the N-Srcs phosphorylate these substrates poorly 
when compared to C-Src. Figure 3.6.2 A - D shows that C-Src phosphorylation of 
both YP1 and YP2 occurs at much lower substrate concentrations than for N1- and 
N2-Src. This indicates that the SH3 domains of the N-Srcs are not able to bind to the 
Class I and Class II sequences in YP1 and YP2 that are able to enhance 
phosphorylation by C-Src and implies that the substrates preferences of the N-Srcs 
differ from those of C-Src.  
Analysis of the kinetics of the phosphorylation reactions (Figure 3.6.2 E) 
showed that the presence of YP1 or YP2 was able to significantly reduce the Km of 
the phosphorylation by C-Src. The affinity of the C-Src SH3 domain is known to be 
slightly higher for Class I sequences than for Class II sequences. It is encouraging 
for the sensitivity of the assay that this is reflected in the calculated Kms of the YP1 
and YP2 phosphorylation. The known Kms of the Class I and Class II sequences 
binding to the Src SH3 domains are 0.45 µM and 1.2 µM respectively (Feng et al, 
1995). The Kms obtained in this study are 4 μM and 6 µM for YP1 and YP2 
respectively. This assay does not directly report the binding affinity of the SH3 
domains to their substrate; instead, it quantifies the change in affinity of the kinase 
domain for the ideal kinase domain substrate induced by SH3 domain binding.  
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Figure 3.6.2 N-Src substrate preferences differ to those of C-Src. 
Phosphorylation of substrates containing the C-Src SH3 domain binding motifs (YP1 
and YP2) was analysed. A) and C) Analysis of phosphorylation by western blot. 
Substrate concentration varied as indicated. Kinase concentration 5 nM, timepoint 
90 minutes. Detection of phosphate incorporation using the phosphotyrosine 
antibody PY20. B) and D) Densitometry analysis of phosphorylation carried out 
using ImageJ. Equivalent substrate concentrations were loaded onto the same blot 
and normalised using a standard to allow direct comparison between the three 
kinases. See materials and methods for more details. E) Comparison of the Km of 
substrate phosphorlyation. Calculated using SIgmaPlot kinetics module. Data 
shown are n=3 experiments, error bars show SEM. Statistical analysis carried out 
by ANOVA and post hoc Tukey test *p<0.05, all conditions compared to YA 
phosphorylation.  
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Therefore, the trend for Class I preference over Class II implies that the assay 
is able to detect subtle differences in substrate affinity and report them accurately. 
For N1- and N2-Src neither the presence of YP1 or YP2 had a significant 
effect on the Km of phosphorylation. However, the Km of phosphorylation was 
partially reduced by the presence of YP2 for N1-Src and by both YP1 and YP2 for 
N2-Src. This indicates that some weak binding between the substrates and the N-Src 
SH3 domains may have occurred. It is interesting that phosphorylation by N1-Src is 
only enhanced by YP2. The Class I and Class II sequences are differentiated by the 
presence of a positively charged arginine residue either before or after the PxxP 
motif. In the Class II sequence the charged residue is after the PxxP motif and the 
partial enhancement in N1-Src phosphorylation by a Class II motif may indicate that 
a charged residue in this position is important for binding to the N1-Src SH3 domain. 
Phosphorylation by N2-Src was partially enhanced by both YP1 and YP2. 
This indicated that the substrate preferences of the N2-Src SH3 domain may not be 
substantially different to those of C-Src. It may be that N2-Src is able to bind to the 
same core consensus motif but that the preferences for the flanking residues are 
altered. This is surprising as the N2-Src SH3 domain has the largest insert within its 
n-Src loop and this would be predicted to significantly alter its substrate preferences. 
Taken together, these data provide evidence that the increased basal kinase 
activity of the N-Srcs does not result in unregulated substrate phosphorylation and 
that an appropriate SH3 domain interaction is required for the N-Srcs to select their 
in vivo substrates. The SH3 domain binding preferences of N1-Src will be 
investigated further in Chapter 4.  
 
3.7 Conformation of the kinases 
 
The increased basal activity of the N-Srcs has previously been suggested to be due to 
a decreased ability to form the SH3:linker association that normally constrains SFK 
kinase activity. The existence of this linker was indicated by the fact that deletions 
and mutations in the SH3 domains of Src and Hck result in increased kinase activity 
(Murphy et al, 1993; Superti-Furga et al, 1993). The structure of full length Src 
revealed the residues that form the linker; it was not obvious from the primary 
sequence as the polypeptide contains only one proline residue (Xu et al, 1997). The 
linker sequence identified by Xu et al (1997) was 
248
SKPQTQGLAKDA. This  
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Figure 3.7.1N-Srcs interact poorly with the SH2:linker sequence. 
Phosphorlyation of the YL substrate by C-, N1- and N2-Src was investigated. A) 
Schematic representation of the basis of the assay. The amino acid sequence of the 
linker region between the SH2 domain and the kinase domain (purple) was cloned 
into to GST-peptide system. This substrate was termed YL where L stands for 
linker. If the linker sequence in YL is able to bind to the SH3 domain of the kinase 
then substrate phosphorylation will occur as depicted in the cartoon on the right 
hand side. C, N1- and N2-Src kinases were incubated individually with the YL 
substrate at 30°C and the amount of substrate phosphorylation assessed by 
western blot using an α-phosphotyrosine antibody. YL concentrations of 25 μM, 8.3 
μM, 2.8 μM and 0.9 μM used, kinase concentration 5 nM, timepoint 90 minutes. B) 
Detection of phosphotyrosine by the PY20 antibody. C) Densitometry analsysis of 
YL phosphorylation carried out using ImageJ. D) Km of YL phosphorylation by C-, 
N1- and N2-Src. Calculated using SigmaPlot kinetics module. n=1 experiment. 
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sequence was cloned into the GST-peptide system and termed YL (where L is an 
abbreviation of linker). A schematic representation of this substrate and the location 
of the amino acid sequence it is derived from are shown in Figure 3.7.1 A with the 
relevant regions highlighted in purple.  
It was hypothesised that the amino acid inserts within the SH3 domains of the 
neuronal Src kinases would result in a reduced affinity between the SH3 domain and 
the linker region. If the SH3 domains of the neuronal kinases interact more weakly 
with the linker region then this would reduce the strength of the intramolecular 
associations constraining the kinase activity and result in a more open and active 
kinase. This could begin to explain the increased activity observed in the neuronal 
Src kinases. 
In order to test this hypothesis phosphorylation of YL by the three kinases 
was investigated. If the SH3 domain of the kinase is able to bind to the YL substrate, 
as shown in the right hand panel of Figure 3.7.1 A, then the tyrosine residue in the 
substrate would be phosphorylated by the Src kinase domain and this could be 
detected by western blot. This experiment relies on the linker sequence in the YL 
substrate being able to bind to the SH3 domain in preference to the linker sequence 
in the endogenous kinase. Incubation of the kinases at 30°C results in 
autophosphorylation of Y416 and promotion of the active conformation of the 
kinase. This conformational rearrangement disrupts the interaction between the SH3 
domain and the linker and allows binding of YL to the SH3 domain.  
This experiment revealed that the neuronal kinases do indeed phosphorylate 
the linker substrate less efficiently than C-Src (Figure 3.7.1). The Km of the 
interaction with C-Src is 5 µM. This is surprising as it is equivalent to the Km for the 
phosphorylation of the ideal substrates YP1 and YP2. As the linker sequence does 
not contain a PxxP motif, this would not be expected. The Km of the phosphorylation 
by both N1- and N2- Src are ~10 and 15 µM respectively. This implies that the 
N-Src SH3 domains are able to bind weakly to the linker sequence but not as well as 
the C-Src SH3 domain. The difference in affinity is presumably due to the inserts 
within their SH3 domains altering the SH3 domain binding site sufficiently to inhibit 
binding.  
Another surprising insight into the conformation of N1-Src was gained 
during the characterisation of an N1-Src specific antibody. A custom antibody 
specific for the N1-Src SH3 domain was commercially generated (GenScript) for use  
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Figure 3.7.2 The N1-Src antibody detects the SH3 domain of N1-Src 
specifically. 
A) The epitope that the antibody is raised against covers the 6 amino acid inset and 
is unique to N1-Src, highlighted in red. B) Detection of the recombinant GST-N1-Src 
SH3 domain by the N1-Src antibody. 100 ng GST-N1-Src SH3 domain loaded into 
each lane, antibody concentration varied as indicated. C) The sensitivity of the 
N1-Src antibody was tested against C- and N2-Src. Amount of GST-Src SH3 
domain loaded as indicated, N1-Src antibody concentration 1:500. 
 
 
  
Chapter 3 
 
100 
Figure 3.7.3 Kinase activation is required for detection by the N1-Src antibody. 
A) Full length N1-Src kinase can be detected specifically from transfected cell 
lysates. COS7 cells were transfected with C-, N1- and N2-Src and lysed 48 hours 
following transfection. FLAG blot shows equal expression levels. N1-Src antibody 
blot shows specific detection of N1-Src. B) Recombinantly expressed C-, N1- and 
N2-Src were activated by incubation with ATP at 30°C. The N1-Src antibody 
specifically detects Δ80 N1-Src following this activation. 
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in studying the in vivo roles of N1-Src. The epitope that the antibody was raised 
against covered the six amino acid insertion in the N1-Src SH3 domain (Figure 3.7.2 
A) and has previously been used to produce an N1-Src specific antibody by Sugrue 
et al (1990). This antibody was shown to be able to specifically recognise the 
isolated GST-tagged SH3 domain of N1-Src (Figure 3.7.2 B and C). However, no 
signal was detected using the full length recombinant kinase. In the full length kinase 
the antibody epitope will be on the surface of the SH3 domain adjacent to the kinase 
domain and would be masked if the kinase were in a closed conformation. 
As an alternative to the recombinant kinase, lysates of COS7 cells expressing 
FLAG-tagged kinases were used. Under these conditions, the antibody was able to 
recognise N1-Src and do so specifically over C- and N2-Src (Figure 3.7.3 A). As 
previously shown (Figure 3.4.1), the neuronal kinases are in an open, active 
conformation within cells and it was therefore hypothesised that the antibody epitope 
might be masked in the recombinant kinase but accessible in the kinases contained  
within the lysates. To test this, recombinant kinases were activated by incubation 
with ATP at 30
o
C; resulting in autophosphorylation at Y416. Surprisingly, under 
these conditions, the antibody was able to detect the recombinant kinase 
(Figure 3.7.3 B). This indicates that the antibody epitope is blocked in recombinant 
N1-Src prior to activation by autophosphorylation and provides evidence that the 
neuronal kinases are partially constrained by intramolecular associations and are not 
permanently in an open state. It can be concluded that, although the SH3:linker 
intramolecular association constraining the activity of the neuronal Src kinases are 
weaker than for C-Src, they are not entirely absent and regulation of the activity of 
the neuronal kinases is possible. 
 The characterisation of the N1-Src specific antibody revealed interesting 
insights into the conformation of the kinases. However, when it was tested for 
immunofluorescent applications it was found that the degree of background staining 
was too high to allow it to be used further. While N1-Src transfected cells could be 
detected using the N1-Src antibody in conjunction with FLAG staining in transfected 
COS7 cells, the background fluorescence made it difficult to identify N1-Src 
transfected cells or endogenous protein in cultured neurons based on α-N1-Src alone. 
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3.8 Discussion 
 
3.8.1 Neuronal Srcs are implicated in the regulation of cytoskeletal 
rearrangement 
 
Morphological analysis of neuronal Src transfected cells has revealed that their 
overexpression induces large scale morphological alterations, presumably due to 
cytoskeletal rearrangement. Cells transfected with N1- or N2-Src have much smaller 
cell soma than either C-Src transfected or control cells. N-Src transfection also 
results in the production of fine, ‘neuron-like’ processes and this result implies a 
broad role for the N-Src kinases in the regulation of cytoskeletal rearrangement, 
particularly in the development of neuronal morphology. This result also provides 
evidence that the neuronal Srcs carry out roles substantially different to those of 
C-Src.  
 The morphology of the N-Src transfected cells is similar to that observed 
following overexpression of a dominant positive form of Rho GTPase (Kolyada et 
al, 2003). The Rho family GTPases are able to link surface receptors to the 
organisation of the actin cytoskeleton (Hall, 1998) and signalling resulting from the 
Rho family has been shown to be important in neuronal cells in the processes of 
axonal growth and guidance (Hall & Lalli, 2010). The similarity in morphology 
means that it is possible that the neuronal Srcs are acting directly in the same 
pathway as the Rho proteins. However, it is also possible that they are acting in a 
parallel pathway also able to influence cell shape, such as signalling arising from 
adhesion molecules. Further elucidation of the substrate preferences of the neuronal 
Srcs will allow discrimination between these two possibilities. The potential for Src 
involvement in small GTPase and cell adhesion molecule signalling pathway will be 
discussed in detail in Chapter 6. 
 The striking morphological changes caused by N-Src transfection led us to 
question whether N-Src overexpression was able to induce a functional neuronal 
differentiation. However, analysis up to 14 days following transfection did not 
identify any expression of the neuronal tubulin (Tuj1). It has previously been shown 
that it is possible to directly convert fibroblasts into functional neurons through the 
expression of a combination of transcription factors (Abdullah et al, 2012; 
Vierbuchen et al, 2010). The effect of N-Src overexpression seems to be purely 
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morphological but it is possible that a stable form of transfection would allow 
sustained N-Src expression and enable reprogramming of the cells to a neuronal 
lineage. This type of reprogramming would rely on N-Src signalling feeding into a 
transcription programme in addition to the cytoskeletal rearrangement observed here.  
 The role in cytoskeletal rearrangement identified in this study is in agreement 
with the available data for neuronal Src function. Kotani et al (2007) identified a role 
for N1-Src in the regulation of dendritic morphogenesis and concluded, through 
ultrastructural analysis, that this occurred through modulation of microtubule 
organisation. However, this study used a constitutively active form of the kinase 
(Y527F) and observed only a mild phenotype following overexpression of the WT 
N1-Src. This supports the theory that, despite the high basal level of kinase activity 
in the neuronal kinases, further activation is required for substrate phosphorylation. 
The mechanism by which signalling downstream of N1-Src is able to influence cell 
morphology remains to be elucidated and will be further discussed in Chapters 5 and 
6.  
The induction of neuronal morphology in heterologous cells implies that 
neuronal Src signalling is involved in cellular differentiation. This would correlate 
with the fact that high levels of the neuronal kinases, in particular N2-Src, are 
associated with a good prognosis for the childhood cancer neuroblastoma 
(Matsunaga et al, 1998). Tumours expressing high levels of N2-Src kinase have an 
increased likelihood of spontaneously differentiating into benign neuronal tissue 
(Matsunaga et al, 1993). It is postulated that the N2-Src is able to drive this 
differentiation, although the mechanisms underlying this are not clear.  
One caveat to the data presented here is that the morphological analyses were 
all carried out following overexpression of the Srcs. It is known that kinase 
overexpression can result in aberrant signalling and the activation of signalling 
pathways not normally controlled by the kinases. But, in the case of Src, this seems 
to act predominantly to exaggerate the normal signalling of the kinases. Kamps and 
Sefton (1988) found that the majority of the proteins phosphorylated by the 
oncoprotein v-Src were also phosphorylated by C-Src. Ongoing work in the Evans 
lab is currently aiming to establish stable cell lines expressing the N-Srcs. Stable cell 
lines will express lower levels of the kinases and will be more comparable to the 
endogenous levels. These will be useful tools for further study of N-Src function and 
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repeating the morphological analysis in these stable cell lines will confirm its 
validity.  
 
3.8.2 An in vitro assay capable of detecting SH3 domain binding preferences of 
SFKs 
 
The development of a novel in vitro kinase assay has enabled the first reported 
investigation of the substrate preferences of the N-Srcs. The testing of the assay has 
resulted in a high degree of confidence in its ability to assess the phosphorylation 
and, by implication, the SH3 domain binding ability of GST-peptide substrates.  
The assay is carried out by detection of phosphorylation using an 
α-phosphotyrosine antibody followed by chemiluminescent detection on film. It has 
been suggested that the use of photographic film to detect chemiluminescence does 
not give linear results. However, this does not seem to be an issue in the context of 
this study. To ensure that the densitometry data collected was accurate, an initial 
comparison between film and computerised detection, using a BioRad Versadoc, was 
carried out and this gave the same calculated Km for the phosphorylation (data not 
shown). The predominant factor in determining a change in Km seems to be the 
detection of a band in a lane of lower substrate concentration. Therefore, even if the 
subsequent analysis and calculation of absolute Km values were not accurate, the 
differences in the blots alone show that the phosphorylation of substrates able to 
interact with the SH3 domains occurs more efficiently (i.e. at lower substrate 
concentrations) than those that cannot.  
Throughout the kinetic experiments, great care was taken to ensure that direct 
comparison of substrate phosphorylation by each of the kinases was possible. Equal 
substrate concentrations phosphorylated by the three kinases were run on the same 
blot, along with a control sample present on all blots. Densitometry data from these 
blots was analysed and normalised to the control sample to reconstruct the 
phosphorylation curve. Therefore, there is a high degree of confidence that the 
differences in phosphorylation observed are due to differential substrate preferences 
of the kinases rather than experimental variation.  
 One drawback to using α-phosphotyrosine detection of incorporated 
phosphate as opposed to 
32
P is that calculation of the rate of reaction cannot be 
calculated as an absolute value. Analysis of the Vmax of the reactions revealed that 
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they all proceed at the same rate, but comparison of this rate to other reported rates 
cannot be carried out.  
 A caveat to the use of recombinantly expressed kinases is that E. coli does 
not express the kinase that carries out the C-terminal phosphorylation of Src (Csk). 
Csk phosphorylation of Y527 enables the formation of the regulatory SH2 
domain:tail interaction that constrains the activity of the kinases. Therefore, the 
kinases used for all in vitro applications in this study are only constrained by the 
SH3 domain:linker association. Yadav and Miller (2007) have confirmed that further 
activation of the kinase by SH3 domain displacement is possible in the absence of 
the SH2:tail interaction. The kinetics of the phosphorylation observed may be 
slightly affected by the lack of the SH2:tail interaction. It may be that the Kms 
obtained are slightly lower than they would be if the SH2:tail interaction were in 
place but the trends should be unaffected.  
 The effects on substrate phosphorylation observed have been attributed solely 
to differences in the SH3 domain binding preferences but the kinases used also have 
functional SH2 domains that can influence substrate binding. The SH2 domain can 
dock onto phosphorylated tyrosine residues, displacing the SH2:tail interaction and 
resulting in an activation of the kinase. Once there are phosphorylated substrates 
within the reaction, SH2 domain binding may provide a mechanism for further 
enhancement of phosphorylation. To assess the role of the SH2 domain, production 
of a loss-of-function mutation (R175A) in the SH2 domain was attempted by site 
directed mutagenesis but was not successful. Therefore, the contribution of the SH2 
domain to the kinetics in the in vitro assays remains unknown. However, the results 
are still valid and physiologically relevant as in endogenous kinases both SH2 and 
SH3 domains influence substrate preferences and kinase activity.  
 The primary difference in the phosphorylation observed in this study 
compared to other studies is the long lag phase before phosphorylation is observed in 
the timecourse experiment. There are a number of possible reasons for this. The 
substrate used in the timecourse experiment (YA) could not bind to the C-Src SH3 
domain and its initial phosphorylation therefore required activation of the kinase by 
autophosphorylation. Moarefi et al (1997) carried out a comparable experiment on 
Hck activation and found a 30 minute lag period before phosphorylation was 
observed when downregulated Hck was used. The faster timepoint used in other 
studies are probably explained either by the use of higher substrate concentrations or 
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use of preactivated kinases either by prior incubation with ATP or extraction from 
mammalian cell lysates. 
 The in vitro kinase assay developed here has been shown to be both accurate 
and sensitive in reporting changes in affinity for the Src kinase domain ideal 
substrate by the presence of SH3 domain binding motifs, providing a valuable tool 
for the assessment of N-Src function. The versatility of the GST-peptide system 
means that it can be readily altered to assess potential substrates of the N-Srcs but 
also other tyrosine kinases. 
 
3.8.3 Insights into the effect of n-Src loop inserts on kinase activity and 
substrate preferences 
  
It has previously been suggested that the N-Srcs are more basally active because they 
are less able to form the SH3:linker intramolecular association. Both the increased 
basal activity of the kinases and the decreased ability to form the intramolecular 
association with the linker have been confirmed in this study. This is the first 
demonstration of the prediction that the N-Srcs show reduced binding to the linker 
sequence. 
This result provides interesting insights into the conformation of the N-Src 
kinases. The N-Srcs are less constrained by the SH3:linker interaction but this does 
not seem to result in a complete activation of the kinase. Kotani et al (2007) 
observed a gain-of-function phenotype by mutating Y527F in N1-Src, indicating that 
the SH2:tail interaction remains intact in vivo and functions to prevent 
phosphorylation until an appropriate ligand is encountered. This is interesting 
because, in other SFK members, the SH3 domain intramolecular interaction is 
thought to be dominant. In Hck, Moarefi et al (1997) showed that further kinase 
activation does not occur by SH2 domain displacement following SH3 displacement. 
Also, in a form of Hck with a strengthened SH2:tail interaction, SH3 domain 
mutation overrides even this strengthened SH2:tail interaction (Porter et al, 2000). 
To confirm the role of the SH2:tail interaction in N-Src activity it would be 
interesting to mutate the residue that forms the SH2:tail interaction (Y527) to assess 
whether further activation of the neuronal kinases occurs. In vitro, the Y527F 
mutation would not be expected to further activate the kinases as they are not 
phosphorylated at Y527 in vitro. In cell based assays, there is the potential for Y527 
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phosphorylation by Csk. The absence of the SH2:tail interaction may therefore result 
in a full activation of the kinase. It would be interesting to assess the morphology of 
Y527F N-Src transfected COS7 cells to assess whether further N-Src activation is 
able to exacerbate the change in morphology observed. N1-Src with a Y527F 
mutation has previously been generated (Marin et al, 2010) and was reported to have 
faster activation kinetics, assessed by autophosphorylation. However no substrate 
phosphorylation or cell based assays were carried out. 
In vitro studies confirm that the decreased linker association does not result 
in a complete activation of the kinase and that substrate phosphorylation remains a 
highly controlled process that requires appropriate ligand binding at the SH3 
domain. It has been demonstrated that the known C-Src consensus motifs are poor 
substrates for the neuronal Src SH3 domains and the enhancement in 
phosphorylation observed for C-Src when a SH3 domain ligand is present is not 
observed for either neuronal Src isoform. This indicates that in vivo the neuronal 
Srcs require substrate recognition via the SH3 domain in order to phosphorylate 
substrates. Therefore, the increased basal levels of kinase activity that are more 
commonly associated with disregulation of the kinase and disease states does not 
cause unregulated protein phosphorylation in the N-Srcs. 
Analysis of the subcellular localisation of the kinases has revealed some 
interesting properties of the N-Srcs. Both N1- and N2-Src display some perinuclear 
association. In the case of C-Src, this is associated with the inactive form of the 
kinase (Kaplan et al, 1992) and not the active form (Kaplan et al, 1994; Sandilands et 
al, 2004), indicating that some N-Src in the cells may be in an inactive conformation 
or that active N-Src is found in different subcellular localisations than active C-Src. 
Further analysis is needed to identify the markers that this population is associated 
with. It should also be confirmed that this perinuclear Src is not the result of 
overexpression and subsequent accumulation in the biosynthetic pathway. The 
production of stable cell lines will allow this experiment to be carried out. Further 
analysis would also be aided by the use of confocal as opposed to epifluorescent 
microscopy.  
The basal kinase of the N-Srcs has been shown to be greatly increased in 
whole cell lysates but it would be interesting to discover whether the localisation of 
the kinases has any effect on activation. This could be carried out by pY416 staining 
in cells as has been described for C-Src (Sandilands et al, 2004). Activation of C-Src 
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results in its relocalisation to the plasma membrane. The effect of N-Src activation is 
unknown. This could be investigated using vanadate treatment of the cells which 
results in a potent activation of kinases.  
 It is possible that the hyper-active state of the neuronal kinases observed in 
cell based assays in this study is partly a result of their overexpression. SFKs are 
able to carry out transphosphorylation at Y416 (Cooper & MacAuley, 1988)and an 
increase in local concentration caused by overexpression may be sufficient to allow 
extensive transphosphorylation, thus driving the active state of the kinase. The 
phenomenon may be more exaggerated in the neuronal kinases than for C-Src 
because the weaker interaction of the SH3 domain with the SH2 domain: kinase 
domain linker makes the transition to the active state more energetically favourable.  
In addition, the N-Srcs are predominantly constrained by the SH2:linker 
association. The presence of a C-terminal tag may therefore be sufficient to partially 
disrupt this interaction. This is tolerated in C-Src as it also has the additional 
SH3:linker association but may result in a further activation of the N-Srcs. It has 
been reported that N-Src isolated from neuroblastoma cell lines do not necessarily 
have a higher basal kinase activity level than C-Src isolated from fibroblasts (Yang 
& Walter, 1988) or glioblastoma cells (O'Shaughnessy et al, 1987). However, this 
activation state rapidly increases following the onset of differentiation (Bjelfman et 
al, 1990b). In contrast, it has been consistently reported that the N-Srcs in mature 
neurons have a higher basal level of kinase activity. The contradiction in these 
results may indicate that high N-Src activity is required for the processes of 
differentiation and maintenance of a differentiated phenotype and therefore be lower 
in proliferating neuroblasts such as neuroblastoma cells. The identification of N-Src 
with low basal kinase activity confirms that the activity of the kinases is able to be 
regulated in vivo and confirms the in vitro data obtained here that show the N-Srcs 
do not phosphorylate the control peptide to any greater extent than C-Src. This 
capacity for regulation of kinase activity is necessary to enable substrate selection by 
the highly related kinases (Sartor & Robbins, 1993). 
Taken together, the data presented here show that the N-Srcs have a high 
basal level of kinase activity but that this does not result in unregulated substrate 
phosphorylation. The SH3 domain is able to influence both substrate specificity and 
kinase activity. The current view is that SH3:linker binding acts to constrain the 
kinase activity and SH3-substrate interaction activates the kinase. In the case of the 
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N-Srcs, the SH3 domain still seems to be required for substrate recognition but its 
role in kinase activation is less clear. The activity of a Src kinase is classically 
assessed by the phosphorylation state at Y416 but the link between 
autophosphorylation and substrate phosphorylation is not entirely clear. V-Src 
phosphorylates substrates 10-fold more than C-Src but its autophosphoylation is only 
between 1 and 2 fold higher than C-Src (Coussens et al, 1985). Lyn 
autophosphorylation results in an increase in kinase activity but a decrease in the 
accessibility of the SH2 domain (Sotirellis et al, 1995). Therefore, the assessment of 
N-Src activity by pY416 may not give an accurate representation of the potential for 
substrate phosphorylation by the kinase.  
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4 Identification of a consensus motif for the N1-Src SH3 
domain 
 
4.1 Introduction 
 
4.1.1 The use of phage display in establishing a consensus motif 
 
The ligand binding specificity of the N1-Src SH3 domain has been shown to differ 
from that of C-Src (Chapter 3). In order to further investigate the functions of N1-Src 
and to identify potential in vivo substrates, it was necessary to establish a consensus 
sequence for the N1-Src SH3 domain. This consensus motif could then be used to 
carry out a bioinformatic screen for potential substrates. The technique chosen for 
these investigations was phage display. This technique is highly applicable to small, 
well folded, isolated domains such as the SH3 domain (recently reviewed by Vodnik 
et al (2011)) and was the technique initially used to identify a consensus motif for 
the C-Src SH3 domain (Cheadle et al, 1994; Rickles et al, 1994).  
Phage display works on the principle of selective enrichment of sequences 
able to bind with high affinity to the protein of interest. It uses a library of random 
peptide sequences and can therefore be used to identify a consensus motif for a 
protein with no requirement for prior knowledge of interacting proteins. One 
possible drawback is that phage display can only identify interactions with linear 
peptide sequences. However, the vast majority of SH3 domains interact with linear 
sequences in their substrates rather than via tertiary contacts (Mayer, 2001). It is 
reasonable to assume that the N1-Src SH3 domain also interacts with its substrates in 
this manner. As there is such versatility in the sequences able to bind to SH3 
domains, an unbiased peptide library was chosen to assess binding to the N1-Src 
SH3 domain as it cannot be assumed that an N1-Src SH3 domain interacting peptide 
will be proline rich. 
 
4.1.2 Bioinformatic analysis of large datasets of gene names 
 
In the post genomic era, bioinformatic analysis using web-based prediction tools has 
become a powerful technique for the identification of putative substrates. There are a 
number of tools available that are able to identify potential substrates based on the 
presence of a particular amino acid motif, prediction of PTM or assessment of 
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biological processes. Bioinformatic techniques are particularly applicable to 
assessing N1-Src function as it only differs from C-Src in the SH3 domain. The 
domain interactions of C-Src are well characterised and can therefore be used to aid 
the identification of potential N1-Src substrates. The web-based bioinformatic tools 
that were used in this study are outlined in Figure 4.8.1. 
Scansite (Obenauer et al, 2003) is able to search genomes for short linear 
peptide motifs within proteins that are likely to be phosphorylated by specific protein 
kinases or bind to well characterised domains such as SH2 domains, 14-3-3 domains 
or PDZ domains. This prediction is based on experimental data obtained using 
peptide library experiments such as phage display. The binding peptides are isolated 
and sequenced and the relative abundance of each amino acid at each position used 
to produce a Position Specific Scoring Matrix (PSSM) that numerically indicates the 
probability of finding each amino acid at each position within a motif. It is also 
possible to search Scansite with a user defined PSSM (Yaffe et al, 2001) and this 
functionality enables genome searching with a novel consensus motif.  
The functional roles of the potential substrates identified by Scansite can then 
be assessed using The Database for Annotation, Visualisation, Integrated Discovery 
(DAVID) (Huang et al, 2009a). DAVID assigns a function to proteins based on a 
series of Gene Ontology (GO) terms. It is also able to report whether any function is 
‘enriched’ i.e. present at a frequency higher than would be expected based on 
occurrence within the genome. This allows unbiased assessment of the predominant 
functions carried out by a large dataset of proteins. 
For a protein containing an appropriate SH3 domain binding motif to be 
considered a potential Src kinase substrate, it must also contain a tyrosine residue 
within a motif likely to be phosphorylated by the relevant kinase. There are a number 
of programmes available that are able to predict potential Src phosphorylation sites 
and, because the kinase domains of C- and N1-Src are identical, these can be used to 
predict which of the potential substrates identified as potential N1-Src SH3 domain 
targets are also likely to be Src phosphorylated. The programme chosen for this was 
the Group based Prediction System (GPS) (Xue et al, 2008). GPS is able to carry out 
large scale batch kinase prediction and operates with a higher degree of specificity 
than Scansite for Src kinase prediction (Xue et al, 2008). It is also able to 
differentiate between substrates likely to be phosphorylated by individual members 
of the Src Family Kinases (SFKs).  
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Substrates that are predicted to be both SH3 domain and kinase domain 
substrates of N1-Src can be compared against the PhosphoSite (Hornbeck et al, 
2004) database of, predominantly Mass Spectrometry (MS) derived, information 
about post-translational modification at specific sites in vivo. It is therefore possible 
to cross reference predicted phosphorylation sites with known sites to assess whether 
there is any prior evidence for phosphorylation at a particular predicted tyrosine 
residue.  
This series of bioinformatic techniques allows for both broad, unbiased 
assessment of large datasets in order to identify general protein functions and also 
more directed analysis of individual proteins where there is biological evidence for 
phosphorylation.  
 
4.2 Aims 
 
The work presented in Chapter 3 confirmed that the consensus motif for binding to 
the N1-Src SH3 domain differs from that of C-Src. The aim of the work presented in 
this chapter was therefore to establish a consensus motif for the N1-Src SH3 domain 
that could be shown to functionally enhance phosphorylation by N1-Src in an in 
vitro kinase assay. This consensus motif could then be used to carry out a 
bioinformatic search for novel potential N1-Src substrates.  
4.3 A novel SH3 domain binding motif identified by phage display 
 
The library chosen for phage display experiments was a commercially available 
random 12-mer library that contains 2x10
9
 unique peptides (NEB Ph.D.-12 Phage 
Display Peptide Library Kit). Each peptide is expressed on the surface of an M13 
phage particle by fusion to one of its coat proteins. The phage are then panned over 
the protein of interest and those that bind are collected and amplified in order to 
successively enrich for high affinity peptides (Figure 4.3.1). Initial phage display 
experiments used the surface panning protocol in which the pool of phage was 
incubated with N1-Src SH3 domain bound to the plastic surface a petri dish. The 
peptides sequenced as a result of this were largely identified as plastic binding. 
Therefore, the protocol was adapted to consist of solution phase panning followed by 
affinity bead capture. The panning process was carried out for a total of five rounds 
and clones were sequenced from round three onwards. 
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Figure 4.3.1. Schematic representation of the phage display panning process.  
Phage expressing random 12-mer peptides on their surface are incubated with a 
protein of interest. Over successive rounds of panning, those peptides that bind with 
the highest affinity are selected while the remaining peptides are discarded. Phage 
plasmids may be sequenced following any panning round with the aim of 
establishing a consensus motif.  
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 When all of the sequences obtained from rounds 3-5 were combined and 
analysed for amino acid content, it was revealed that certain amino acids were over-
represented (Figure 4.3.2). The dotted line in Figure 4.3.2 represents the expected 
amino acid frequency based on codon usage. Proline (P), histidine (H), lysine (K) 
and to a lesser extent tryptophan (W) and tyrosine (Y) occur in the sequences more 
often than would be expected based on codon usage. This indicates that the phage 
display method is able to selectively enrich for certain amino acids, and implies that 
these amino acids are selected for by the binding interaction. 
Looking more specifically at the sequences obtained by sequencing clones 
from round 3 onwards, selective enrichment of certain peptides was observed (Table 
4.3.1). In rounds 3 and 4, a total of 18 clones were successfully sequenced and each 
contained a unique peptide sequence. In contrast, a total of 22 clones were sequenced 
following the fifth round of panning and 17 of these contained the same peptide 
sequence, WHRMPAYTAKYP. Due to this high level of enrichment it was decided 
that further rounds of panning were not required. Additionally, as the rounds of 
panning were carried out, there was an increasing degree of contamination from wild 
type phage.  
It is interesting to note that one sequence was obtained from both rounds 4 
and 5 of sequencing. This sequence was KPPQHTSAPYLP. The fact that an 
identical sequence was obtained from two subsequent rounds of panning indicated 
that the number of unique clones in the pool was being significantly reduced as the 
panning process selects for peptides that are able to bind. Were this not the case, then 
the probability of obtaining the same sequences from two subsequent rounds would 
be very small.  
In total, there were 7 unique peptide sequences obtained following the fifth 
round of panning. One of these, SVWVGMKPSPRP, was immediately discarded as 
there is evidence that it is present due to propagation related bias (Kolb & Boiziau, 
2005; Vodnik et al, 2011). The remaining peptides were named Phage Display (PD) 
peptides 1-6 (Figure 4.4.1), and this nomenclature will be used from this point 
onwards.  
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Table 4.3.1. Selective enrichment of peptide sequences by phage display. 
Individual phage clones were isolated and their plasmids sequenced following 
rounds 3, 4 and 5 of panning. Following the fifth round of panning, one peptide 
sequence was identified in 17 of 22 sequenced plasmids. 
 
 
Figure 4.3.2. Amino acid distribution in the sequenced clones.  
Pooled sequence information from all sequences obtained from rounds 3, 4 and 5 of 
panning reveal an over-representation of certain amino acids (shown using the 
single letter code). Dotted lines represent the expected frequency based on codon 
usage. 
 
  
Round 3  Round 4  Round 5  
Sequence Freq. Sequence Freq. Sequence Freq. 
FSLPSKALPWQL  1 IELQTIYYSSTS  1 WHRMPAYTAKYP   17 
GVIPPRAFNHGV 1 LPLHGMHLLRSS  1 GHWHSPHKLTRN   1 
VSRHQSWHPHDL  1 FYQQPPSWPHWG 1 SVWVGMKPSPRP  1 
YMPHSASLLTTP  1 APHVRDHLSSTP 1 KNPTSTPAMYAN  1 
AIPNKLNVWPPH 1 LNAQPLRFNIKV  1 GHRNRANTSKNP  1 
HWKHPWGAWDTL  1 ATWSHHLSSAGL 1 KPPQHTSAPYLP  1 
QHANHQAWNNLR  1 ITTKYSMRYNTT 1 WHRMPMHTAKPL  1 
NLGKPNYHAYYS  1 KPPQNTSAPYLP 1     
HHGHSPTSPQVR  1         
ILANDLTAPGPR 1         
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4.4 The presence of the PD GST-peptides enhances 
phosphorylation by N1-Src 
 
The amino acid sequences of the PD peptides were cloned into the GST-peptide 
system described in Chapter 3 so that they could be tested for their ability to enhance 
phosphorylation by N1-Src. A schematic representation of the PD GST-peptides is 
shown in Figure 4.4.1 A. They contain the same ideal Src substrate as the GST-
peptides described in Chapter 3 and the phosphorylation of the tyrosine residue 
contained in this motif can be monitored by western blot using an α-phosphotyrosine 
antibody. In the schematic this tyrosine residue is represented as ‘Y’. The PD peptide 
sequences identified by phage display have been inserted in the same position as the 
SH3 domain binding sequences in the substrates YP1 and YP2 used in Chapter 3.  
In vitro kinase assays were carried out between C- and N1-Src and the PD 
GST-peptides. If the amino acid sequences identified by phage display are able to 
bind to the SH3 domain of N1-Src then this will enhance the phosphorylation of the 
tyrosine residue within the PD GST-peptide substrate. In these experiments, a band 
in the highest substrate concentration lane represents an enhancement in 
phosphorylation over a construct lacking the ability to bind to the SH3 domain (YA).  
 The presence of the majority of the PD sequences was able to enhance 
phosphorylation by N1-Src (Figure 4.4.1 B), but with varying degrees of specificity 
and affinity. A subset of PD sequences resulted in an enhancement in 
phosphorylation by both N1-Src and C-Src. This result implies that the technique of 
phage display has been able to successfully identify peptides that are able to 
functionally interact with the N1-Src SH3 domain, resulting in an enhancement of 
phosphorylation.  
 Based on the results of the in vitro kinase experiments the PD peptides were 
ranked according to their specificity for N1-Src (Figure 4.4.1 C). The two GST-
peptides that showed absolute specificity for N1-Src over C-Src were PD1 and PD6. 
This is very interesting because the sequences of these two peptides are highly 
similar, with only four amino acids difference between them. It is also worth noting 
that PD1 is the peptide that was present in 17 (77%) of the 22 clones sequenced from 
round 5. Once the PD GST-peptides were ordered according to their specificity for 
N1-Src, it was possible to align the sequences to reveal a consensus motif of 
+xPxxTx+ (where + represents a positively charged amino acid) (Figure 4.4.1 C).  
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Figure 4.4.1. Enhancement in phosphorylation by the presence of the phage 
display (PD) GST-peptides.  
A) Schematic representation of the PD GST-peptides. The amino acid sequences 
identified as binding to the N1-Src SH3 domain using phage display were cloned 
into the GST-peptide system as shown in panel A. The substrates also contained a 
tyrosine residue able to be phosphorylated by the Src kinase domain. 
Phosphorylation of this tyrosine residue was monitored by western blot. Binding of 
the PD sequences to the SH3 domain would result in an increase in the 
phosphorylation observed. B) Phosphorylation of PD GST-peptides by C- and N1-
Src. GST-PD concentrations of 8.3, 2.8, 0.9 and 0.3 μM used. A band in the highest 
concentration lane represents an enhancement in phosphorylation over a substrate 
that can’t bind to the SH3 domain (YA). C) A consensus motif for N1-Src. PD 
peptide sequences ordered based on their specificity for N1-Src over C-Src. Grey 
bars represent amino acids conserved between the sequences. The consensus 
sequence is highlighted in bold. 
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Figure 4.5.1. Kinetics of PD1 and PD6 phosphorylation by C- and N1-Src.  
A) and C) Phosphorylation of A) GST-PD1 and C) GST-PD6 by C and N1-Src. 
Substrate concentrations varied as indicated. Analysis by α-phosphotyrosine blot 
and detection using the PY20 antibody. B) and D) Quantification of B) GST-PD1 
and D) GST-PD6 phosphorylation by C- and N1-Src. Densitometry analysis carried 
out using ImageJ. n=3 experiments, error bars shoe SEM. E) Kms of the 
phosphorylation of PD1, PD6 and the control YA by C- and N1-Src. Km calculated 
using curve fitting in SigmaPlot, n=3 experiments. Statistical analysis carried out 
using ANOVA followed by post hoc Tukey test *p<0.05, all conditions compared to 
YA phosphorylation.  
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This proposed consensus motif differs from the known C-Src binding Class I and 
Class II PxxP motifs (+xxPxxP and PxxPx+ respectively) (Feng et al, 1994) and 
represents a novel SH3 domain binding sequence.  
 
4.5 The kinetics of PD1 and PD6 phosphorylation are comparable 
to good C-Src ligands 
 
Initial experiments identified both PD1 and PD6 as being highly specific for N1-Src. 
In order to determine the extent to which they are able to enhance phosphorylation, a 
more detailed analysis of the kinetics of their phosphorylation was carried out.  
 Full kinetic analysis over a larger substrate concentration range (Figure 4.5.1) 
revealed that both PD1 and PD6 enhance phosphorylation to approximately the same  
extent and that the Km for the phosphorylation falls within the low micromolar range 
The Km for PD1 phosphorylation is 6.5 ± 1.2 μM and the Km for the PD6 
phosphorylation is 5.0 ± 1.6 μM. Therefore, the affinity of the interaction between 
the N1-Src SH3 domain and PD1/6 is similar to that of known SH3 domain ligands 
such as the Class I and II motifs binding to the C-Src SH3 domain (Chapter 3) (Feng 
et al, 1995).  
 
4.6 Mutation of the PD1 sequence reveals critical residues for 
binding 
 
PD1 and PD6 have both been shown to enhance phosphorylation by N1-Src to a 
similar extent. However, it was decided to use the PD1 sequence as the basis of 
future work because it was so highly enriched during the phage display screen.  
 To determine the residues within the PD1 sequence that were required for the 
observed enhancement in phosphorylation, selected mutations were made. These 
mutations were based on the residues that were conserved between the PD peptides 
shown to enhance phosphorylation by N1-Src (Figure 4.4.1). The majority of the 
mutations made were substitutions to alanine (A) (Figure 4.6.1 A). An additional 
mutation of the threonine (T) residue at position 8 to valine (V) was made in order to 
determine whether the hydroxyl group in the threonine side chain was important for 
the interaction.  
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 Figure 4.6.1 B shows the results of these experiments. As for Figure 4.4.1, a 
band present in the highest concentration lane represents an enhancement in 
phosphorylation over the control peptide. The majority of the mutations abolish the 
enhancement in phosphorylation previously observed. This implies that they are 
required for the binding interaction between the substrate and the N1-Src SH3 
domain. The exception to this is the threonine residue at position 8. Here, mutation 
to either alanine or valine has little effect on the phosphorylation observed. This 
indicates that the presence of a threonine residue at position 8 is not absolutely 
required. Interestingly, there is a requirement for a positively charged amino acid at 
both ends of the consensus motif. The Class I and Class II SH3 binding motifs have 
positively charged amino acid at one end, but this dual requirement is novel for an 
SH3 domain binding motif.  
 
4.7 The interaction between PD1 and the N1-Src SH3 domain is 
direct 
 
In order to confirm that the enhancement in phosphorylation caused by the presence 
of the PD1 peptide in the in vitro assay is due to a direct interaction between the 
N1-Src SH3 domain and the PD1 peptide, a peptide titration experiment was carried 
out. The free peptide of the PD1 sequence was titrated into a phosphorylation 
reaction between the control peptide (YA) and N1-Src kinase. The presence of a high 
affinity SH3 domain ligand in conjunction with the ideal substrate is known to 
increase substrate phosphorylation (Chapter 3, (Scott & Miller, 2000) but the effect 
of titrating in a free peptide was not known. Surprisingly, the titration of the free 
PD1 peptide sequence resulted in an inhibition of phosphorylation (Figure 4.7.1). 
Importantly, there is no effect of titrating in the point mutant PD1-P5A, meaning that 
the interaction between PD1 and the N1-Src SH3 domain is sequence specific. This 
result implies that the PD1 sequence may also act as an N1-Src inhibitor in cell 
based assays.  
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Figure 4.6.1. Mutation of PD1 sequence reveals critical residues. 
A) Representation of the amino acid substitutions made within the PD1 sequence. 
B) Phosphorylation of the mutant GST-peptides by C- and N1-Src. Substrate 
concentrations of 8.3 µM and 2.8 µM used. Analysis carried out by 
α-phosphotyrosine blot using the PY20 antibody. C) Quantification of PD peptide 
mutant phosphorylation. Densitometry analysis carried out using ImageJ, n=3 
experiments, normalised to the PD1 WT signal at 8.3 μM. 
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Figure 4.7.1 Titration of PD1 peptide inhibits C-Src phosphorylation of YA. 
The free peptides of PD1-WT and PD1-P5A were titrated into a phosphorylation 
reaction between N1-Src (5 nM) and YA (25 μM). The peptide concentrations 
indicated were added to individual in vitro kinase assay reactions. A) Analysis of 
phosphotyrosine incorporation into YA using the PY20 antibody. B) Densitometry 
analysis of the phosphotyrosine incorporation, carried out using Image J. n=3 
experiments, error bars show SEM. 
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4.8 Bioinformatics reveals a potential role for N1-Src in 
cytoskeletal rearrangement 
 
The phage display consensus sequence obtained has been demonstrated to be able to 
specifically enhance N1-Src to an extent similar to that of known SH3 domain 
ligands. It therefore contains a potentially physiologically relevant sequence that can 
be used to predict potential N1-Src substrates using bioinformatic techniques. A 
series of bioinformatic techniques were utilised (depicted schematically in Figure 
4.8.1) that were able to systematically identify potential N1-Src substrates based 
initially on the presence of the consensus motif and subsequently on the prediction of 
tyrosine kinase phosphorylation.  
 In order to identify potential SH3 domain binding partner of N1-Src, a PSSM 
was constructed that contained information about the probability of finding 
eachamino acid at each position within the motif (Table 4.8.1). A score of 21 
represents an absolute requirement for that residue to be found in that position, 
whereas a score of 0 excludes that residue. Scores between 1 and 20 represent an 
increasing likelihood of a residue being present in a position with a score of 1 having 
neither a positive or negative effect on the selection. This matrix was then used to 
carry out a Scansite (Obenauer et al, 2003) search for proteins that contain sequences 
meeting the criteria. This produced a total of 771 unique proteins within the human 
genome. 
 To broadly identify the functions of these proteins, analysis was carried out 
using the online bioinformatic tool DAVID (Huang et al, 2009b). This analysis 
assigned functional roles to 541 (70%) of the Scansite hits using the GO Term 
‘Biological Process’. Proteins not assigned a functional role consisted mainly of 
uncharacterised or unknown proteins. DAVID was then used to assign the proteins 
into clusters based on their function and to assign these clusters an enrichment factor. 
The enrichment factor represents the prevalence of a functional group within the 
dataset compared to the expected prevalence based on occurrence in the genome. An 
enrichment factor cut off of 1.5 was enforced as suggested by Huang et al (2009b). 
 This analysis revealed 10 functional clusters containing 377 proteins that 
were present more commonly than would be expected based on their occurrence 
within the genome (Table 4.8.3). The enriched categories fall into six main 
functional groups: regulation of neuronal development, cytoskeletal rearrangement,  
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Figure 4.8.1. Schematic representation of bioinformatic analysis.  
An outline of the bioinformatic toools  used and the steps taken in order to identify 
both potential functional roles and specific protein targets of N1-Src kinase. 
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Table 4.8.1 PSSMs for Scansite predition of N1-Src SH3 domain substrates. 
Data from the round 5 sequenced peptides and the mutational analysis was 
combined and the probability of finding an amino acid in a given position entered 
into the matrix. A score of 21 means the residue must be found in that position and 
a score of 0 means that it must be excluded. A score of 1 has neither a positive or 
negative influence and was included when there was no data about a residue. 
There must be one fixed residue at position 0 (P in this case). 
 A C D E F G H I K L M N P Q R S T V W Y 
-7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-2 1 1 1 1 1 1 3 1 20 1 1 1 1 1 20 1 1 3 1 1 
-1 1 1 1 1 1 3 1 1 1 1 6 6 3 1 1 3 1 1 1 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 
1 6 1 1 1 1 1 3 1 3 1 3 1 1 3 1 3 1 1 1 1 
2 1 1 1 1 1 1 9 1 3 1 1 3 3 1 1 3 1 1 1 1 
3 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 10 10 1 1 
4 6 1 1 1 1 1 1 1 1 1 1 1 6 1 1 6 6 1 1 1 
5 6 1 1 1 1 1 1 1 20 1 1 1 1 1 20 1 5 1 1 1 
6 1 1 1 1 1 1 1 1 1 1 3 6 9 1 1 1 1 1 1 3 
7 1 1 1 1 1 1 1 1 1 4 1 1 8 1 1 1 1 1 1 4 
 
Table 4.8.2 PSSM for Scansite prediction of C-Src SH3 domain substrates. 
Constructed according to the same principles as the N1-Src PSSM but using data 
from a phage display experiment carried out by Sparks et al, 1996.  
 A C D E F G H I K L M N P Q R S T V W Y 
-7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-5 1 1 1 1 1 1 1 1 1 10 1 1 1 1 1 1 1 1 1 1 
-4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-3 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
-2 10 1 1 1 1 1 1 1 1 1 1 1 10 1 20 1 1 1 1 1 
-1 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 
0 1 1 1 1 1 1 1 1 1 10 1 1 10 1 1 1 1 1 1 1 
1 1 1 1 1 1 1 1 1 1 10 1 1 10 1 1 1 1 
 
1 1 
2 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 
3 1 1 1 1 1 1 1 5 1 10 1 1 10 1 1 1 5 5 1 1 
4 1 1 1 1 1 1 1 1 1 1 1 1 15 1 10 1 1 1 1 1 
5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
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regulation of Rho/Ras signalling, adhesion molecule signalling, catabolism and 
chromatin rearrangement. It is particularly striking that there is such a strong 
association with proteins that carry out functions in neuronal development, 309 
(51%) of the input proteins are reported as playing such as role. Although, N1-Src is 
neuronally expressed, there was no requirement for the searches carried out to 
produce neuronal hits.  
 Taken together, the functional clusters of cytoskeletal rearrangement, 
regulation of Rho/Ras signalling and adhesion molecule signalling are all processes 
that will influence cell morphology. This implies a possible role for N1-Src in the 
modulation of neuronal development and cell shape, which will be discussed further 
in Chapter 5.  
 To confirm that the DAVID tool is able to provide a reasonable assessment 
of protein function based on consensus motif, a similar analysis was carried out for 
C-Src, whose functional roles are already well characterised. A PSSM was produced 
using the known C-Src SH3 domain binding motifs (Table 4.8.2). This matrix was 
constructed using information about the individual peptides obtained from a phage 
display experiment using the C-Src SH3 domain (Sparks et al, 1996). The sequences 
used to construct the PSSM conform to a Class II PxxP motif. This motif was chosen 
because, although the C-Src SH3 domain is able to bind to both Class I and Class II 
PxxP motifs it has a strong bias towards Class II motifs (Wu et al, 2007). 
Scansite analysis was carried out using the C-Src PSSM and this identified 
1032 unique proteins containing the consensus motif. 734 of these were assigned a 
functional role by DAVID, with 717 being present in enriched clusters. The 
functional clusters identified for C-Src are shown in Table 4.8.4 and include 
regulation of cellular differentiation, cytoskeletal rearrangement and angiogenesis, 
all of which are functions that C-Src is known to carry out. Interestingly, although 
neuronal development appears as a cluster, there are only 11 (1%) proteins contained 
within this cluster, far fewer than for the N1-Src analysis.  
There are a number of roles assigned to C-Src in neuronal development and it 
is possible that some of these are actually carried out by N1-Src. As there are no 
commercially available inhibitors capable of specifically inhibiting only one isoform 
it is difficult to assign a function to only one isoform. The overlap between C- and 
N1-Src kinase substrates predicted by Scansite was very small (Figure 4.8.2) and this  
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Table 4.8.3. Enriched functional roles for N1-Src substrates identified by 
Scansite analysis.  
DAVID analysis of protein functions that occur more frequently than would be 
expected based on their occurrence in the genome (enrichment factor). Input 
proteins were those identified by Scansite as containing the N1-Src SH3 domain 
consensus motif. 
Cluster name Enrichment Factor No. of proteins 
Rho/Ras protein signal transduction 6.5 62 
Chromatin rearrangement 3.3 39 
Regulation of Rho/Ras GTPase activity 2.4 27 
Cytoskeletal rearrangement 2.4 27 
Catabolism 2.3 132 
Actin rearrangement 2.3 33 
Regulation of neuronal differentiation 1.9 86 
Regulation of neuronal development 1.6 183 
Adhesion molecule signalling 1.5 40 
Regulation of cell morphology 1.5 62 
 
Table 4.8.4 Enriched functional roles for C-Src substrates identified by 
Scansite analysis.  
DAVID analysis of protein functions that occur more frequently than would be 
expected based on their occurrence in the genome (enrichment factor). Input 
proteins were those identified by Scansite as containing the C-Src SH3 domain 
consensus motif. 
Cluster name Enrichment Factor No. of proteins 
Regulation of metabolism 13.7 285 
Cell differentiation 8.3 54 
Actin cytoskeleton organisation 7.6 164 
Regulation of transcription 6.9 148 
Regulation of gene expression 6.6 135 
Embryonic development 5.7 44 
Cell differentiation 3.9 108 
Chromatin rearrangement 3.4 42 
Neuronal development 3.2 11 
Angiogenesis 2.3 40 
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Figure 4.8.2. There is only a small degree of overlap between bioinformatic C- 
and N1-Src substrates.  
The extent of the overlap between protein hits arising from both A) Scansite 
analysis and B) enriched clusters identified by DAVID analysis for C- and N1-Src. 
Circle sizes are proportional to the number of proteins they represent.  
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supports the prediction that they interact with different substrates and play different 
roles within the cell.  
 For the potential substrates to be phosphorylated by N1-Src they should 
contain a tyrosine residue that can be phosphorylated by the kinase domain. As the 
kinase domains of C- and N1-Src are identical, prediction programmes can be used 
to assess which of the potential N1-Src SH3 domain substrates are also likely to be 
phosphorylated. The GPS kinase prediction programme (Xue et al, 2008) was used 
to carry out this analysis. 
GPS analysis was initially used to predict whether a protein can be tyrosine 
phosphorylated and, if it is, whether that phosphorylation is carried out by Src. This 
analysis was carried out for both C- and N1-Src (Figure 4.8.3) and reveals that a 
large proportion (~75%) of both the C- and N1-Src predicted SH3 domain substrates 
are also predicted to be tyrosine phosphorylated. Of these, ~70% are predicted to be 
Src phosphorylated. As the C-Src SH3 domain consensus motif is known to be found 
in in vivo phosphorylated substrates, it is encouraging that approximately the same 
proportion of C- and N1-Src predicted substrates are also predicted to be tyrosine 
phosphorylated. 
More detailed analysis was then carried out using GPS to predict the SFK 
member responsible for a phosphorylation event. This revealed a preference for the 
Src kinase domain over that of any other SFK member for both the N1- and C-Src 
datasets (Figure 4.8.3 B and C). In order to confirm that this is not a general bias 
towards the Src kinase domain a series of controls were carried out by GPS analysis 
of Scansite predicted Src kinase domain, Lck SH3 domain and PKA kinase domain 
substrates (Figure 4.8.4).  
Src was the predominant kinase predicted to phosphorylate the substrates 
identified by Scansite as being Src kinase domain substrates (Figure 4.8.3 A). This 
confirms that Scansite and GPS use similar criteria to define a Src substrate and 
provides confidence that this method is capable of producing meaningful results.  
The Scansite defined Lck SH3 domain substrates were predicted to be 
predominantly phosphorylated by Lck kinase (Figure 4.8.3 B). Importantly, this 
demonstrates that there is a link between substrates identified by Scansite as SH3 
domain interacting partners and those identified as kinase substrates by GPS. This is 
crucial because it shows that substrates identified as SH3 domain interacting are also 
highly likely to be phosphorylated by the relevant kinase. Additionally, this result  
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Figure 4.8.3. Scansite predicted N1-Src substrates are also predicted to be 
kinase substrates by GPS.  
A) GPS prediction of the proportion of Scansite identified C-Src, N1-Src and PKA 
which are i) tyrosine phosphorylated and ii) Src phosphorylated. B) and C) GPS 
prediction of the SFK member which phosphorylates the substrates predicted to be 
Src phosphorylated for B) N1-Src and C) C-Src. 
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Figure 4.8.4. GPS is able to accurately predict SFK preferences from known 
datasets.  
Scansite generated datasets for substrates of the A) Src kinase domain, B) Lck SH3 
domain and C) PKA kinase domain were entered into the GPS kinase prediction 
programme and were predicted to be predominantly phosphorylated by A) Src, B) 
Lck and C) no preference. 
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shows that there is not an inbuilt bias into the GPS programme to predict Src kinase 
substrates. This was considered to be a potential problem as Src is the most 
extensively studied of the SFKs.  
A final control experiment utilised Scansite predicted PKA substrates. PKA 
is not a tyrosine kinase and so there should be no reason for phosphorylation by any 
member of the SFKs to be enriched within its predicted substrates. The total number 
of substrates predicted to be tyrosine phosphorylated by PKA was approximately 
20% lower than for either C- or N1-Src (Figure 4.8.2 A) and, of those predicted to be 
Src phosphorylated, there is no bias towards any member of the SFKs (Figure 4.8.3 
C).  
As a result of the GPS analysis control experiments, it can be concluded that 
the approach taken is able to identify potential kinase substrates from SH3 domain 
substrates and that there is no inbuilt bias for Src kinase. Therefore, there is a high 
degree of confidence in the ability of this technique to select potential N1-Src kinase 
domain substrates from the list of potential SH3 domain interactors.  
The list of proteins identified by GPS as potentially phosphorylated by N1-
Src represents a more refined set of potential N1-Src substrates as they are now 
predicted to both contain the consensus motif for the N1-Src SH3 domain and to be 
phosphorylated by the kinase domain. These substrates were re-submitted into 
DAVID in order to gain an updated list of enriched clusters (Table 4.8.5). This 
analysis revealed that the enriched clusters now no longer contain functions such as 
catabolism and chromatin rearrangement. It is likely that the proteins associated with 
these functions do not contain a potential phosphorylation site and have therefore 
been excluded from the analysis. The remaining enriched clusters indicate a strong 
relationship between N1-Src function and the regulation of cell shape during 
neuronal differentiation.  
Following the second round of DAVID analysis, 134 proteins remained as 
potential N1-Src substrates. To identify whether there was any evidence of in vivo 
phosphorylation of these proteins, PhosphoSite database analysis was carried out. 
The PhosphoSite database is a repository of experimental data, predominantly 
obtained through high throughput screens, containing information about protein 
residues that are post translationally modified. Comparison of the potential N1-Src 
substrates with the PhosphoSite database produced a final list of 52 potential N1-Src 
substrates for which there is experimental evidence of phosphorylation at the correct 
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Table 4.8.5 Enriched functional roles for potential N1-Src substrates identified 
by GPS as being Src phosphorylated.  
DAVID analysis of protein functions that occur more frequently than would be 
expected based on their occurrence in the genome (enrichment factor). Input 
proteins were those predicted by GPS as being Src phosphorylated. 
Cluster name Enrichment Factor No. of proteins 
Cell adhesion molecule signalling 4.1 23 
Ras/Rho protein signalling 3.1 21 
Post translational modification 2.5 46 
Neuronal differentiation 2.1 56 
Cytoskeletal rearrangement  1.7 73 
 
tyrosine residue (Table 4.8.6). Of the 52 final proteins, 25 (48%) are assigned by 
DAVID as performing a role in neuronal development.  
Processive phosphorylation is commonly carried out by SFKs as the SH2 
domain docks onto a phosphorylated tyrosine residue, allowing the protein to be 
further phosphorylated and resulting in sustained kinase activation (Mayer et al, 
1995). Scansite is also able to predict which tyrosine residues would be able to act as 
a scaffold for the kinase (i.e. are able to bind to the Src SH2 domain), allowing 
further phosphorylation to occur. When this analysis was carried out on the final set 
of substrates, 14 (27%) of the potential substrates were shown to also contain a 
tyrosine residue predicted to act as a SH2 domain scaffold (Table 4.8.6). However, 
only 5 (10%) of these occur at the same tyrosine residue identified as the site of 
potential phosphorylation. 
The proteins that fit all of the criteria of an ideal potential N1-Src kinase 
substrate i.e. they contain the SH3 domain consensus binding motif, are predicted by 
GPS to be Src phosphorylated, have prior evidence of in vivo phosphorylation and 
are predicted to act as a SH2 domain scaffold are; AHNAK2, collagen alpha-1(V) 
chain, mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1), 
methionine synthase and tyrosine-protein phosphatase non-receptor type 6 (PTPN6). 
All of these proteins are expressed in neuronal tissue and have defined roles in the 
brain. They therefore represent a promising list of candidate substrates that could be 
further investigated as putative in vivo N1-Src substrates.  
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Table 4.8.6. Potential N1-Src substrates play a role in neuronal development.  
Proteins that were shown to be phosphorylated in the Phosphosite database at the same residue predicted to be phosphorylated by GPS were 
included in the final list of potential N1-Src substrates. Proteins assigned by DAVID as playing a role in neuronal development are highlighted 
(grey). The ability of the protein to act as an SH2 domain scaffold is indicated Yes (Y) or No (N). If Y then the residue(s) predicted to act as the 
scaffold is stated. Proteins that fit all of the criteria for a potential N1-Src substrate are highlighted in red. 
UniProt ID Protein Name Phosphorylated 
residue(s) 
Phosphorylated  
peptide(s) 
SH3 binding 
residue(s) 
SH3 binding peptide(s) SH2 scaffold? 
ADAM9 Disintegrin and metalloproteinase domain-containing protein 9 815 PAPAPPLYSSLT*** 8 MGSGARFPSGTLRVR Y – Y42 
ADNP Activity-dependent neuroprotector homeobox protein 936 QKEDGSKYETIHLTE 779 TKYFNKQPYPTRREI N 
AFF4 AF4/FMR2 family member 4 668 PSSQTPKYPESNRTP 567 RTVGKKQPKKAEKAA N 
  712 LSEPDDRYPLIVKID    
AHNK2 Protein AHNAK2 59 PQGSSPVYEYTTEAA 1092 EMPSFKMPKVALKGP Y – Y59 
APOL3 Apolipoprotein L3 193 LMELTQIYQRLNPCH 308 ARARARLPVTTWRIS N 
ARFGAP3 ADP-ribosylation factor GTPase-activating protein 3 279 VSSLRLAYKDLEIQM 218 SSIIKKKPNQAKKGL N 
  349 NDDSDDSYFTSSSSY    
  408 TARRKPDYEPVENTD    
BIG1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 662 HPETINRYGSLNSLE 791  FLEGFRLPGEAQKID Y-Y874 
  852 NKMTKEQYIKMNRGI    
BMP2K BMP-2-inducible protein kinase 813 YEQAKAKYSDMSSVY 1015 LKPTYRTPERARRHK N 
BSN Bassoon 669 EDLVGKPYSQDASRS 2245 LTSLTRVPMIAPRVP Y – Y1257, 
Y905, Y3161 
  1126 HRSSCSEYSPSPSLD    
  1470 TPQPSRAYSYFASSS    
  1472 QPSRAYSYFASSSPP    
  3220 TYPSDSHYTSLEQNV    
  3388 VESDLASYPPPAVSS    
  3620 ARHSYHDYDEPPEEG    
  3705 GYPSSAEYSQPSRAS    
BSN (cont.)  3715 PSRASSAYHHASDSK    
C1QR1 Complement component C1q receptor 628 PQNAADSYSWVPERA 506 TASPTRGPEGTPKAT N 
  644 SRAMENQYSPTPGTD    
CBPC2 Cytosolic carboxypeptidase 2 150 LRSRQLLYDELDEVN 175 SILSTKRPLQAPRWP N 
  764 RKQRNEQYQKKNLMQ    
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UniProt ID Protein Name Phosphorylated 
residue(s) 
Phosphorylated  
peptide(s) 
SH3 binding 
residue(s) 
SH3 binding peptide(s) SH2 scaffold? 
CKAP5 Cytoskeleton-associated protein 5 1854 KEGLAELYEYKKKYS 222 EEEWVKLPTSAPRPT N 
CO5A1 Collagen alpha-1(V) chain 338 EDVGIGDYDYVPSED 71 TRRSSKGPDVAYRVT Y – Y338, 
  442 PANQDTIYEGIGGPR 296 EPTPSKKPVEAAKET Y420, Y442 
CTRO Citron Rho-interacting kinase 1929 NKRGPPTYNEHITKR 2007 DSSRGRLPAGAVRTP N 
CYLD Ubiquitin carboxyl-terminal hydrolase CYLD 376 SKSKNTWYIDEVAED 151 GVVRFRGPLLAERTV N 
DNLI1 DNA ligase 1 919 GSDPEDTY******* 221 EEEQTKPPRRAPKTL N 
DSG2 Desmoglein-2 882 MVNSENTYSSGSSFP 538 FSVIDKPPGMAEKWK N 
  1013 QHLQDVPYVMVRERE    
  1061 ASTLQSSYQIPTENS    
  1117 HSTVQHSYS******    
DYHC1 Cytoplasmic dynein 1 heavy chain 1 4357 EDEDDLAYAETEKKT 4239 NISPDKIPWSALKTL Y – Y3130 
GAK Cyclin-G-associated kinase 615 VASTSQEYDKMRDFK 1167 EERGVRAPSFAQKPK N 
IQGA3 Ras GTPase-activating-like protein IQGAP3 13 AGPGWAAYERLTAEE 635 TERVLRNPAVALRGV N 
ITCH E3 ubiquitin-protein ligase Itchy homolog 420 QFNQRFIYGNQDLFA 260 PPRPSRPPPPTPRRP Y – Y103 
L1CAM Neural cell adhesion molecule L1 310 GEEDDGEYRCLAENS 139 AEGAPKWPKETVKPV N 
  418 ELAKDQKYRIQRGAL    
LMTK3 Serine/threonine-protein kinase LMTK3 296 HSNYKEDYYLTPERL 1012 ENGGLRFPRNTERPP Y – Y515 
  297 SNYKEDYYLTPERLW    
M4K1 Mitogen-activated protein kinase kinase kinase kinase 1 381 SESSDDDYDDVDIPT 352 RGMETRPPANTARLQ Y – Y381 
 
MAF Transcription factor Maf 348 RDAYKEKYEKLVSSG 36 KFEVKKEPVETDRII N 
MAST2 Microtubule-associated serine/threonine-protein kinase 2 812 ESEDDTSYFDTRSER 868 LLEERRTPPPTKRSL N 
METH Methionine synthase 913 FEEIMEEYEDIRQDH 640 DLIWNKDPEATEKLL Y – Y630, 
Y913 
MYCB2 Probable E3 ubiquitin-protein ligase MYCBP2 3902 PEGEEKVYNATSDAD 3820 IKIELKGPENTLRVR N 
NRX2A Neurexin-2-alpha 1710 KKNKDKEYYV***** 1699 APAAPKTPSKAKKNK N 
NTHL1 Endonuclease III-like protein 1 68 AQRLRVAYEGSDSEK 58 SHSPVKRPRKAQRLR N 
NUMB Protein numb homolog 15 FRRKKDVYVPEASRP 410 QPGHKRTPSEAERWL N 
NXF2 Nuclear RNA export factor 2 120 SQNTQDGYTRNWFKV 618 LQTEGKIPAEAFKQI N 
PGCA Aggrecan core protein 131 RSNDSGVYRCEVMHG 212 
634 
ADGSLRYPIVTPRPA  
SDQTVRYPIQTPREA 
N 
PLD1 Phospholipase D1 42 FEGEEVDYDVSPSDP 140 YKAFIRIPIPTRRHT N 
PRDM9 Histone-lysine N-methyltransferase PRDM9 191 RERKGHAYKEVSEPQ 104 PRQQVKPPWMALRVE Y – Y302 
PTN6 Tyrosine-protein phosphatase non-receptor type 6 276 ENKGKNRYKNILPFD 212 AFVYLRQPYYATRVN Y – Y412, 
  536 QKGQESEYGNITYPP   Y564 
  564 SKHKEDVYENLHTKN    
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UniProt ID Protein Name Phosphorylated 
residue(s) 
Phosphorylated  
peptide(s) 
SH3 binding 
residue(s) 
SH3 binding peptide(s) SH2 scaffold? 
PYR1 CAD protein 1890 GTPDGTCYPPPPVPR 1477 VHVHLREPGGTHKED Y – Y1749  
RBM15 Putative RNA-binding protein 15 608 AATSVPAYEPLDSLD 52 MKGKERSPVKAKRSR N 
  684 LSSSRDRYNSDNDRS    
RELN Reelin 2821 KGWKRITYPLPESLV 1571 LPQDAKTPATAFRWW N 
RNPS1 RNA-binding protein with serine-rich domain 1 205 HPHLSKGYAYVEFEN 26 KKSSTRAPSPTKRKD N 
  207 HLSKGYAYVEFENPD    
RS10 40S ribosomal protein S10 12 KKNRIAIYELLFKEG 33 DVHMPKHPELADKNV N 
  127 GEADRDTYRRSAVPP    
SCG2 Secretogranin-2 135 APKENKPYALNSEKN 467 EKVLPRLPYGAGRSR N 
  349 PLDSQSIYQLIEISR    
SEC63 Translocation protein SEC63 homolog 106 EYQEYNPYEVLNLDP 520 WQQKSKGPKKTAKSK Y – Y432 
SHAN1 SH3 and multiple ankyrin repeat domains protein 1 (Shank1) 900 AAEDDRPYLAPPAMK 506 
771 
SPSRGRHPEDAKRQP 
EAVHKKAPQQAKRLP 
N 
SHRM2 Shroom2 210 HSKRDSAYGSFSTSS 363 QPRGDRRPELTDRPW N 
SI1L3 Signal-induced proliferation-associated 1-like protein 3 1265 HSKGEPQYSSHSSSN 327 EADEGRSPPEASRPW N 
SLAF5 SLAM family member 5 279 QPAESRIYDEILQSK 270 LNTFTKNPYAASKKT Y – Y296, Y279, 
Y316 
  299 EEPVNTVYSEVQFAD    
SPT6H Transcription elongation factor SPT6 321 EEEADWIYRNAFATP 812 VTDFLRLPHFTKRRT Y – Y425 
TB10A TBC1 domain family member 10A 328 VKACQGQYETIERLR 428 SKAKPKPPKQAQKEQ N 
TDRD7 Tudor domain-containing protein 7 502 EDEMKEYYSKNPKIT 374 EMYKVKFPEDALKNL N 
UBP31 Ubiquitin carboxyl-terminal hydrolase 31 1123 KSASALTYTASSTSA 1019 PGSLAKKPESTTKRS N 
XIRP2 Xin actin-binding repeat-containing protein 2 90 KSNNTREYGRPEVLK 1847 EVNLPKAPKGTVKIV Y – Y1156, 
Y3283 
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4.9 Discussion 
 
4.9.1 Identification of a novel consensus motif for the N1-Src SH3 domain 
 
The technique of phage display has been successfully used to establish a consensus 
motif for the N1-Src SH3 domain. This consensus motif is +xPxxTx+ (where + 
represents a positively charged amino acid). Phage display has been demonstrated 
multiple times to be an effective way of determining the consensus sequence of 
modular domains such as the SH3 domain (Cheadle et al, 1994; Rickles et al, 1994) 
and the sequences that it identified have been demonstrated to be contained in in vivo 
substrates (Songyang, 1999). Non-specific selection of peptides can occur due to 
plastic binding and propagation related amplification of certain peptide sequences 
(Vodnik et al, 2011). In this study, negative selection steps were carried out during 
the panning process and all peptide sequences obtained were compared to known 
plastic binding or propagation related sequences (Vodnik et al, 2011). Only one 
peptide was found to be the result of non-specific amplification and it was removed 
from consideration in subsequent analysis. Therefore, peptides have been included in 
the alignment with a high degree of confidence that they are present due to a specific 
interaction with the N1-Src SH3 domain.  
In vitro kinase assays have been used to demonstrate that the presence of 
PD1 is able to enhance phosphorylation specifically by N1-Src and mutagenic 
analysis has confirmed that the residues identified as being part of the consensus 
motif are required for the observed enhancement in phosphorylation. The exception 
to this is the threonine residue, where mutation to both alanine and valine was shown 
to have little effect on the phosphorylation observed. The reason for this remains 
unclear, but ongoing work in the lab aims to obtain the structure of the N1-Src SH3 
domain in complex with PD1. This would reveal the structural basis of the 
interaction and could inform any future mutations that could be made.  
 The consensus motif differs from the general SH3 domain consensus motif of 
PxxP, meaning that the N1-Src SH3 domain binds to an atypical binding motif. The 
motif identified is novel and has not previously been shown to bind to any other SH3 
domain. As the only difference between the C- and N1-Src SH3 domains is the 
presence of an insert within the N1-Src n-Src loop, this structural difference must be 
the cause of the atypical binding. The requirement for a positively charged residue 
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either side of the central motif is a novel property of an SH3 binding motif and 
results in the consensus motif for N1-Src being longer than for many other known 
SH3 domains (Mayer, 2001). The structural basis for substrate binding to the C-Src 
SH3 domain was introduced in section 1.2.1.3 and is known to involve residues in 
the n-Src loop. Therefore, alteration of n-Src loop residues would be predicted to 
alter the substrates able to bind. It is possible that the extra residues contained within 
the N1-Src SH3 domain are themselves able to contribute to the substrate binding 
site. 
 Very few SH3 domains contain inserts within their n-Src loops. Two known 
examples are the amphiphysin1/2 (Amph1/2) and PI3K SH3 domains. Amph1/2 are 
brain enriched proteins implicated in the regulation of clathrin-mediated endocytosis. 
The Amph1/2 SH3 domains bind to the sequence PSRPNR in the proline rich 
domain (PRD) of dynamin (Grabs et al, 1997). This sequence corresponds to a Class 
II PxxP motif. However, phage display using an oriented peptide library identified 
the consensus motif for the Amph2 SH3 domain as PxRPxR(H)R(H) (Grabs et al, 
1997), which is also longer than most SH3 domain binding sequences and contains 
an additional positively charged arginine residue. The crystal structure of the Amph2 
domain shows that the n-Src loop projects out from the core of the SH3 domain but 
is positioned adjacent to the substrate binding site (Owen et al, 1998). Both the 
inserts in the N1-Src and the Amph1/2 n-Src loops contain predominantly basic 
residues (Levy & Brugge, 1989; Owen et al, 1998). In the crystal structure of the 
Amph2 SH3 domain this is shown to result in an extended negatively charged patch 
on the surface of the protein. If this is also true of the N1-Src SH3 domain then it 
could explain the requirement for two positively charged residues within the 
consensus motif. Elucidation of the structure of the N1-Src SH3 domain would 
determine whether this is the case. 
 
4.9.2 Validity of the bioinformatic approach taken 
  
The bioinformatic approach used in this study has provided insight into the possible 
functions of N1-Src. The validity of the subsequent bioinformatic approaches relies 
on the accuracy of the initial PSSM used to identify potential N1-Src SH3 domain 
binding substrates. The matrix constructed was based on experimental evidence, both 
from the initial phage display experiments and from the subsequent validation 
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experiments. Therefore, there is a high degree of confidence that the matrix contains 
accurate information about the amino acid preferences of the N1-Src SH3 domain. 
The only position at which the information may not be as accurate is the threonine 
residue at position 8. As none of the mutations made significantly affected the 
observed phosphorylation of the substrate it is not entirely clear what the substrate 
preferences are at this position. In the matrix, the amino acids that have been shown 
to facilitate phosphorylation (T, A and V) have been included. However, there is 
currently no evidence that other amino acids should be excluded from this position. 
The reason for imposing some constraints on the amino acids present in this position 
was to limit the number of potential N1-Src substrates identified to a number on 
which meaningful further analysis could be carried out. It is not suggested that the 
substrates identified may be incorrect but it is possible that some potential substrates 
have been excluded by constructing the matrix in this manner. 
 In order to ascertain whether there is any amino acid preference at position 8 
it would be informative to carry out a phage display experiment using a directed 
peptide library. The amino acids that have been confirmed to be required for 
phosphorylation can be fixed to be present in all peptides in the library with other 
positions still randomised (R/KxPxxxxR/K). This technique has been used in order 
to identify the flanking residues for the Class I and Class II PxxP motifs that bind to 
the C-Src SH3 domain (Feng et al, 1995) and would reveal whether there is any 
amino acid preference at positions other than those already shown to be required.  
The use of PSSMs to discover novel protein-protein interactions has been 
validated previously. Scansite uses a library of PSSMs derived from experimental 
data to predict substrates of protein domains, including a number of SH3 domains 
(Obenauer et al, 2003). Other groups have successfully employed user defined 
PSSMs to identify physiologically relevant interactions. Chan et al (2011) produced 
a PSSM from peptide array data and used it to carry out a Scansite search for 
potential 14-3-3 protein interacting proteins. This led to the identification of two 
residues within Cdc25C required for 14-3-3 binding and the confirmation of the 
interaction by immunoprecipitation.  
An oriented peptide library has been used to produce a consensus 
phosphorylation motif for the leucine rich repeat kinase 2 (LRRK2). Construction of 
a PSSM and a Scansite search identified potential novel substrates and peptides 
derived from these novel substrates could be phosphorylated in vitro (Pungaliya et 
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al, 2010). User defined PSSMs have also been used on a larger scale to map the 
interactions of many individual PDZ domains (Tonikian et al, 2008) and the yeast 
SH3 domain interactome (Tonikian et al, 2009). 
The use of a combination of bioinformatic techniques has been able to 
provide an informative list of potential N1-Src substrates that fit all of the criteria of 
a Src kinase substrate. The combination of techniques used is novel to this study and 
the validity of the proteins identified must be treated with caution. Applying 
consecutive algorithms will inevitably introduce error at each stage. All 
bioinformatic techniques were carried out with a high degree of stringency and 
therefore it can be concluded that it is more likely that potential Src substrates have 
been excluded rather than those that are not potential substrates included 
erroneously. In a recent review, Reimand et al (2012) assessed current methods for 
prediction of domain mediated protein-protein interaction and concluded that 
combined approaches are commonly able to make predictions with a higher degree 
of confidence than methods based on a single prediction parameter. The use of GO 
terms (used here to select enriched clusters by DAVID analysis) has also been shown 
to reduce the amount of false positive hits in bioinformatic prediction of protein-
protein interactions (Mahdavi & Lin, 2007). 
 Other groups have also exploited the modular domain organisation of 
signalling molecules such as the Src kinases in order to carry out integrated 
bioinformatic studies. Akiva et al (2012) used Scansite prediction of SH2, SH3 and 
PDZ domains coupled with NetPhorest (Miller et al, 2008) prediction of 
phosphorylation sites in order to demonstrate the existence of interaction-regulation 
units whose phosphorylation prevents substrate interaction. In this case the kinase 
site prediction was confirmed by comparison to low throughput experimental data. 
 Hou et al (2011) utilised different bioinformatic tools but still employed a 
hierarchical approach in order to identify novel potential A-kinase anchoring 
proteins (AKAPs), that act as scaffolds for PKA signalling. This group carried out 
their initial selection of potential substrates using a PSSM, in this case obtained from 
virtual mutagenesis studies. Further refinement of this dataset was carried out by 
sequential analysis of peptide secondary structure prediction, transmembrane region 
prediction and sequence conservation in vertebrate genomes. Validation of the hits 
was carried out by confirmation of the inclusion of known AKAPs and literature 
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searching for evidence that proteins containing the identified peptides may act as 
AKAPs.  
 Therefore, there is a precedent for the use of a combination of bioinformatic 
techniques to generate potential substrates that interact with the protein of interest 
under physiologically relevant conditions.  
  
4.9.3 Insights into the functions of N1-Src 
 
The use of DAVID analysis to identify enriched clusters allows unbiased screening 
of the dataset. The majority of the enriched clusters identified pointed to a role for 
N1-Src in cytoskeletal rearrangement. This is in agreement with the morphological 
changes observed following overexpression of the neuronal kinases (Chapter 3). 
DAVID identified that N1-Src may be acting the Rho/Ras signalling and cell 
adhesion molecule signalling pathways, both of which have documented roles in the 
regulation of cell morphology and cytoskeletal rearrangement.  
It is known that signalling through the Rho/Ras pathway influences cell 
morphology. The major role of Rho GTPases is to control the assembly, 
disassembly, and dynamic rearrangements of the actin and microtubule cytoskeletons 
(Hall, 1998). Therefore, they play crucial roles in axon growth, guidance, and 
branching (Hall & Lalli, 2010). Ras GTPases are activated by a large number of 
plasma membrane growth factor receptors and adhesion receptors to promote key 
signal transduction pathways, including ERK, MAP kinase, and PI3-kinase that play 
a variety of important roles in axonogenesis (Hall & Lalli, 2010). Overexpression of 
a dominant positive form of Rho causes a contractile phenotype (Kolyada et al, 
2003) similar to that observed in neuronal Src transfected fibroblasts (Chapter 3).  
 The final list of possible protein substrates reveals some interesting potential 
binding partners of N1-Src. The list includes some well characterised neuronal 
proteins such as Reelin and L1-CAM. There are also a number of less well 
characterised proteins that, although they have been identified as playing a role in 
neuronal development, are much less well understood. The presence of L1-CAM in 
this final dataset is interesting as there is some evidence that Src is involved in L1-
CAM signalling, but the isoform of Src responsible remains unknown (Ignelzi et al, 
1994). However, both the SH3 domain interacting site and the potential 
phosphorylation site identified in this study are contained within the extracellular 
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domain of L1-CAM. The Src kinases are not known to phosphorylate extracellular 
residues on transmembrane proteins and it seems unlikely that N1-Src would be 
responsible for a physiologically relevant phosphorylation at this site. The link 
between L1-CAM and N1-Src will be discussed in more detail in Chapter 5.  
The proteins that fulfil all of the criteria of a potential N1-Src substrate are of 
particular interest and the evidence for tyrosine phosphorylation involvement in the 
regulation of their functions is discussed further below. 
 
4.9.3.1 AHNAK2 
 
AHNAK2 is a member of the AHNAK family, also known as desmoyokins. They 
are giant proteins (~700 kDa) and the specific functions of AHNAK2, as opposed to 
other AHNAK family members, are poorly understood. AHNAK was first identified 
as a component of desmosomal plaques (Hieda & Tsukita, 1989). It was 
subsequently independently identified in a screen for genes that undergo 
transcriptional repression in non-differentiated tumours of neural crest origin; the 
neuroblastomas (Shtivelman & Bishop, 1993). Its expression has also been shown to 
increase following spinal cord injury (von Boxberg et al, 2006). The full length form 
of AHNAK is known to be expressed in the adult CNS but its expression is thought 
to be localised to the blood cells of the blood brain barrier (Gentil et al, 2005). A 
smaller (~300 kDa) isoform has also been identified (Carlson et al, 2010; Huang et 
al, 2008b) and shown to be expressed in cardiac cells and the Torpedo electric organ; 
a structure of the electric eel that is analogous to the mammalian neuromuscular 
junction (NMJ). This smaller AHNAK isoform has also been shown by PCR to be 
expressed in developing mouse motor neurons (Carlson et al, 2010).  
In cardiac cells AHNAK is known to link voltage gated calcium channels to 
the cytoskeleton (Hohaus et al, 2002) and is able to bind to the CavB subunit 
(Komuro et al, 2004). In the electric organ, AHNAK is found localised to 
presynaptic sites and associated with nerve terminals in a complex that also contains 
calcium channels, integrins and laminins (Carlson et al, 2010). AHNAK is therefore 
predicted to function in the modulation of cytoskeletal organisation as a result of 
calcium signalling in the CNS.  
AHNAK2 is known to be tyrosine phosphorylated only through high 
throughput studies and there is currently no information available about the tyrosine 
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kinase that carries out the phosphorylation or the functional effect of the 
phosphorylation event. The sites identified as being potential N1-Src SH2, SH3 and 
kinase domain substrates in this study are contained within the smaller AHNAK 
isoform and it is therefore possible that N1-Src phosphorylation of AHNAK would 
occur under physiological conditions. 
 
4.9.3.2 Collagen alpha-1(V) chain 
 
Type V collagens are a minor component of collagen that are found in many tissues 
including the brain (Rhodes & Miller, 1978). The alpha-1 chain can exist as a 
homotrimer or as a heterotrimer in complex with alpha-2 and alpha-3 chains (Morris 
et al, 1990). Type V collagen fibrils are secreted and function as components of the 
ECM. Phosphorylation of secreted proteins is very unusual and there is currently no 
evidence, other than mass spectrometry data, for tyrosine phosphorylation of Type V 
collagen.  
 
4.9.3.3 Mitogen activated protein kinase kinase kinase kinase 1 (MAP4K1) 
 
MAP4K1 is more commonly known as hematopoietic progenitor kinase 1 (HPK1). It 
is a serine/threonine kinase that is predominantly expressed in hematopoietic cells 
but is also present in other tissues, including the brain (Hu et al, 1996). The majority 
of the work into the function of HPK1 has been carried out in T cells, where it has 
been shown to act in the MAP kinase pathway to link cell surface receptors to the c-
Jun NH2-terminal kinase (JNK) pathway (Hu et al, 1996). To do this, HPK1 has 
been shown to interact with many adaptor proteins including Grb2, Nck, Crk and 
SLP-76 (Anafi et al, 1997; Boomer & Tan, 2005).  
 More recently, HPK1 has been shown to function in the brain in pathways 
that induce injury following cerebral ischemia. Importantly, the activation of HPK1 
in this context is dependent on a tyrosine phosphorylation event (Li et al, 2008a). It 
is thought that Src is activated through its phosphorylation of the NMDA-R and 
activated Src subsequently phosphorylates HPK1 (Zhang et al, 2007). This increases 
the activity of HPK1 and results in the sequential activation of MLK3, MKK7 and 
JNK3 (Li et al, 2008b), a pathway involved in the induction of apoptosis following 
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ischemia. The site of phosphorylation in the HPK1 sequence has not yet been 
identified.  
 The Src isoform responsible for the HPK1 phosphorylation is currently 
assumed to be C-Src (Li et al, 2008b). However, these experiments were carried out 
using a broad spectrum SFK inhibitor and therefore the isoform responsible could be 
another SFK member or, as would be predicted by this study, N1-Src. As HPK1 fits 
all of the criteria imposed in this study for an ideal N1-Src substrate candidate it 
would be interesting to carry out in vitro experiments to determine the Src isoform 
responsible for the phosphorylation.  
 
4.9.3.4 Methionine synthase 
 
Methionine synthase is an enzyme that catalyses the remethylation of homocysteine 
to methionine. Mutations in methionine synthase are risk factors for sporadic 
Alzheimer’s Disease (AD) (Beyer et al, 2003) due to the resultant accumulation of 
homocysteine in the cell. Homocysteine is known to sensitise hippocampal neurons 
to β-amyloid induced damage in cell culture experiments (Sai et al, 2002) and to 
increase vulnerability to DNA damage induced excitotoxicity (Kruman et al, 2000). 
Therefore, methionine synthase activity is required for normal neuronal function. 
The function of tyrosine phosphorylation of methionine synthase remains unknown 
and has so far only been reported in high throughput screens but could potentially 
regulate its activity. Further investigation is therefore required to ascertain whether 
tyrosine phosphorylation of methionine synthase occurs under physiological 
conditions and whether the phosphorylation has any effect on enzyme activity. If 
methionine synthase is demonstrated to be tyrosine phosphorylated then N1-Src 
would be a good candidate for the kinase carrying out the phosphorylation as it 
meets all of the criteria outlined in this study.  
 
4.9.3.5 Tyrosine-protein phosphatase non-receptor type 6 (PTPN6) 
 
The tyrosine protein phosphatase non-receptor type 6 (PTPN6) identified is better 
known as SHP-1 (SH2 domain-containing tyrosine phosphatase 1) or PTP1C 
(protein tyrosine phosphatase 1C). SHP-1 (along with other phosphatases) is able to 
catalyse the dephosphorylation of Src and catalyses the dephosphorylation of Src at 
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pY527 more effectively than it does at pY416 (Somani et al, 1997). SHP-1 therefore 
plays a role in the activation of Src by pY527 dephosphorylation and removal of the 
SH2:tail regulatory interaction. SHP-1 is also able to effectively catalyse the 
dephosphorylation of Src substrates (Frank et al, 2004). 
 Interestingly, Frank et al (2004) also showed that Src can phosphorylate 
Y538 and Y566 of SHP-1. SHP-1 phosphorylation activates its phosphatase activity 
and upregulates the dephosphorylation of Src substrates. This regulatory cycle means 
that Src signalling in the presence of SHP-1 is transient. These experiments were 
carried out using transfection of C-Src into HEK293 cells. Therefore C-Src is 
definitely able to carry out the phosphorylation event. However, it is possible that 
N1-Src is also able to phosphorylate SHP-1 at these or other sites. This would 
provide an interesting mechanism of regulation and may be a way to explain why we 
do not observe large numbers of N1-Src phosphorylated proteins in cells despite the 
high activity of N1-Src (Chapter 3). Active N1-Src would also result in active SHP-1 
and therefore any substrate proteins phosphorylated by N1-Src would be rapidly 
dephosphorylated by SHP-1. This supports the idea that N1-Src signalling may be 
involved in dynamic signalling processes such as cytoskeletal rearrangement rather 
than more stable phosphorylation events.  
 The tyrosine residues identified as being potential N1-Src substrates in this 
study are Y276, Y536 and Y564. Y536 and Y564 in the human SHP-1 variant 1 
sequence are analogous to Y538 and Y566 in the human SHP-1 variant 2 sequence 
used by Frank et al (2004). Phosphorylation at these residues by C-Src had an 
activating effect on SHP-1. It is possible that N1-Src phosphorylation here would 
also result in SHP-1 activation and regulation of N1-Src substrate phosphorylation. 
There is currently no biochemical evidence for SHP-1 at Y276 and it therefore 
remains unknown what effect phosphorylation at this site may have on SHP-1 
activity.  
 
The potential N1-Src substrates identified in this study provide attractive targets for 
further research into the functions of N1-Src. The proteins identified in this study are 
involved in functions in both the developing and mature brain. N1-Src is known to 
be highly expressed throughout development and in the adult mouse (Wiestler & 
Walter, 1988) and therefore it would be predicted that it is performing functions at 
all developmental stages.  
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In vitro experiments could be used to confirm firstly an interaction between 
N1-Src and the substrate and secondly that N1-Src is able to phosphorylate the 
substrate. Site directed mutagenesis could then be used to ascertain whether the 
interaction takes place at the residues predicted in this study. Alternatively, sites of 
phosphorylation could be identified by MS analysis of the recombinant 
phosphorylated protein. Cell based experiments using transfected or endogenous 
substrates and kinases would then be used to confirm that the interaction takes place 
under physiologically relevant conditions. The use of functional assays looking at 
the activity or localisation of the substrate proteins would allow elucidation of the 
biological relevance of the phosphorylation reaction. As there is evidence for the in 
vivo tyrosine phosphorylation of HPK1 and SHP-1 they would seem to be the best 
candidate substrates with which to begin further investigations into N1-Src function.  
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5 Functional studies of N1-Src kinase 
 
5.1 Introduction 
 
5.1.1 Culture based models of neuronal development 
 
The in vitro and heterologous cell techniques presented in Chapter 3 pointed to a role 
for N1-Src in the development of neuronal morphology. This was supported by the 
bioinformatic analysis carried out in Chapter 4. A neuronal culture system was 
therefore required to allow manipulation of the endogenous protein. Cerebellar 
granule neurons (CGNs) are a good model culture system for studying the effects of 
proteins that may have a role in neuronal development. Of the main cerebellar 
neuronal types (granule cells, Purkinje cells and inhibitory interneurons), granule 
neurons are by far the most numerous and are the most abundant type of neuron in 
the mammalian brain. In rodents, cerebellar granule neurons are generated during the 
first two post-natal weeks from progenitor cells in the outermost layer of the 
cerebellar cortex, the external granule layer (EGL). The development of CGNs in 
culture closely mirrors their in vivo differentiation (Powell et al, 1997). To prepare 
CGNs in culture, the cerebellum is taken from P7 rats, at which stage the CGNs are 
still migrating, lack processes and therefore are able to survive the dissociation and 
transfer to culture. The development of CGNs is very well studied and therefore any 
deviation from this normal development can be clearly identified and quantified. 
 When CGNs are plated onto culture dishes, they begin as small, rounded 
cells that extend a single neurite, followed by a second from the opposite pole. One 
of these processes will extend further and become the axon, bifurcating to form the 
two arms of the parallel fibres observed in vivo. The second original neurite will 
retract and dendrites will form at this opposite pole (Tahirovic & Bradke, 2009) 
(Figure 5.1.1).  
 One drawback to the use of the CGN model culture system is that CGNs 
have quite a simple neuronal architecture with limited axonal branching. They are 
also very small. Hippocampal neurons are much larger cells with a more complex 
branching architecture. They can therefore be used to identify more subtle changes in 
neuronal architecture and have been used for this purpose in this study. Development 
of hippocampal neurons follows a similar programme to that of CGNs, with the  
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Figure 5.1.1. Development of neurons in culture.  
Adapted from Tahirovic and Bradke, 2009. A) Development of rodent cerebellar 
granule neurons (CGNs). CGNs initially extend several short filopodia (Stage 1) and 
then begin to extend one longer process, led by a growth cone (Stage 2). This is 
followed by the growth of  a second process from the opposite pole, to form a 
neuron with bipolar morphology (Stage 3). One of the long process will extend 
further, begin branching and go on to form a functional axon (Stage 4 and 5). The 
second long process will retract and dendrites will form at the opposite pole to the 
axon (Stage 5). B) Development of rodent hippocampal neurons. Hippocampal cells 
also begin as small cells with multiple protrusions (Stage 1) but then develop into 
multipolar cells (Stage 2). One neurite will rapidly extend and become the axon 
(Stage 3). The other neurites will become dendrites (Stage 3) while the axon 
continues to extend (Stage 4) and branch (Stage 5). 
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initial formation of multiple processes, one of which will go on to become the axon 
(Tahirovic & Bradke, 2009) (Figure 5.1.1). The final morphology of hippocampal 
neurons is much more variable than that of CGNs and this can make analysis of 
morphological changes caused by protein manipulation more challenging than for 
CGNs. In addition, cells obtained from the hippocampus are a mixed culture with 
CA1, CA3 and DG neurons present. This can make it difficult to assess a difference 
that occurs in only one or a subset of the neuronal types. 
 
5.1.2 Mechanisms regulating neurite outgrowth and branching 
 
The process of neuronal branching is a fundamental property of neurons, with the 
vast majority of neurons able to produce branched processes. The process of 
branching allows neurons to simultaneously connect to multiple targets, facilitating 
the formation of a complex neuronal network. The guidance cues that mediate axon 
guidance were introduced in Chapter 1 and many of the same pathways are involved 
in the molecular processes of axon branching. 
There are two distinct mechanisms by which an axonal branch may form. 
Firstly, a growth cone may split with each half continuing to grow and extend, this 
process can only occur during axonal outgrowth and is the mechanism that CGNs 
use to branch. Secondly, a new outgrowth may form from the main axonal shaft; this 
process is known as interstitial or collateral branching and may occur in mature 
neurons. This process is used by hippocampal neurons. Both processes have been 
demonstrated to occur in culture and in vivo (O'Leary & Terashima, 1988; Schmidt 
et al, 2007). Whether the molecular mechanisms underlying these two processes are 
the same or distinct remains to be shown but they are known to involve broadly 
similar signalling pathways (Schmidt & Rathjen, 2010).  
 Axon guidance is a highly regulated process that needs to co-ordinate neurite 
size and position through growth and guidance with the addition of complexity 
through branching. Multiple proteins and pathways have been identified as playing a 
role in the regulation of the axonal branching process. These include signalling 
arising from; axon guidance cues, growth factors, calcium, electrical activity, 
extracellular ligands, morphogens, transcription factors and cell adhesion molecules 
(Tessier-Lavigne & Goodman, 1996). These pathways do not appear to be 
degenerate as perturbation of only one can be sufficient to inhibit branching and it is 
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likely that they respond to a variety of intracellular and extracellular cues to 
stimulate branching. 
 The formation of a branch relies on the convergence of multiple signalling 
pathways to result in asymmetrical remodelling of the cytoskeleton. The axonal 
cytoskeleton consists predominantly of filamentous actin and α/β-tubulin and is 
highly dynamic, being continually remodelled both during development and in 
mature neurons. The inhibition or destabilisation of the microtubule or F-actin 
networks inhibits axonal branching (Dent & Kalil, 2001), indicating the reliance of 
the branching process on cytoskeletal remodelling. 
Some neuronal cells have highly branched and complex dendritic arbours. 
The signalling processes underlying dendritic branching involve the same broad 
classes of molecules but are considered distinct from those underlying axonal 
branching. As the neuronal types used within this study do not exhibit any complex 
dendritic branching, the molecular mechanisms controlling this process will not be 
discussed further (for a recent review see (Jan & Jan, 2010)).  
 
5.1.3 N1-Src and L1-CAM 
 
Ignelzi et al (1994) identified that the rate of growth of neurons taken from src
-/-
 
mice is slower than that of control neurons when grown on a substrate of the cell 
adhesion molecule L1-CAM. This effect is specific to signalling arising from the L1-
CAM pathway as neurite outgrowth is unaffected by growth on laminin. It is also 
specific to Src, because the growth of neurons taken from Fyn
-/-
 or Yes
-/-
 mice was 
normal. However, the nature of the cloning carried out to create the Src knockout 
mouse means that it is null for all three Src isoforms, C-Src, N1-Src and N2-Src. The 
particular isoform responsible for the defective neurite outgrowth has not been 
identified.   
 
5.2 Aims 
 
Studies in heterologous cells (Chapter 3) and bioinformatic investigations (Chapter 
4) have identified a potential role for N1-Src in the modulation of neurite outgrowth. 
To test this hypothesis, and to investigate the in vivo functions of N1-Src 
overexpression and inhibition, experiments were carried out in cultured neurons. 
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This allowed the manipulation of endogenous N1-Src activity and function. The 
culture systems chosen for these investigations were CGNs and hippocampal 
neurons, two well characterised models of neuronal differentiation. A secondary aim 
of this work was to investigate the possible link between N1-Src and signalling in 
the L1-CAM pathway. This was achieved by investigating the growth of neurons on 
a substrate of L1-CAM following inhibition of N1-Src.  
 
5.3 N1-Src overexpression causes aberrant neurite outgrowth 
 
In the experiments presented in Chapter 3, overexpression of WT N1-Src caused the 
induction of a neuronal phenotype in heterologous cells, characterised by the 
production of neuronal-like processes and a decrease in cell area. In a neuronal 
system, it has previously been shown that overexpression of constitutively active 
N1-Src (Y527F) in Purkinje neurons causes aberrant neurite outgrowth, primarily 
affecting dendrite morphology (Kotani et al, 2007). Kotani et al found that 
overexpression of the WT protein had little effect on cell morphology.  
In order to further investigate the functions of N1-Src and its effects on 
neuronal morphology, WT N1-Src was overexpressed in cultured CGNs and the cell 
morphology analysed 24 hours following transfection. The morphology of N1-Src 
transfected cells was compared to control and C-Src transfected cells. Control 
neurons were visualised by transfection with CFP and stained with an α-CFP 
antibody. The Src constructs used were the same constructs that were used in 
Chapter 3 for COS7 cell transfection. The constructs were FLAG tagged and 
transfected cells detected using an α-FLAG antibody. Transfected neurons were 
identified as CGNs by morphology. 
Transfection of CGNs revealed that, in contrast to the findings in Purkinje 
neurons, neurite outgrowth of CGNs was inhibited by overexpression of WT N1-Src 
(Figure 5.3.1). Morphological analysis showed that the axons are primarily affected, 
with approximately 40% of the cells having duplicated axons (Figure 5.3.2). During 
normal CGN development the cells initially extend two axonal-like processes before 
one retracts and dendrites form (Figure 5.1.1). The morphology observed here may 
be as a result of either a delayed developmental programme or a failure in the cues 
that distinguish axonal formation from dendrite formation. Regardless of the  
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Figure 5.3.1 Overexpression of N1-Src causes aberrant neuronal morphology 
CGNs were prepared from P7 rats and plated onto PDL coated coverslips. Neurons 
were transfected 24 hours following plating and fixed for morphological analysis 24 
hours after transfection. Control cells were transfected with CFP and visualised with 
α-GFP. C- and N1-Src constructs were FLAG tagged and transfected cells were 
visualised by α-FLAG staining. Representative epifluorescent images shown.n=3 
experiments. 
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Figure 5.3.2 N1-Src overexpression induces axon duplication. 
The morphology of CGNs transfected with CFP (control), C-Src and N1-Src was 
analysed 24 hours after transfection using the NeuronJ plugin for ImageJ. 
Parameters measured were A) axon length B) axon number C) branch length D) 
branch number E) dendrite length F) dendrite number. n=3 experiments, 
approximately 30 cells analysed per condition for each experiment. Error bars show 
SEM. Statistical analysis carried out by ANOVA and post hoc Tukey test * p < 0.05, 
** p < 0.01, *** p<0.001.All conditions compared to control neurons. 
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mechanism, this result indicates that N1-Src plays a role in the initial processes of 
axon formation.  
 In addition to the axon duplication observed, the axons that form are 
approximately 50% shorter than either control (CFP transfected) or C-Src transfected 
cells. They are also much less highly branched, although the branches that do form 
are of approximately the same length as those found in control cells. In contrast to 
the study by Kotani et al (2007), the dendrite number and length remain unaffected. 
While N1-Src overexpression had striking effects on CGN morphology, C-
Src overexpression had little effect. The only morphological factor analysed that was 
significantly different to control cells following C-Src overexpression was the 
number of branches per axon, which increases by approximately 15%. As CGNs 
have so few axonal branches it is unclear whether this is a true effect of C-Src 
overexpression or an artefact caused by the fact that CGN axons are not highly 
branched and therefore a small increase in branch number produces a large 
percentage increase. Repeating the overexpression of C-Src in a neuronal type with 
more extensive axonal branching would confirm whether axonal branching is 
increased by C-Src overexpression. 
The reasons why N1-Src overexpression has a gain-of-function phenotype 
while C-Src overexpression has little effect remain unclear, but may be related to the 
high constitutive activity of N1-Src. The high basal activity of N1-Src demonstrated 
in Chapter 3 may result in N1-Src overexpression having a greater effect than C-Src 
overexpression because, even when overexpressed, C-Src activity is tightly 
regulated. The differences between the effects of C-Src and N1-Src overexpression 
also support the view that the in vivo functions of C-Src and N1-Src are different and 
it may be that C-Src plays limited roles in the regulation of neuronal morphology  
 In order to determine whether the differences in cell morphology observed 
following N1-Src overexpression are due to a delayed developmental programme, 
the period of maturation in culture following the transfection was extended. Figure 
5.3.3 shows that even after 72 hours in culture the N1-Src transfected cells are not 
able to form a normal CGN architecture. The average axon length extends slightly 
but does not reach that of control cells. This implies that the morphology observed is 
not simply the result of delayed development and that N1-Src overexpression is able 
to influence both the processes of axonal growth and branching. The only factor that 
appears to be rectified by this longer incubation is the axon number with very few  
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Figure 5.3.3 N1-Src transfected cell morphology is not rescued by longer 
expression 
Control (CFP), C- and N1-Src transfected CGNs were fixed 24, 48, and 72 hours 
following transfection and morphology analysed using the NeuronJ plugin for 
ImageJ. Parameters measured were A) axon length B) axon number and C) branch 
number. Plotted data were obtained from 1 experiment with 15-20 neurons analysed 
per condition. Error bars show SEM. 
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cells displaying duplicated axons by the 72 hour timepoint. This may be because 
there are other signalling processes within the cell that are able to compensate for the 
perturbation of N1-Src signalling by these later timepoints or it may be that cells 
with duplicated axons are identified as defective and destroyed by apoptosis at later 
timepoints. The only cells then remaining for quantification would be those with a 
less severe phenotype.  
At timepoints over 72 hours, both C- and N1-Src transfected cells began to die 
while control cells remained healthy. For C-Src transfected cells this was surprising 
as they appeared morphologically normal. This implies that, while C-Src was not 
influencing neuronal morphological development, over longer time periods, 
overexpression of the kinase was detrimental to the cell. C-Src plays well 
documented roles in signalling pathways distinct from the regulation of cell 
morphology including cell survival. As aberrant kinase signalling is frequently 
associated with disease processes, prolonged overexpression of a kinase can result in 
the induction of apoptosis (Zhong et al, 2002).  
 
5.4 PD1 is a specific inhibitor of N1-Src in cells 
 
To study the functions of N1-Src in more detail, a specific inhibitor of N1-Src was 
required. There are no commercially available pharmacological inhibitors of N1-Src 
but the PD1 peptide characterised in Chapter 4 had been shown to be able to inhibit 
N1-Src substrate phosphorylation in vitro. To confirm that PD1 is able to interact 
with N1-Src in cells, FLAG-tagged N1-Src and CFP-tagged PD1 constructs were 
co-transfected into COS7 cells. N1-Src was transfected as COS7 cells do not 
endogenously express neuronal Src isoforms. CFP-tagged PD1 was used because the 
isolated peptide is not predicted to be membrane permeable. The CFP tag also 
allowed for the efficient immunoprecipitation of the peptide and its resolution on an 
SDS-PAGE gel.  
In order to confirm an association between N1-Src and PD1, an 
immunoprecipitation experiment was carried out. This showed that N1-Src and PD1 
are present within a complex (Figure 5.4.1) and co-immunoprecipitate when the tag 
on either protein is used to perform the immunoprecipitation. In contrast, the point 
mutant PD1-P5A co-immunopreciptates poorly with N1-Src. This shows that the 
interaction between PD1 and N1-Src is due to the specific sequence of PD1. N1-Src  
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Figure 5.4.1 N1-Src and PD1 are contained within a complex 
An immunoprecipitation experiment was carried out between FLAG-tagged N1-Src 
and CFP-tagged PD1 or the point mutant PD1-P5A. COS7 cells were co-transfected 
and lysed 48 hours following transfection. The immunoprecipitation experiment was 
set up using either α-FLAG or α-GFP (to detect CFP). The top panels show that 
CFP-PD1 co-immunoprecipiates with N1-Src following immunoprecipitation using 
the FLAG antibody whereas PD1-P5A co-immunoprecipitates much less efficiently. 
The lower panels show that N1-Src-FLAG co-immunoprecipitates with PD1 
following immunoprecipitation with the GFP antibody but PD1-P5A does not. The 
input represents 1% of the cell lysate used in the immunoprecipitation. 
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Figure 5.4.2 PD1 expression prevents induction of neuronal morphology 
COS7 cells were co-transfected with C-, N1- or N2-Src and PD1-WT or PD1-P5A as 
indicated and either fixed or lysed 48 hours following transfection. Control cells were 
transfected with CFP (blue) to allow visualisation. Src constructs were FLAG tagged 
and visualised using an α-FLAG antibody (red). PD1 and PD1-P5A were CFP 
tagged and visualised using an α-GFP antibody (blue) A) Merged images are shown 
for co-transfected cells (purple). Nuclei are visualised using DAPI (green). Images 
are representative epifluorescent images from n=3 experiments. B) Analysis of Src 
activity was assessed using α-pY416 (active Src) and α-pY527 (inactive Src). Equal 
expression of shown by α-FLAG and α-GFP.  
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Figure 5.4.3. Morphology of N1-Src PD1 co-transfected cells is the same as 
control cells 
COS7 cells were transfected 24 hours after plating and fixed for morphological 
analysis 48 hours following transfection. ImageJ analysis was used to assess A) cell 
body area B) neurite number and C) neurite length. n=3 experiments. 20 fields of 
view (approximately 50 cells) analysed for each condition per experiment. Error bars 
show SEM. Statistical analysis carried out using ANOVA and post hoc Tukey test. 
* p<0.05, ** p<0.01, ***p<0.001, all conditions compared to control cells (CFP 
transfected).  
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and PD1 are presumably linked by a direct interaction because PD1 was identified 
for its ability to bind to the N1-Src SH3 domain. To further confirm the suitability of 
PD1 as a N1-Src inhibitor, the morphology of the co-transfected COS7 cells was 
analysed. For this experiment COS7 cells were co-transfected with a FLAG tagged 
Src construct and CFP tagged PD1 or the point mutant PD1-P5A. Control cells were 
visualised by transfection with CFP and staining using an α-CFP antibody. The 
results of this experiment are shown in Figure 5.4.2 A. Control cells are transfected 
with CFP, shown in blue. The co-transfected cells are shown as a merged image of 
the FLAG-Src (red) and CFP-PD1/PD1-P5A (blue) staining and appear as purple. 
The nuclei are visualised using DAPI and are shown in green.  
This experiment revealed that the neuronal morphology induced by N1-Src 
transfection into heterologous cells (described in Chapter 3) is prevented by the co-
expression of CFP-PD1 (Figure 5.4.2 A). Importantly, the induction of neuronal 
morphology was not prevented by the point mutant PD1-P5A, indicating that the 
effect is specifically due to the PD1 sequence. In addition to the effect on cell 
morphology, biochemical analysis of the activation state of the kinases revealed that 
PD1 co-expression resulted in a specific decrease in N1-Src activity (characterised 
by a decrease in α-pY416 immunoreactivity), while C- and N2-Src activity remained 
unaffected (Figure 5.4.2 B).  
The decrease in the α-pY416 signal is not total, indicating that some active 
N1-Src remains but it does not seem to be enough to induce the morphological 
changes previously seen. It is also possible that there is some cross-reactivity and the 
antibody also detects the corresponding residues of other SFK members. A third 
explanation for this result would be that the degree of co-transfection between 
N1-Src and CFP-PD1 was poor but this did not appear to be the case as when images 
were taken for morphological analysis, a high degree of co-transfection (>90%) was 
observed. The binding of PD1 to the N1-Src SH3 domain would be predicted to 
block the kinase-substrate interactions and so therefore be expected to perturb 
N1-Src function even if some pY416 immunoreactivity remained.  
Quantification of the transfected cells (Figure 5.4.3) showed that, for all 
parameters measured, the morphology of cells co-transfected with N1-Src and PD1 
is not statistically different to that of control cells. Importantly, control experiments 
also showed that the morphology of C-Src and N2-Src (Figure 5.4.2 and 5.4.3) 
transfected cells is not significantly affected by the presence of the PD1 peptide.  
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 The PD1 peptide, identified through its ability to bind to the SH3 domain of 
N1-Src has been demonstrated to be a potent and specific inhibitor of N1-Src activity 
and function in cells. These experiments also confirm that the linkage of the PD1 
peptide to CFP does not decrease its ability to interact with and inhibit N1-Src 
activity. CFP-PD1 transfection has no demonstrable off-target effects as the 
morphology of C- and N2-Src transfected cells was not affected by CFP-PD1 
expression. CFP-PD1 also showed no toxic effects over the timecourse of the 
experiments carried out. Therefore, there is a high degree of confidence that 
CFP-PD1 transfection into neuronal cells will act specifically to inhibit N1-Src, 
allowing the investigation of endogenous N1-Src function. 
 
5.5 N1-Src inhibition prevents axonal branching 
 
The PD1 peptide sequence had been demonstrated to be a specific N1-Src inhibitor 
and to work effectively as a CFP-fusion in heterologous cells. The effects of N1-Src 
inhibition in CGNs were therefore investigated by CFP-PD1 transfection, followed 
by morphological analysis. Figure 5.5.1 shows that the morphology of PD1 
transfected CGNs was perturbed, while neurons transfected with the control peptide 
PD1-P5A appeared morphologically normal. This means that the effects of PD1 
transfection are sequence specific in CGNs as well as in heterologous cells. 
Unfortunately, due to the low transfection of neuronal cultures, biochemical analysis 
of the activation state of endogenous N1-Src in the presence of CFP-PD1 was not 
possible. 
 Quantification of the transfected CGNs (Figure 5.5.2) showed that N1-Src 
inhibition predominantly affected axonal growth, with dendrite number and length 
not being significantly different to control cells. This trend is the same as previously 
seen following N1-Src overexpression, but the effects of N1-Src inhibition are not 
identical to the effects of N1-Src overexpression. The average axonal length for PD1 
transfected cells is reduced (Figure 5.5.2 A), as it was for N1-Src overexpressing 
cells, but the number of cells with an identifiable axon is reduced to approximately 
60% (Figure 5.5.2 B). This is in contrast to N1-Src overexpression experiments that 
identified a tendency for axon duplication (Figure 5.3.2 B). The contrasting results of 
N1-Src overexpression and inhibition support the hypothesis that N1-Src plays a role 
in the initial processes of axon formation. 
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Figure 5.5.1 PD1 expression in CGNs causes aberrant neuronal morphology. 
CGNs were transfected with PD1-WT or PD1-P5A 24 hours after plating and fixed 
for morphological analysis 24 hours after transfection. Control cells were transfected 
with CFP and all constructs were visualised using α-GFP. Images shown 
representative from n=3 experiments. 
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Figure 5.5.2 PD1 expression in CGNs results in inhibition of axon formation. 
The morphology of CGNs transfected with CFP (control), CFP-PD1-WT and CFP-
PD1-P5A was analysed 24 hours after transfection using the NeuronJ plugin for 
ImageJ. Parameters measured were A) axon length B) axon number C) branch 
length D) branch number E) dendrite length F) dendrite number. n=3 experiments, 
approximately 30 cells analysed per condition for each experiment. Error bars show 
SEM. Statistical analysis carried out by ANOVA and post hoc Tukey test * p < 0.05, 
** p < 0.01, *** p<0.001, all conditions compared to control cells. 
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As previously seen in N1-Src overexpressing CGNs, axon branching is 
inhibited in PD1 transfected neurons (Figure 5.5.2 D), while the length of the 
branches that do form remain the same as control cells (Figure 5.5.2 C). This result 
implies that N1-Src plays a role in the formation of branches as well as axon 
formation. It is interesting that N1-Src overexpression and inhibition has the same 
effect on axonal branching in CGNs. If the normal signalling of N1-Src is required 
for efficient branching, perturbing N1-Src activity either by overexpression or 
inhibition would result in the disruption of the balance of the signalling pathways 
involved and the inhibition of branch formation. In contrast to this, N1-Src 
overexpression drove axon formation whereas N1-Src inhibition prevented axon 
formation. This may indicate that N1-Src acts in multiple distinct signalling 
pathways to regulate both axon formation and branch formation.  
 While CGNs are a good model system for investigating neuronal 
development, the cells are relatively small and their branching architecture is quite 
simple. As a potential role for N1-Src had been identified in the processes of axonal 
initiation and branching, further analysis was carried out in hippocampal neurons. 
The axons of hippocampal neurons are much longer and more highly branched than  
those of CGNs. The analysis of hippocampal neuron architecture can reveal more 
subtle effects such as specific effects on branch formation as opposed to elongation 
and effects on primary or secondary branching.  
 Cultured hippocampal neurons were transfected with PD1 and PD1-P5A 24 
hours after plating and morphology analysed 24 hours following transfection. The 
traces of representative transfected cells produced using the NeuronJ plugin for 
ImageJ are shown in Figure 5.5.3. Quantification of these images (Figure 5.5.4) 
revealed that, while the total neurite length measured for PD1 transfected cells is 
reduced (Figure 5.5.4 A), the primary axon length remains unaffected (Figure 5.5.4 
B). All transfected cells analysed had one axonal process, identified by morphology. 
This is in contrast to the findings in CGNs and implies that, in the hippocampal 
neuron system, N1-Src is not required for the initial processes of axon formation or 
growth. 
 The reduction in total neurite length indicated that PD1 transfected cells were 
not morphologically identical to control cells. Further analysis showed that this 
difference is due to a reduction in both the number (Figure 5.5.4 C) and length 
(Figure 5.5.4.D) of branches formed in PD1 transfected cells. This supports a role for 
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N1-Src in the molecular processes of axonal branching in hippocampal neurons. 
PD1-P5A transfected neurons did not show any morphological differences to control 
cells (Figure 5.5.4 A-D).  
Detailed analysis of the cell morphology was carried out using Sholl analysis 
(Sholl, 1953). Sholl analysis measures the number of times concentric circles 
originating at the cell body are intersected by neurites and provides a measure of 
complexity of the cell. This analysis revealed that PD1 transfected neurons were 
indeed less complex than control cells (Figure 5.5.4 E). However, as in the CGNs, 
the differences were specific to axonal branching. The intersections that occur 
closest to the cell body (within ~50 µm) will primarily represent the dendrites and 
this peak was identical for PD1 and control transfected cells. There was a second 
peak approximately 180 μm from the cell body and this was also identical for PD1 
and control transfected cells. This indicates that branching that occurs close to the 
cell body is able to occur in PD1 transfected cells as in control cells. The difference 
between PD1 and control cells becomes evident in the region over 200 μm from the 
cell body and represents distal axonal branches. Inhibition of N1-Src can therefore 
be said to specifically inhibit distal axonal branching in hippocampal neurons. 
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Figure 5.5.3. Expression of PD1 in hippocampal neurons causes aberrant 
neuronal morphology. 
Hippocampal neurons were transfected with the indicated constructs 24 hours after 
plating and fixed for morphological analysis 24 hours after transfection. Control cells 
were transfected with CFP for visualisation. PD1 WT and PD1 P5A constructs were 
CFP tagged. All transfected cells were detected using an α-CFP antibody. Traces 
were created using the NeuronJ plugin for ImageJ are shown. Red dot represents 
the centre of the cell body used for Sholl analysis. Representative images shown 
from n=3 experiments with approximately 20 neurons analysed per condition. 
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Figure 5.5.4 Expression of PD1 in hippocampal neurons inhibits axonal 
branching. 
Hippocampal neuron morphology was analysed 24 hours after transfection using 
the Neuron J plugin for ImageJ. Transfected cells were visualised using α-CFP. 
Parameters measured were A) total neurite length, B) axon length, C) branch 
number and D) branch length. Sholl analysis (E) was carried out using an ImageJ 
plugin. Data shown calculated from n=3 with approximately 20 neurons analysed 
per condition per experiment. Error bars show SEM. Statistical analysis carried out 
by ANOVA followed by post hoc Tukey test * p<0.05, ** p<0.01, *** p<0.001.  
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5.6 N1-Src inhibition impairs L1-CAM dependent neurite 
outgrowth 
 
The SFKs have previously been identified as playing a role in the processes of 
neuronal outgrowth. In particular, it is known that cerebellar neurons taken from src
-
/-
 mice are unable to extend neurites when the adhesion molecule L1-CAM is 
provided as a substrate (Ignelzi et al, 1994). Src
-/-
 mice lack the Src gene and 
therefore C-, N1- and N2-Src protein. The isoform responsible for the impaired 
neurite outgrowth on L1-CAM has not been identified. Due to the link between N1-
Src and neuronal outgrowth identified in this study, an experiment was designed to 
test whether N1-Src is the isoform responsible. 
The assay used is depicted in Figure 5.6.1 A and involved plating a spot of 
recombinant L1-CAM (extracellular domain) mixed with the fluorescent dye FITC 
onto the centre of a 13 mm coverslip. The L1-CAM dried onto the coverslip and its 
location could subsequently be identified using the fluorescence of FITC (Figure 12 
A). CGNs were then plated over the whole surface of the coverslip. The neurons 
were transfected 24 hours after plating and their morphology analysed 24 hours after 
transfection. The advantage of this technique was that the growth of transfected 
neurons on and off the L1-CAM substrate could be compared on the same coverslip.  
 Growth of CGNs on L1-CAM is known to result in an increase in axon 
length of WT neurons. An appropriate L1-CAM concentration was determined by 
assessing the extent of axon elongation of neurons grown on L1-CAM as compared 
to control cells. An L1-CAM concentration that induces a quantifiable increase in 
control neuron length was required in order to assess whether inhibition of N1-Src 
could prevent this and recapitulate the effect of src
-/-
 neurons seen by Ignelzi et al 
(1994). A concentration of 25 µg/ml was chosen because this induces approximately 
a 50% increase in the axon length of control (CFP transfected) CGNs (Figure 5.6.1 
B).  
 Transfection of PD1 resulted in the generation of axons shorter than those in 
the control neurons, as previously seen when grown on PDL (Figure 5.6.2). 
However, when PD1 transfected neurons were grown on the L1-CAM substrate they 
failed to extend any further (Figure 5.6.2). This implies that N1-Src is acting within 
the signalling pathway that would normally result in neurite elongation following 
interaction with extracellular L1-CAM. This result positively identifies N1-Src as the  
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Figure 5.6.1 Basis of the L1-CAM neurite outgrowth assay. 
A) Schematic representation of the L1-CAM neurite outgrowth assay. Coverslips 
were coated with PDL followed by a spot of recombinant L1-CAM mixed with FITC. 
FITC fluorescence used to identify the location of L1-CAM as shown in the image on 
the right. B) Determination of the L1-CAM substrate concentration for use in the 
assay. Individual neurons visualised by transfection with CFP and detection using α-
GFP. Data shown n=1 experiment, 12-15 neurons measured per condition. Error 
bars show SEM. 
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Figure 5.6.2 CGN axons cannot extend when grown on L1-CAM following N1-
Src inhibition. 
CGNs were transfected 24 hours following plating and fixed for morphological 
analysis 24 hours after transfection. Control cells were transfected with CFP and all 
transfected neurons visualised using α-CFP. FITC fluorescence was used to assess 
whether a transfected neuron was on the L1-CAM substrate A) Representative 
images of transfected neurons on and off the L1-CAM substrate. B) and C) 
Transfected neurons were quantified using the NeuronJ plugin for ImageJ. Data 
plotted from n=3 with 15-20 neurons analysed per condition per experiment. Error 
bars show SEM. Statistical analysis carried out by ANOVA and post hoc Tukey 
test.*p<0.05, **p<0.01  
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isoform responsible because the neurons in this study still have active C- and 
N2-Src. 
 
5.7 Discussion 
 
The work presented in this chapter comprises studies carried out in two distinct 
neuronal cell types that have demonstrated a role for N1-Src in axonal growth and 
branching through both overexpression and inhibition techniques. This role in 
neurite outgrowth has been demonstrated to be, at least partially, mediated through 
the L1-CAM signalling pathway. In order to study the functions of N1-Src in cells, a 
potent and specific inhibitor of N1-Src activity and function has been characterised. 
 
5.7.1 Characterisation of a specific N1-Src inhibitor 
 
The characterisation of the PD1 peptide sequence as a specific inhibitor of N1-Src 
provides a valuable tool for the study of the kinase both in the context of this study 
and for further study of N1-Src function. The PD1 peptide, expressed as a CFP 
fusion, has been demonstrated to be a potent and specific inhibitor of N1-Src in cell 
based assays and is able to functionally inhibit N1-Src while not affecting the 
activities of either C- or N2-Src. 
The techniques chosen to confirm N1-Src inhibition by CFP-PD1 give a high 
degree of confidence in its effectiveness. In heterologous cells, co-transfection of 
CFP-PD1 along with N1-Src was demonstrated to prevent the induction of neuronal 
morphology caused by N1-Src alone. The expression level of N1-Src following 
overexpression in COS7 cells is likely to be higher than the endogenous levels found 
in CGNs or hippocampal neurons because expression in COS7 cells was driven by 
the strong promoter CMV. As CFP-PD1 is able to inhibit the actions of 
overexpressed N1-Src, it is thought that transfection of CFP-PD1 into neurons will 
also effectively inhibit endogenous N1-Src. The specific targeting and effective 
inhibition of N1-Src by CFP-PD1 is supported by the fact that the results of N1-Src 
overexpression and inhibition experiments are well correlated, with both indicating a 
role for N1-Src in axon formation and elongation.  
No off-target effects of CFP-PD1 expression were observed in COS7 cells. 
The most likely off-target effects would be the simultaneous inhibition of C- or 
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N2-Src because of their high degree of structural similarity. This did not occur when 
C- and N2-Src were overexpressed in COS7 cells so it would be predicted that cross 
reactivity would also not occur in CGNs or hippocampal neurons where the 
expression levels of the kinases are lower. The low transfection efficiency of neurons 
meant that confirmation of N1-Src inhibition in neurons by biochemical analysis was 
not possible.  
In order to confirm that PD1 transfection does not have off-target effects and 
that the changes in morphology observed were due to N1-Src inhibition it would be 
informative to also knockdown N1-Src expression using shRNA. shRNA constructs 
specific to each isoform of the kinase have been generated in the Evans lab and their 
effectiveness at inhibiting the expression of the specific Src isoforms in COS7 cells 
confirmed. However, the transfection of the shRNA plasmids into CGN cultures was 
toxic to the transfected neurons. This was true even of the control, empty shRNA 
plasmid. Further optimisation of the transfection protocol should allow for the 
comparative experiment between PD1 expression and N1-Src knockdown to be 
carried out.  
It is likely that there will be a small amount of N1-Src remaining active 
within the PD1 transfected cells but as this is not sufficient to induce morphological 
change in COS7 cells then it is not considered to be a significant amount. 
Biochemical analysis of transfected COS7 cells showed that, while CFP-PD1 
expression reduced the amount of α-pY416 (active Src) immunoreactivity, it did not 
eliminate it. In neurons, where N1-Src expression is lower, it may be that less active 
Src remains but this cannot currently be tested. As PD1 binding to the N1-Src SH3 
domain will prevent correct substrate targeting then the function of N1-Src will be 
perturbed even if some pY416 immunoreactivity remains.  
Further investigation into the interaction between PD1 and the N1-Src SH3 
domain by biochemical techniques such as ITC will be able to accurately ascertain 
the affinity of the interaction. However, it is estimated to be in the low micromolar 
range as this is typical of SH3 domain interactions with their ligands. Preliminary 
results show that the phosphorylation of the YA-PD1 peptide occurs with a Km of 6.5 
µM (Chapter 4) and that the titration of the free PD1 peptide has an IC50 of 
approximately 20 µM (Chapter 4).  
Peptide inhibitors of kinases have been the focus of a large amount of recent 
research due to the prevalence of unregulated kinase signalling in disease processes 
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including cancer. Inhibitory peptides may target a number of locations within the 
structure of a tyrosine kinase. Pseudosubstrates for the kinase domain have been 
developed but would not have been applicable in this study because the kinase 
domains are identical for the three isoforms of C-, N1- and N2-Src. As an alternative 
to the pseudosubstrate, there is also interest in the development of SH2 and SH3 
domain inhibitors due to their ability to regulate signalling pathways in cancer and 
their potential as anti-tumour agents. However, therapeutic research into the 
development of SH2/SH3 domain inhibitors has stalled because SH3 domain binding 
peptides commonly interact with too low affinity for therapeutic use and SH2 
domain binding peptides have limited cell permeability. The binding preferences of a 
large number of tyrosine kinase SH3 domains are known these have not commonly 
been shown to be able to inhibit kinase activity in cell based assays. Currently, the 
majority of high affinity SH3 domain peptide based inhibitors contain non-natural 
amino acids. These have been developed for C-Src, Lck, PI3K and Zap70 (Vidal et 
al, 2001; Yeh et al, 2001).  
Within the context of this study, it is not necessary that the SH3 domain 
inhibition occurs with an affinity as low as that required for therapeutic applications. 
There are examples of SH3 domain inhibitory peptides that have been used to 
successfully inhibit kinase function in cell based assays. For instance, Kardinal et al 
(2000) developed a SH3 domain peptide inhibitor for the tyrosine kinase Abl that is 
capable of inhibiting proliferation. The data presented here show that PD1 is capable 
of functionally inhibiting N1-Src in cells but further research would be required 
before the isolated peptide could be used because, in its current state, it is not 
predicted to be membrane permeable.  
 
5.7.2 A role for N1-Src in the regulation of axon and branch initiation 
 
The PD1 peptide provided a useful tool to allow the comparison of overexpression 
and inhibition of N1-Src in cultured neurons. CGNs overexpressing N1-Src tended 
to have a duplicated axon whereas those expressing PD1 were more likely not to 
have an identifiable axon. Together, these results suggest that N1-Src may be playing 
a role in the processes driving the initial formation of axons.  
Evidence for a role of N1-Src in the determination of neuronal morphology is 
strengthened by the use of the complementary techniques of N1-Src overexpression 
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and inhibition. Without the correlative result from N1-Src inhibition, the effect of 
N1-Src overexpression would need to be treated with caution because kinase 
overexpression can result in aberrant signalling and effects not mediated by the 
kinase under endogenous conditions. In this case both N1-Src overexpression and 
inhibition indicate a role for N1-Src in axon formation in CGNs. These opposing 
results strengthen the evidence that the manipulations are having physiologically 
relevant effects. 
The axons that do form in N1-Src overexpressing or inhibited CGNs are 
shorter than control axons. As there seems to be a fundamental defect in the process 
of axon initiation caused by N1-Src manipulation it is difficult to assess whether the 
shorter axons occur as a consequence of the defect in axon initiation or are due to a 
secondary defect in axon elongation. The branching of CGN axons is reduced 
following N1-Src manipulation but this may also be a secondary effect of the 
reduced axon length. CGN axons bifurcate at the growth cone and the primary axon 
therefore needs to reach a certain length before branching occurs. It is likely that 
CGN axons do not reach this minimum length following N1-Src manipulation, 
making the assessment of the role of N1-Src in CGN axon branching difficult. 
Therefore, although the data presented here suggest a role for N1-Src in axon 
initiation, further investigation is required to ensure that this is not due to a 
branching defect as it is currently difficult to distinguish the effects of axon initiation 
and branching. 
It is interesting that both N1-Src overexpression and inhibition resulted in a 
decrease in axon outgrowth in CGNs. In heterologous cells, N1-Src overexpression 
resulted in the induction of a neuronal morphology (Chapter 3). The opposing effects 
of N1-Src overexpression in these cell types may be due to the fact that N1-Src is not 
endogenously expressed in COS7 cells, they do not normally grow long processes 
and probably lack neuronal regulation mechanisms. N1-Src therefore provides the 
only mechanism for process growth and proceeds unhindered. In cultured neuronal 
cells there are multiple pathways that are involved in the initiation and elongation of 
neurites. Overexpression of N1-Src therefore perturbs the normal balance of 
signalling processes and results in aberrant neurite outgrowth.  
In a previous study of N1-Src function, Kotani et al (2007) reported that 
overexpression of WT N1-Src had little effect on neuronal morphology. This 
contradicts the finding in this study that WT N1-Src induces large scale alterations in 
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neuronal morphology. Kotani et al (2007) expressed N1-Src under the control of the 
Purkinje cell specific L7 promoter. This promoter does not drive expression of 
transgenes as strongly as the CMV promoter used for overexpression in all 
mammalian cell types in this study. Therefore, the greater expression levels and high 
constitutive activity of N1-Src may explain the morphological effects of WT N1-Src 
overexpression observed in this study.  
In this study N1-Src overexpression predominantly affected the axons, with 
dendrite morphology not significantly altered from control cells. This is again in 
contrast to the findings of Kotani et al (2007) and is probably explained by the fact 
that the Purkinje neurons studied by Kotani et al (2007) have complex dendritic and 
simple axonal architectures. N1-Src may function in the process of branching in both 
axons and dendrites but the dendritic arbours of the neurons used in this study were 
not complex enough to reveal any effect on dendrite branching. This could be 
confirmed by overexpressing and inhibiting N1-Src in cultured Purkinje neurons. 
In contrast to the studies in CGNs, there was no observed decrease in axon 
initiation or elongation when N1-Src was inhibited in hippocampal neurons. One 
explanation for this is the fact that the hippocampal neurons taken from neonatal 
rodents are predominantly post-mitotic, polarised cells that are already committed to 
axon formation (Polleux & Snider, 2010). As CGN development continues 
postnatally, CGNs taken from P7 mice are still migrating and, at least a 
subpopulation, are not committed to a neuronal lineage (Okano-Uchida et al, 2004). 
It may be that N1-Src is involved in the molecular processes of axon generation in 
hippocampal neurons but that this is masked because they are already polarised prior 
to N1-Src inhibition. In utero or ex utero electroporation of CFP-PD1 into 
developing hippocampal neurons before their exit from the cell cycle would be 
required in order to elucidate whether N1-Src is required for axon generation in 
hippocampal neurons. These techniques have been developed and used successfully 
by Saito and Nakatsuji (2001) and Tabata and Nakajima (2001). 
In hippocampal neurons, the primary axonal projections of PD1 transfected 
cells reached the same length as control cell axons. However, they were significantly 
less highly branched, implying that N1-Src activity is required for axonal branches to 
form. Sholl analysis revealed that the effect of N1-Src inhibition was specific to the 
distal axonal branches. The reason for this is unclear as there is no evidence that the 
mechanism of axonal branching is different in different parts of the axon. This result 
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may have been caused by the mixed population of neurons in the hippocampal 
culture. During the analysis it was noted that there was a large amount of variation in 
the size of the transfected cells. It may be that the branching phenotype is specific to 
the largest neurons, with the branches of shorter neurons appearing as proximal 
branches in the Sholl analysis. To test this, markers for specific neuronal types could 
be used and analysis of the morphology carried out. This would reveal whether the 
branching defect is specific to a certain neuronal cell type.  
The differences in the results between CGNs and hippocampal neurons may 
be due to differences in the mechanisms by which axons form and branch in these 
two cell types. In vivo, CGNs put out an initial axon that then bifurcates at the 
growth cone, with the two portions growing in opposite directions to form parallel 
fibres. In culture the same process occurs, although the lack of guidance cues means 
that the parallel fibres do not necessarily grow in opposite directions (Tahirovic & 
Bradke, 2009). In contrast, hippocampal neurons undergo interstitial branching, with 
branches forming from the existing axonal shaft. These two methods of branching 
are considered mechanistically distinct and may involve different signalling 
pathways and molecules (Dent & Kalil, 2001). There are a limited number of studies 
that assess the role of a protein in both bifurcation and interstitial branching, but it is 
known that inhibition of the receptor guanylyl cyclase, Npr2, selectively prevents 
bifurcation in sensory axons while not affecting interstitial branching (Schmidt et al, 
2007). 
Taken together, the studies in CGNs and hippocampal neurons provide 
informative insights into the endogenous roles of N1-Src. In CGNs N1-Src played a 
role in the initial processes of axon formation, while in hippocampal neurons it was 
required for the initiation of interstitial branches. There are a number of parallels 
between the molecular basis of these processes, notably that both require the 
formation of a novel protrusion that extends away from the existing cell body or 
axonal shaft. Therefore, it would be predicted that N1-Src plays a role in the 
regulation of the cytoskeletal rearrangements that are required in order for these 
processes to occur.  
All morphological analyses carried out in this study were based on neurite 
appearance rather than identification through the use of specific markers. 
Identification of axons and dendrites in this manner means that there is the potential 
for mis-identification. As the neuronal types used in this study are highly polarised 
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and their morphology is well characterised, we are confident that axon and dendrite 
assignments were made correctly. In CGNs, the stunted axons caused by N1-Src 
overexpression or inhibition were still longer than the dendrites and could therefore 
be identified. The dendrite morphology remained unchanged following N1-Src 
manipulation, which aided their identification. In hippocampal neurons each neuron 
had a single long process that was easily identified by morphology as an axon. 
In order to further investigate the role of N1-Src in axon formation it would be 
beneficial to repeat the experiments presented here using axonal markers, such as 
neurofilament. Processes that morphologically appear to be axons and those that are 
expressing the relevant axonal markers could then be distinguished. Analysis of how 
far through the developmental programme the stunted axons are able to progress 
could then be carried out. This result would help to identify whether N1-Src is 
required for the initial steps of axonal formation or is more involved in the 
subsequent growth and elongation processes.  
There is a growing body of work investigating the molecules that are able to 
promote the formation of an axon but there is considerable debate about factors that 
are true determinants of axon formation and those that only promote growth once 
axon formation has been initiated. It is agreed that axon formation is commonly, 
although not exclusively, promoted by exposure to extracellular factors including 
laminin, BDNF and TGFβ (Polleux & Snider, 2010) but the downstream signalling 
processes that respond to these extracellular factors are less clear.  
Cheng and Poo (2012) defined several determinants of axon formation that 
adhere to the following criteria: i) a change in concentration or activity in the neurite 
immediately prior to the development of axonal characteristics; ii) removal or 
inhibition prevents axon formation and iii) upregulation of expression or activity 
triggers axonal differentiation. Under these criteria they identified Ras, cAMP/PKA, 
PI3K/PIP3 and pLKB1 as being determinants of axon formation. It is likely that 
multiple independent axon determinants exist in order to allow integration of diverse 
extracellular signals. If N1-Src is able to modulate axon generation, it would be 
predicted to be acting within one or more of these pathways.  
 There is limited evidence for the role of kinases signalling the formation of 
axons. The serine/threonine kinase PI3K is involved in the cytoskeletal 
rearrangement required to form branches in sensory neurons (Ketschek & Gallo, 
2010). The actions of tyrosine kinases in the processes of axon guidance are quite 
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well known and are outlined in Chapter 1, but their specific roles in the processes 
governing axon initiation are less well understood. The lack of evidence for tyrosine 
kinase signalling in neurite initiation is probably because there is so much debate 
about the molecular basis of initiation as opposed to elongation. The data presented 
here provide strong evidence that N1-Src is required for axon initiation in CGNs and 
branch initiation in hippocampal neurons. This implies a role for N1-Src in the 
modulation of the cytoskeletal rearrangements that need to occur to generate a new 
neurite. Further elucidation of the substrates of N1-Src will allow determination of 
the signalling processes through which N1-Src mediates its effects. It is interesting 
that small GTPase signalling was identified as a determinant of axon initiation 
(Cheng & Poo, 2012) as targets in this signalling pathway were identified in Chapter 
4 as possible substrates of N1-Src. This will be discussed further in Chapter 6. 
 
5.7.3 A role for N1-Src in the L1-CAM signalling pathway 
 
A significant finding of this study is the link between L1-CAM mediated signalling 
and N1-Src function. N1-Src function is required for neurite outgrowth on L1-CAM 
as CFP-PD1 expressing neurons still have functional C- and N2-Src. The additional 
involvement of C- and N2-Src in the L1-CAM signalling pathway cannot be ruled 
out, however, as individual inhibition of these isoforms has not been carried out in 
this study. 
The neuronal adhesion molecule L1-CAM is strongly expressed on the 
surface of migrating neurons and developing axons from E9.5 onwards (Kallunki et 
al, 1997). There is also a large body of research that has identified L1-CAM as a 
potent regulator of axon growth when overexpressed, mutated or offered as a 
substrate for developing neurons (Cheng & Lemmon, 2004; Hoffman et al, 2008; 
Moon & Gomez, 2010; Schäfer et al, 2010). Notably, in relation to this study, the 
development and branching of dendrites appears to be unaffected by L1-CAM 
manipulation (Schäfer et al, 2010). Additionally, L1-CAM signalling does not seem 
to be required for initial axon formation (Cohen et al, 1998) and results 
predominantly in axon branching rather than growth (Cheng & Lemmon, 2004). 
These findings correlate well with the findings presented here that N1-Src function 
does not affect dendrite formation and is required for axonal branching. As L1-CAM 
signalling has not been demonstrated to be required for axon formation N1-Src may 
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also act in other signalling pathways that are able to regulate axon formation. This 
would be typical of tyrosine kinases as they commonly play diverse roles in multiple 
signalling pathways.  
Previous studies have shown that branching of wild type CGNs is increased 
when grown on a substrate of L1-CAM (Cheng and Lemmon, 2004) but this study 
found no effect on axonal branching. Cheng and Lemmon (2004) used L1-CAM 
covalently linked to the coverslip; this eliminated the need for the use of FITC. It is 
possible that the FITC is having a slightly toxic effect on neuronal development and 
that this is preventing the axons from branching. The control neurons in this 
experiment are shorter than those in experiments where no FITC is used. 
Optimisation of the FITC concentration, or covalent L1-CAM linkage, may rectify 
this problem. It would also be interesting to repeat the L1-CAM outgrowth assay 
using cultured hippocampal neurons. The more highly branched architecture of 
hippocampal neurons may reveal an effect of N1-Src inhibition on axonal branching.  
The mechanisms by which L1-CAM signalling affects axonal branching are 
not fully understood. Ankyrin and ERM proteins can both bind to the cytoplasmic 
tail of L1-CAM and provide links to the actin cytoskeleton. L1-CAM binding to 
ankyrin is controlled by MAPK pathway-dependent phosphorylation of the 
cytoplasmic tail (Whittard et al, 2006). Phosphorylation by an unknown kinase 
abolishes the L1-CAM-ankyrin interaction, releasing the ties between the actin 
cytoskeleton and L1-CAM and promoting axon growth. Transgenic mice that cannot 
be phosphorylated at the MAPK dependent residue (Y1229) have abnormal 
interstitial branching of their retinal axons (Buhusi et al, 2008) and impaired 
elongation and branching of interneurons (Guan & Maness, 2010). However, 
truncation of L1-CAM at residue 1180, prior to the ankyrin interaction site, has no 
effect on axon branching (Cheng et al, 2005). Therefore the role of the L1-CAM 
ankyrin interaction in axonal branching is not clear. 
In contrast to the association with ankyrin, a direct role for the ERM protein 
ezrin has been identified in L1-CAM mediated axonal branching. Two binding sites 
for ezrin have been identified in the L1-CAM cytoplasmic tail and ezrin interaction 
via these sites has been demonstrated to be required for L1-CAM mediated axon 
branching (Cheng et al, 2005a; Sakurai et al, 2008). 
The direct links between L1-CAM and the actin cytoskeleton are quite well 
understood. Further research into the regulatory mechanisms controlling these 
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interactions and the downstream effects of L1-CAM signalling is required to 
understand how L1-CAM is able to exert its influence on axonal branching. This 
study has shown that N1-Src is likely to be involved in one or more of these 
regulatory pathways but further work is required to ascertain how this regulation is 
achieved. 
The Src kinases are known to regulate L1-CAM signalling, with C-Src 
directly phosphorylating the L1-CAM tail at Y1176, the site of interaction of L1-
CAM with the adaptor AP2. This affects the trafficking of L1-CAM (Schaefer et al, 
2002) and also presumably influences axon growth. Stimulation of L1-CAM also 
results in a transient upregulation of Src expression in embryonic carcinoma cells 
(Takayama et al, 1997), indicating that Src kinases are also acting downstream of 
L1-CAM mediated signalling.  
Taken together, the data presented here provide strong evidence for a role of 
N1-Src in the regulation of axonal growth and branching. This signalling has been 
demonstrated to act through the L1-CAM pathway, a pathway that is known to 
influence axonal growth and branching. The immediate effectors of L1-CAM 
signalling are well characterised but much of the downstream signalling pathways 
remain to be elucidated. N1-Src has been identified as acting downstream of 
L1-CAM although the mechanism of this action remains unknown. It is also possible 
that the kinase is acting in other pathways, such as the small GTPase signalling 
pathways, to influence axon initiation. These concepts will be discussed further in 
Chapter 6.  
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6 Discussion 
 
The work presented in this thesis represents the first comprehensive assessment of 
N-Src activity and function, with a focus on how these properties are affected by the 
presence of inserts within the n-Src loop. It was previously known that the N-Srcs do 
not bind to many of the binding partners identified for C-Src (Cicchetti et al, 1992; 
Foster-Barber & Bishop, 1998; Messina et al, 2003; Reynolds et al, 2008). The work 
presented here has shown that this difference is due to the altered substrate 
preferences of the N-Src SH3 domains (Chapter 3). Further investigation into the 
binding preferences of the N1-Src SH3 domain has shown that it binds to the 
consensus motif R/KxPxxTxR/K (Chapter 4). This requirement for a positively 
charged residue at both ends of a SH3 domain binding motif is novel and the 
possible structural basis of this binding is discussed in Chapter 4. Functional studies 
into the roles of N1-Src kinase have identified a role in cytoskeletal rearrangement 
both in heterologous cells (Chapter 3) and cultured neurons (Chapter 5) and a role 
for N1-Src in the L1-CAM signalling pathway. Finally, a number of putative N1-Src 
substrates capable of mediating the observed cytoskeletal rearrangements have been 
identified though bioinformatic techniques (Chapter 4) and these will form the basis 
of further study into N1-Src function. The development of a specific inhibitor of 
N1-Src will aid further investigations. 
 
6.1 Insights into the effect of n-Src loop insertion on Src kinase 
activity and function 
 
The most important point made by the combinatorial approaches used here to study 
N-Src function is that the SH3 domain mediates two separate functions. Firstly, it 
acts as a scaffold to anchor substrates to the kinase. This allows both substrate 
selection and phosphorylation. Secondly, the SH3 domain is able to control the 
activity of the kinase; constraining it by forming intramolecular associations and 
activating it by SH3 domain displacement. In the majority of kinases there is a direct 
link between these two processes with SH3 domain displacement directly resulting 
in a functional activation of the kinase. In the case of the N-Srcs there appears to be a 
distinction between the two processes. The SH3 domains of the N-Srcs are less able 
to form the SH3:linker intramolecular association that normally constrains kinase 
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activity and this results in a higher basal level of activity as measured by Y416 
autophosphorylation. However, the SH3 domains of the N-Srcs are still required for 
the substrate selection of the kinases. It may be that, despite the high pY416 levels, 
the kinase domain is not able to associate with its substrates with a high enough 
affinity unless the SH3 domain is also able to bind. 
 Kinase activity is generally assessed by the measurement of pY416 but, for 
the N-Srcs, there does not seem to be a linear relationship between the level of Y416 
phosphorylation and the level of substrate phosphorylation. It would be interesting to 
monitor the pY416 signal in vitro while the N1-Srcs are phosphorylating substrates 
but the low kinase concentrations (5 nM) used in the in vitro assay currently means 
that assessment of Y416 phosphorylation in vitro is not possible under the ideal 
conditions required for kinetic analysis.  
The identification of N1-Src SH3 domain ligands capable of reducing the Km
 
of ideal substrate phosphorylation indicated that, despite their increased basal level 
of kinase activity, the signalling of the N-Srcs in cells is regulated and substrate 
selection is dependent on appropriate SH3 domain interactions. In support of this, in 
the absence of an SH3 binding interaction, phosphorylation by the three Src splice 
variants occurs with the same kinetics. In addition, overexpression of the N-Srcs in 
heterologous cells does not reveal a large number of phosphoproteins in cell lysates. 
The identification of SHP-1 as a potential N1-Src substrate (Chapter 4) could explain 
the lack of N1-Src substrates. Activation of SHP-1 by N1-Src phosphorylation 
would result in the rapid dephosphorylation of N1-Src substrates. If SHP-1 could be 
confirmed as a N1-Src substrate then it would provide evidence that N1-Src signals 
transiently in highly dynamic signalling processes, such as the modulation of 
cytoskeletal rearrangement.  
 To test whether SHP-1 is an N1-Src substrate, SHP-1 could be expressed as a 
recombinant fusion protein for use in an in vitro kinase assay. If this confirms SHP-1 
as a N1-Src substrate then the sequence identified as being the SH3 domain binding 
region could be cloned into the GST-peptide kinase assay system to assess its ability 
to enhance phosphorylation of the ideal substrate. The site of phosphorylation in 
SHP-1 could be confirmed by MS. To assess whether SHP-1 acts to dephosphorylate 
N1-Src substrates in vivo, SHP-1 expression could be knocked down using shRNA 
either in COS7 cells overexpressing N1-Src or in cultured neurons. Analysis of the 
cell lysates by Western blotting with an α-phosphotyrosine would reveal whether this 
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results in more observable N1-Src substrates. More detailed analysis using 
phosphoproteomic MS analysis may then be able to reveal novel N1-Src substrates. 
SHP-1 acts to dephosphorylate substrates phosphorylated by other kinases, including 
C-Src (Frank et al, 2004). Therefore, potential substrates identified by SHP-1 
inhibition must be verified by further in vitro kinase assays.  
 
6.2 A suggested role for N1-Src in cytoskeletal modelling required 
for neurite outgrowth 
 
A role for N1-Src in the modulation of the cytoskeleton was first implied through 
investigations in heterologous cells. More specifically, studies in cultured neurons 
sugguested a role in the regulation of the molecular processes underlying axon 
initiation (in CGNs) and axon branching (in hippocampal neurons). The role in axon 
elongation is less clear but as the molecular processes involved in initiation and 
elongation use broadly the same pathways then it is conceivable that N1-Src acts in 
both. In contrast to the work of Kotani et al (2007), no role for N1-Src was identified 
in dendritic growth. 
 The dynamic regulation of the actin and microtubule cytoskeleton is critical 
in the polarisation of neurons required for axon formation. Localised actin-
depolymerisation in the neurite of a morphologically unpolarised hippocampal 
neuron is sufficient to induce that neurite to become an axon (Bradke & Dotti, 1999). 
In contrast, the stabilisation of the microtubule cytoskeleton promotes axon growth 
(Witte et al, 2008). There are many signalling pathways that are able to regulate the 
neuronal cytoskeleton; see Polleux and Snider (2010) for a comprehensive review. 
Modulation of the cytoskeleton for neurite outgrowth is activated downstream of the 
interaction of guidance cues with their plasma membrane receptors and as such can 
occur through multiple pathways. The signalling cascades downstream of guidance 
cue signalling are now quite well established but how they interact with each other to 
create a co-ordinated response is still unclear. 
 The suggested role of N1-Src in cytoskeletal rearrangement could occur at 
any point during the pathway. It is not practical to assess the potential of substrates 
of N1-Src at all points in these pathways as the number of candidates is vast. A 
recent review by Dent et al (2011) produced a comprehensive list of actin and 
microtubule associated proteins that have been identified as playing a role in 
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neuronal development. Cross referencing this list with that of N1-Src SH3 domain 
interacting proteins (Appendix 1) revealed N1-Src SH3 domain binding sites in 7 
proteins known to both interact with cytoskeletal elements and play a role in axon 
growth. The proteins identified in this way were Ankyrin B, dynein, MAP1B, 
Neuron Navigator, Profilin, Tau and β-Spectrin. These putative N1-Src substrates are 
all known to play roles in neuronal development and therefore represent attractive 
targets to explain the role of N1-Src in cytoskeletal rearrangement. The potential 
functional implications of Ankyrin B phosphorylation by N1-Src are discussed in 
section 6.2.2. 
In addition to direct phosphorylation of cytoskeletal interacting proteins, N1-
Src signalling could also act further upstream. Two signalling pathways were 
highlighted in the course of this study; small GTPase signalling and the L1-CAM 
pathway. 
 
6.2.1 Small GTPase signalling 
 
The morphology of N-Src transfected cells (Chapter 3) resembled that of RhoA 
overexpressing cells (Kolyada et al, 2003), indicating that N1-Src may act to regulate 
small GTPase signalling. In addition, the small GTPases were identified as potential 
N1-Src targets in the bioinformatic analysis carried out in Chapter 4.  
 The small GTPase families play well defined roles in the regulation of neurite 
initiation, elongation, guidance and branching. The major role of Rho GTPases is to 
control the dynamic rearrangement of the actin and microtubule cytoskeleton. Ras 
GTPases are activated by signalling from many guidance cues and feed into many 
signalling transduction pathways including PI3K, ERK and MAPK all known to play 
roles in the regulation of axonogenesis (Huber et al, 2003).  
 A recent review by Hall and Lalli (2010) outlined the roles of Rho and Ras 
GTPases in axon initiation and growth. Cross referencing the proteins in the major 
signalling pathways identified in axon initiation and elongation with putative N1-Src 
SH3 domain ligands (Appendix 1) showed that N1-Src regulation of small GTPases 
is largely restricted to regulation of the factors that activate and inhibit the GTPases, 
GEFs and GAPs respectively (Table 6.2.1.1). GAPs and GEFs for Rho, Rac and Arf, 
but not Ras or Cdc42, were identified. Domain analysis using UniProt data showed 
that the majority of these sites are not contained within any defined domain. This 
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implies that N1-Src phosphorylation may regulate the formation of protein-protein 
interactions rather than GAP and GEF activity.  
Table 6.2.1.1 GAP and GEF proteins that contain the N1-Src SH3 domain 
consensus motif.  
ID Protein name Res. Sequence 
GTPase activating proteins (GAPs) 
ARFG2 
ADP-ribosylation factor GTPase 
activating protein 2 
218 SIIGKKKPAAAKKGL 
ARFG3 
ADP-ribosylation factor GTPase 
activating protein 3 
218 SSIIKKKPNQAKKGL 
ASAP3 
ArfGAP with SH3 domain, ankyrin repeat 
and PH domain 3 
825 SEEGLREPPGTSRPS 
IQGA3 
IQ motif containing GTPase activating 
protein 3 
635 TERVLRNPAVALRGV 
RGAP1 Rac GTPase activating protein 1 432 FLRNLKEPLLTFRLN 
RHG01 Rho GTPase activating protein 1 224 LKSTQKSPATAPKPM 
RHG05 Rho GTPase activating protein 5 1361 LLEAAKIPDKTERLH 
RHG18 Rho GTPase activating protein 18 367 TEGLLRIPGAAIRIK 
RICH2 
Rho-type GTPase-activating protein 
RICH2 
485 DPADRRQPEQARRPL 
SRGP2 
SLIT-ROBO Rho GTPase activating 
protein 3 
2870 PPKKNRSPADAGRGV 
GTPase exchange factors (GEFs) 
ARHG1 
Rho guanine nucleotide exchange factor 
(GEF) 1 
765 TAGSLKVPAPASRPK 
ARHGH 
Rho guanine nucleotide exchange factor 
(GEF) 17 
439 ARTRAKGPGGTSRAL 
BIG1 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 1(brefeldin A-
inhibited) 
791 FLEGFRLPGEAQKID 
BIG2 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 (brefeldin 
A-inhibited) 
736 FLEGFRLPGEAQKID 
KALRN Kalirin, RhoGEF kinase 2948 NGSYSKIPLDTSRLA 
OBSCN 
Obscurin, cytoskeletal calmodulin and 
titin-interacting RhoGEF 
709 GLTANKPPAAAAREV 
PREX2 
Phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange factor 2 
1587 LGVRDRTPQSAPRLY 
 
If these interactions could be confirmed then N1-Src signalling may represent 
a general mechanism of regulation of the activity of small GTPases. Cloning of the 
individual GAPs and GEFs for bacterial expression followed by in vitro kinase 
assays would confirm whether they are able to be phosphorylated by N1-Src. If N1-
Src is able to act at multiple points in the pathway and regulate both GEFs and 
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GAPs, then perturbing its signalling either by overexpression or inhibition would 
result in aberrant neurite outgrowth, as has been observed in this study. It is 
interesting that GAPs and GEFs for both Rho and Rac were identified. Classically, 
Rac signalling is associated with increased neurite outgrowth, while Rho signalling 
is associated with inhibition of neurite outgrowth (Hall & Lalli, 2010).  
 There is a precedent for the regulation of both GAPs and GEFs by tyrosine 
phosphorylation. The best characterised of these is probably the phosphorylation of 
the Ras GAP p120. p120RasGAP was found to be phosphorylated in vivo following 
activation of receptor and non-receptor tyrosine kinases, including SFK family 
members (Ellis et al, 1990; Molloy et al, 1989). It was subsequently shown that both 
Src and Lck phosphorylate p120RasGAP but that the phosphorylation events have 
different effects on GAP activity (Giglione et al, 2001). Phosphorylation by Src 
results in an increase in GAP activity, whereas phosphorylation by Lck does not 
affect GAP activity but may play a role in mediating interactions with SH2 domain 
containing proteins (Amrein et al, 1992; Pleiman et al, 1993). p190RhoGAP has also 
been identified as a major Src substrate in the brain (Brouns et al, 2001) and Src 
phosphorylation of p190RhoGAP is required for EGF-induced actin disassembly 
(Haskell et al, 2001). Therefore, phosphorylation of GAPs and GEFs can modulate 
both activity and interacting proteins and have functional effects on cytoskeletal 
rearrangement.  
 
6.2.2 L1-CAM signalling 
 
Signalling in the L1-CAM pathway has also been identified as a role of N1-Src 
during this study. A literature search was carried out to identify the downstream 
effectors of homophilic or heterophilic L1-CAM interaction at the plasma 
membrane. The proteins identified as containing the N1-Src SH3 domain motif 
(Appendix 1) are shown in Table 6.2.2.1. A direct phosphorylation of L1-CAM by 
N1-Src was also identified in the bioinformatic study but this seems unlikely as both 
the SH3 domain binding site and predicted phosphorylation site are extracellular.  
The proteins identified as potential N1-Src substrates in the L1-CAM 
pathway act at multiple points. Neurocan and EphB2 are plasma membrane receptors 
that L1-CAM is able to heterodimerise with to induce intracellular signalling 
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Table 6.2.2.1 Proteins in the L1-CAM signalling pathway that contain the N1-
Src SH3 domain consensus motif. 
ID Protein Name Res. Sequence 
ANK2 Ankyrin 2 (Ankyrin B), neuronal 2002 RVEKEKGPILTQREA  
NUMB Numb  437 QAGHRRTPSEADRWL  
EPHB2 EPH receptor B2 993 GQPLARRPRATGRTK  
NCAN Neurocan 317 ADGSVRYPIQTPRRR  
RAF1 Raf1 311 GWSQPKTPVPAQRER  
SOS1 Sos1 1306 SQHIPKLPPKTYKRE  
 
(Buhusi et al, 2008; Oleszewski et al, 2000). Ankyrin B provides a direct link 
between the C-terminal tail of L1-CAM and the actin cytoskeleton (Whittard et al, 
2006). Sos and Raf act in the MAPK signalling pathway known to be activated by 
the interaction of many guidance cues with their receptors (Hall & Lalli, 2010). 
Numb interacts with L1-CAM in axonal growth cones and is implicated in the 
regulation of L1-CAM endocytosis (Nishimura et al, 2003b).  
Of the potential N1-Src substrates identified in this study, further 
characterisation of the potential N1-Src interaction with ankyrin B would be 
particularly interesting. N1-Src signalling has been shown experimentally to be 
involved in the L1-CAM signalling pathway (Chapter 5). Ankyrin B interacts 
directly with both L1-CAM and the actin cytoskeleton and is able to modulate 
cytoskeletal rearrangement. Ankyrin B binds a well-defined motif on L1-CAM 
(FIGQY) and phosphorylation of the tyrosine residue in this sequence prevents the 
L1-CAM-ankyrin B interaction (Whittard et al, 2006). The interaction with ankyrin 
B is of interest as mutations in L1-CAM that prevent its interaction with ankyrin are 
implicated in the rare X-linked neurological disorder CRASH (Needham et al, 2001).  
The association of ankyrin with the cytoskeleton is known to be regulated by 
the serine/threonine kinase CKII (casein kinase II). Phosphorylation of ankyrin by 
CKII reduces its ability to bind spectrin (Ghosh & Cox, 2001; Ghosh et al, 2002). 
Tyrosine phosphorylation of ankyrin has never been investigated in detail. 
Interestingly, a study in MDCK cells found that ankyrin G was tyrosine 
phosphorylated following ATP depletion (Woroniecki et al, 2003). The site of this 
phosphorylation and its functional effect was not further investigated. Therefore, 
there is some preliminary evidence for stimulus dependent ankyrin tyrosine 
phosphorylation.  
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To pursue Ankyrin B as a potential N1-Src substrate it would be informative to 
carry out an in vitro kinase assay. As ankyrin B is such a large protein, bacterial 
expression of the entire protein may not be applicable. The region of Ankyrin B 
predicted to be Src phosphorylation could be expressed in isolation or alternatively, 
ankyrin B could be immunoprecipitated from CGN lysates using ankyrin specific 
antibodies (Ghosh et al, 2002). The immunoprecipitate could then be heat treated to 
eliminate the activity of co-precipitating kinases and an in vitro kinase assay using 
N1-Src carried out. If ankyrin B was shown to be an N1-Src substrate, mutation of 
the predicted SH3 domain binding site would reveal whether this site is required for 
the phosphorylation. The functional effects of the N1-Src – ankyrin B interaction can 
be assessed using the L1-CAM outgrowth assay that has been developed (Chapter 5).  
  
6.3 Development of a specific inhibitor of N1-Src 
 
Due to the highly related nature of the SFKs, and in particular C-Src and its splice 
variants, there were no commercially available tools capable of functionally 
inhibiting only one splice variant specifically. During the course of this study it has 
been discovered that the PD1 sequence, identified for its ability to bind to the N1-Src 
SH3 domain, also acts as a potent inhibitor of N1-Src function both in heterologous 
cells and in neurons. It therefore represents a valuable tool for the further study of 
N1-Src function. The PD1 sequence could either be transfected into developing 
neuronal cultures using lentiviral transfection or by fusion to an arginine/lysine rich 
sequence such as Penetratin, which has been shown to induce membrane 
permeability in cultured neurons (Ahmed et al, 2006). These approaches would 
vastly increase the efficiency of transfection and allow assessment of N1-Src 
function through biochemical techniques such as Western blotting and high 
throughput techniques such as MS.  
 Currently, the affinity of PD1 for the N1-Src SH3 domain is unknown but is 
likely to be in the region of 1 – 10 µM as this is typical for SH3 domain peptide 
ligands (Pawson, 2004). Also, its presence enhances phosphorylation of the ideal 
substrate to approximately the same extent as the C-Src SH3 domain binding Class I 
and Class II sequences known to interact with low micromolar affinity. Planned ITC 
experiments will elucidate the precise affinity of the interaction.  
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 The establishment of the structure of the N1-Src SH3 domain in complex 
with PD1 will reveal the nature of the binding interaction and could potentially 
inform further mutations that could be made to improve the affinity of the interaction 
in a rational design approach. Another approach to produce an inhibitor of a higher 
affinity would be to carry out a screen for small molecule inhibitors that are able to 
disrupt the interaction of PD1 with the N1-Src SH3 domain. A similar approach has 
been used by Atatreh et al (2008) to design small molecule inhibitors that prevent the 
interaction of C-Src with its SH3 domain ligands.  
Further functional characterisation of N-Src function would be benefitted by 
the creation of knockout mice. The genetics of creating a N1-Src knockout mouse is 
complex but its production could potentially be very informative. The C-Src 
knockout mouse that exists is also null for N1- and N2-Src due to the nature of the 
cloning carried out but surprisingly shows no gross morphological or developmental 
abnormalities. There are examples of strain background having a large effect on Src 
knockout phenotype (Grant et al, 1992; Yagi et al, 1993) and this could possibly 
explain the lack of phenotype observed. It would therefore be informative to create 
individual splice variant knockouts of C-, N1- and N2-Src in the same strain 
background so that they could be directly compared. As the N2-Src n-Src loop insert 
is created from both the N1- and N2- exons spliced together then preventing the 
expression of the N1- exon would also prevent the expression of N2-Src. Therefore, 
the simplest way to create a N1-Src null mouse would be to constitutively express an 
N1-Src siRNA. This technique was developed by Tiscornia et al (2003) and has been 
used successfully to assess neuronal morphology following specific protein 
knockdown (Grasselli et al, 2011).  
The development of a high affinity, membrane permeable inhibitor of the N1-
Src SH3 domain, either a modified peptide or a small molecule, would open up the 
potential for N1-Src inhibition to be used as a therapeutic. Evidence from 
hippocampal neurons presented in this study shows that N1-Src inhibition acts to 
prevent the formation of axonal branches. There are a number of disease states that 
are associated with an overgrowth of axonal branching but therapeutic use of N1-Src 
inhibition would probably only be applicable if excess branching occurs following 
normal initial neuronal development.  
Temporal lobe epilepsy (TLE) is one of the most common types of epilepsy in 
adult humans and is characterised clinically by the progressive development of 
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spontaneous and recurrent epileptic seizures. Abnormal morphology of hippocampal 
neurons is commonly observed in TLE patients (Masukawa et al, 1995) and animal 
models (Wenzel et al, 2000), characterised by the addition of axonal branches in a 
process known as sprouting. Importantly, the neurons are morphologically normal 
before the onset of seizures. Therefore, N1-Src inhibition may be able to prevent the 
production of these abnormal branches without affecting the morphology of already 
established neurons. For the study of TLE in mouse models, normal initial neuronal 
development is required. This could be achieved either by chemical inhibition of N1-
Src in adult mice or use of an inducible siRNA (Seibler et al, 2007) that would 
prevent N1-Src protein expression only when desired. 
 
6.4 Future directions 
 
The N-Srcs have been demonstrated in this study to have a striking effect on cell 
morphology. The insights into N1-Src SH3 domain binding specificity and the 
identification of some potential binding partners should allow further elucidation 
into the molecular basis of N-Src mediated cytoskeletal rearrangement.  
 The majority of the potential N1-Src substrates identified in this study are 
involved in the processes of initial neurite outgrowth and elongation. N-Src 
expression is known to remain high throughout development and in the adult mouse 
(Wiestler & Walter, 1988) and would therefore be predicted to also play roles in the 
adult brain. Recent work by Groveman et al (2011) has investigated a potential role 
for N1-Src in the modulation of the NMDA-R. Phosphorylation of the NMDA-R 
subunits by C-Src and Fyn is already known (Groveman et al, 2012; Salter & Kalia, 
2004). Groveman et al (2011) identified an in vitro interaction between the N1-Src 
and the NMDA-R NR2A subunit. However, mutation of the kinase, SH2 and SH3 
domains of N1-Src had little effect on the interaction. They therefore conclude that 
the binding is not mediated by a classical interaction with any of these domains. 
However, the SH3 domain mutation they made is a point mutation known to prevent 
C-Src interaction with classical PxxP motif containing proteins. The N1-Src SH3 
domain is now known to bind an atypical motif and such motifs do not necessarily 
form the same contacts with the SH3 domain as classical ligands, further mutational 
analysis of the SH3 domain should be carried out before its role in the interaction is 
ruled out.  
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I would predict that as a result of further work into the N-Src kinases they will 
come to be considered functionally distinct from C-Src. Currently, there are many 
neuronal roles assigned to C-Src that may in the future be reassigned to the N-Srcs. 
In particular, the role of C-Src in cytoskeletal rearrangement and neurite outgrowth 
is not supported by the overexpression experiments both in heterologous cells 
(Chapter 3) and in cultured neurons (Chapter 5) presented in this study. Furthermore, 
bioinformatic prediction of N1-Src and C-Src SH3 domain substrates showed very 
little overlap (Chapter 4). There is a high degree of functional redundancy between 
SFK family members and it may be that roles assigned to C-Src through cell based 
Src inhibition studies are those that cannot be compensated for by Fyn or Yes and 
are actually carried out by the N-Srcs, that will also be inhibited by C-Src kinase 
domain inhibitors. This issue will only be resolved when C-Src kinase domain 
inhibitors are replaced by splice-variant specific inhibitors targeted to the SH3 
domain, such as PD1. 
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Appendix 1  
 
ID Protein Res. Sequence 
ABCAC  ATP-binding cassette, sub-family A (ABC1), member 12 1448 LYGSIKVPHWTKKQL  
ABCAD  ATP-binding cassette, sub-family A (ABC1), member 13 3945 LFASIKAPQWTKKEL  
ABCC8  ATP-binding cassette, sub-family C (CFTR/MRP), member 8 1413 GIDIAKLPLHTLRSR  
ABCC9  ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1381 GIDISKLPLHTLRSR  
ACACB  acetyl-Coenzyme A carboxylase beta 82 EPASHKGPKDAGRRR  
ACOT1  acyl-CoA thioesterase 1 138 PPGVRREPVRAGRVR  
ACOX3  acyl-Coenzyme A oxidase 3, pristanoyl 20 LPEFPRGPLDAYRAR  
ACPH  N-acylaminoacyl-peptide hydrolase 197 EIARLKKPDQAIKGD  
ADA19  ADAM metallopeptidase domain 19 (meltrin beta) 28 RPRAAREPGWTSKGS  
ADA1D  adrenergic, alpha-1D-, receptor 490 PVASRRKPPSAFREW  
ADAM9  ADAM metallopeptidase domain 9 (meltrin gamma) 8 MGSGARFPSGTLRVR  
ADNP  activity-dependent neuroprotector homeobox 779 TKYFNKQPYPTRREI  
ADO  aldehyde oxidase 1 1118 EPIISKNPKGTWKDW  
AEBP1  AE binding protein 1 125 KKGKEKPPKATKKPK  
AFF3  AF4/FMR2 family, member 3 200 LQTQERPPAMAAKHS  
AFF4  AF4/FMR2 family, member 4 567 RTVGKKQPKKAEKAA  
AHNK  AHNAK nucleoprotein 532 VQGDVKGPQVALKGS  
AHNK2  AHNAK nucleoprotein 2 1092 EMPSFKMPKVALKGP  
AIFM3  apoptosis-inducing factor, mitochondrion-associated, 3 320 NVFTIRTPEDANRVV  
AKAP2  
A kinase (PRKA) anchor protein 2; paralemmin 2; PALM2-
AKAP2 readthrough transcript 
235 SQAVKKNPGIAAKWW  
ALEX  GNAS complex locus 12 PVDPQRSPDPTFRSS  
AMD  peptidylglycine alpha-amidating monooxygenase 64 FALDIRMPGVTPKQS  
AMPH  Amphiphysin 294 APARPRSPSQTRKGP  
AMZ1  archaelysin family metallopeptidase 1 89 ASLQHRKPRLARKHI  
ANDR  androgen receptor 15 GRVYPRPPSKTYRGA  
ANK2  ankyrin 2, neuronal 2002 RVEKEKGPILTQREA  
ANR11  ankyrin repeat domain 11; hypothetical protein LOC100128265 1239 KKNKQKLPEKAEKKH  
ANT3  serpin peptidase inhibitor, clade C (antithrombin), member 1 73 EGSEQKIPEATNRRV  
AP2C  
transcription factor AP-2 gamma (activating enhancer binding 
protein 2 gamma) 
372 LLSQDRTPHGTSRLA  
APOL3  apolipoprotein L, 3 308 ARARARLPVTTWRIS  
ARFG2  ADP-ribosylation factor GTPase activating protein 2 218 SIIGKKKPAAAKKGL  
ARFG3  ADP-ribosylation factor GTPase activating protein 3 218 SSIIKKKPNQAKKGL  
ARHG1  Rho guanine nucleotide exchange factor (GEF) 1 765 TAGSLKVPAPASRPK  
ARHG8  neuroepithelial cell transforming 1 132 LRGDHRSPASAQKFS  
ARHGH  Rho guanine nucleotide exchange factor (GEF) 17 439 ARTRAKGPGGTSRAL  
ARP5  ARP5 actin-related protein 5 homolog (yeast) 580 IYVPIRLPKQASRSS  
ASAP3  ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 825 SEEGLREPPGTSRPS  
ASH1L  ash1 (absent, small, or homeotic)-like (Drosophila) 119 IKTTIKHPRKALKSG  
ASNS  asparagine synthetase 506 ANAAQKFPFNTPKTK  
ATP4B  ATPase, H+/K+ exchanging, beta polypeptide 80 YQDQLRSPGVTLRPD  
ATP9A  ATPase, class II, type 9A 442 DPPAQKGPTLTTKVR  
ATR  
ataxia telangiectasia and Rad3 related; similar to ataxia 
telangiectasia and Rad3 related protein 
1899 NSYRAKEPILALRRA  
ATS16  ADAM metallopeptidase with thrombospondin type 1 motif, 16 46 SPSVPRPPPPAERPG  
ATS17  ADAM metallopeptidase with thrombospondin type 1 motif, 17 68 RRRRPRTPPAAPRAR  
ATS18  ADAM metallopeptidase with thrombospondin type 1 motif, 18 852 ILMQGKNPGIAWKYA  
B2L10  BCL2-like 10 (apoptosis facilitator) 102 GTLLERGPLVTARWK  
B3A2  
solute carrier family 4, anion exchanger, member 2 (erythrocyte 
membrane protein band 3-like 1) 
306 SGREGREPGPTPRAR  
BAI3  brain-specific angiogenesis inhibitor 3 1469 NPAPNKNPWDTFKNP  
BAIP3  BAI1-associated protein 3 193 RVRKAKAPTYALKVS  
BANK1  B-cell scaffold protein with ankyrin repeats 1 612 SFIINRPPAPTPRPT  
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BAZ1B  bromodomain adjacent to zinc finger domain, 1B 902 KLVMRRTPIGTDRNH  
BIG1  
ADP-ribosylation factor guanine nucleotide-exchange factor 
1(brefeldin A-inhibited) 
791 FLEGFRLPGEAQKID  
BIG2  
ADP-ribosylation factor guanine nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
736 FLEGFRLPGEAQKID  
BIRC6  baculoviral IAP repeat-containing 6 2520 GIPVAKPPANTEKNG  
BIRC8  baculoviral IAP repeat-containing 8 99 VQTTKKTPSLTKRIS  
BMP2K  BMP2 inducible kinase 265 LKPTYRTPERARRHK  
BMP8A  bone morphogenetic protein 8a 63 GRPRPRAPPAASRLP  
BMP8B  bone morphogenetic protein 8b 63 GRPRPRAPPAASRLP  
BMS1  
BMS1 homolog, ribosome assembly protein (yeast) pseudogene; 
BMS1 homolog, ribosome assembly protein (yeast) 
1078 IKKALRAPEGAFRAS  
BPTF  bromodomain PHD finger transcription factor 573 DIDNVKSPEETEKDK  
BRD2  bromodomain containing 2 102 FAWPFRQPVDAVKLG  
BSN  bassoon (presynaptic cytomatrix protein) 2245 LTSLTRVPMIAPRVP  
C1QR1  CD93 molecule 506 TASPTRGPEGTPKAT  
CA2D4  calcium channel, voltage-dependent, alpha 2/delta subunit 4 73 AWGQAKIPLETVKLW  
CABL2  Cdk5 and Abl enzyme substrate 2 32 PTSAARAPPQALRRR  
CAD22  cadherin-like 22 421 GVVTARDPDAANRPV  
CAF1B  chromatin assembly factor 1, subunit B (p60) 395 PVLNMRTPDTAKKTK  
CAN12  calpain 12 482 LLRADRSPLSARRDV  
CBPC2  ATP/GTP binding protein-like 2 175 SILSTKRPLQAPRWP  
CBX7  chromobox homolog 7 142 LPFPLRKPRKAHKYL  
CC14A  CDC14 cell division cycle 14 homolog A (S. cerevisiae) 111 VIYLKKTPEEAYRAL  
CC14B  CDC14 cell division cycle 14 homolog B (S. cerevisiae) 148 VIYLGRTPEEAYRIL  
CD28  CD28 molecule 199 MNMTPRRPGPTRKHY  
CDA7L  cell division cycle associated 7-like 247 DFFPVRTPTSASRKK  
CE290  centrosomal protein 290kDa 1719 KEANSRAPTTTMRNL  
CELF3  trinucleotide repeat containing 4 458 LKVQLKRPKDANRPY  
CELF4  bruno-like 4, RNA binding protein (Drosophila) 479 LKVQLKRPKDANRPY  
CELF6  bruno-like 6, RNA binding protein (Drosophila) 474 LKVQLKRPKDANRPY  
CENPE  centromere protein E, 312kDa 2369 TTQDNKNPHVTSRAT  
CHD3  chromodomain helicase DNA binding protein 3 1890 PATLSRIPPIAARLQ  
CHD4  chromodomain helicase DNA binding protein 4 1879 PATIARIPPVAVRLQ  
CHD5  chromodomain helicase DNA binding protein 5 1886 PSMLSRIPPVAARLQ  
CHD6  chromodomain helicase DNA binding protein 6 342 MEELEKDPRIAQKIK  
CKAP5  cytoskeleton associated protein 5 222 EEEWVKLPTSAPRPT  
CKLF6  CKLF-like MARVEL transmembrane domain containing 6 168 QESQLRKPENTTRAE  
CLC1A  C-type lectin domain family 1, member A 43 RRTEHRAPSSTWRPV  
CLIC5  chloride intracellular channel 5 261 TLTPEKYPKLAAKHR  
CLK3  CDC-like kinase 3 248 RRSRERGPYRTRKHA  
CLSPN  claspin homolog (Xenopus laevis) 1238 SKSLLRNPFEAIRPG  
CO5A1  collagen, type V, alpha 1 71 TRRSSKGPDVAYRVT  
CO5A3  collagen, type V, alpha 3 296 EPTPSKKPVEAAKET  
COPE  coatomer protein complex, subunit epsilon 267 SQHLGKPPEVTNRYL  
CORA1  collagen, type XXVII, alpha 1 385 SIVPIKSPHPTQKTA  
CP250  centrosomal protein 250kDa 1716 RAEEGKGPSKAQRGS  
CP2B6  cytochrome P450, family 2, subfamily B, polypeptide 6 318 FLLMLKYPHVAERVY  
CP2C8  cytochrome P450, family 2, subfamily C, polypeptide 8 317 LLLLLKHPEVTAKVQ  
CP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 317 LLLLLKHPEVTAKVQ  
CP2CI  cytochrome P450, family 2, subfamily C, polypeptide 18 317 LLLLLKYPEVTAKVQ  
CP2CJ  cytochrome P450, family 2, subfamily C, polypeptide 19 317 LLLLLKHPEVTAKVQ  
CP2U1  cytochrome P450, family 2, subfamily U, polypeptide 1 392 VIGANRAPSLTDKAQ  
CPEB2  cytoplasmic polyadenylation element binding protein 2 481 TDPELKYPKGAGRVA  
CPLX1  complexin 1 28 GGDEEKDPDAAKKEE  
CPT1A  carnitine palmitoyltransferase 1A (liver) 175 QTSLPRLPVPAVKDT  
CPXM2  carboxypeptidase X (M14 family), member 2 79 RPQEPRPPKRATKPK  
CROCC  ciliary rootlet coiled-coil, rootletin 1450 GLGLGRAPSPAPRPV  
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CRX  cone-rod homeobox 272 DSLEFKDPTGTWKFT  
CSKI1  CASK interacting protein 1 923 RSHSVRAPAGADKNV  
CSPG2  Versican 209 ADQTVRYPIRAPRVG  
CTBL1  catenin, beta like 1 254 KRLKAKMPFDANKLY  
CTR9  
Ctr9, Paf1/RNA polymerase II complex component, homolog (S. 
cerevisiae) 
986 PKPKKRRPPKAEKKK  
CTRO  citron (rho-interacting, serine/threonine kinase 21) 2007 DSSRGRLPAGAVRTP  
CY24A  cytochrome b-245, alpha polypeptide 160 SNPPPRPPAEARKKP  
CYH1  cytohesin 1 155 FLWSFRLPGEAQKID  
CYH2  cytohesin 2 154 FLWSFRLPGEAQKID  
CYH3  cytohesin 3 159 FLWSFRLPGEAQKID  
CYH4  cytohesin 4 154 FLWSFRLPGEAQKID  
CYLD  cylindromatosis (turban tumor syndrome) 151 GVVRFRGPLLAERTV  
DGC14  DiGeorge syndrome critical region gene 14 340 TPYVDRTPGPAFKIL  
DGKZ  diacylglycerol kinase, zeta 104kDa 440 WILRARRPQNTLKAS  
DHB1  hydroxysteroid (17-beta) dehydrogenase 1 248 FLTALRAPKPTLRYF  
DHCR7  7-dehydrocholesterol reductase 90 SDIWAKTPPITRKAA  
DIAP1  diaphanous homolog 1 (Drosophila) 1218 AFRRKRGPRQANRKA  
DIDO1  death inducer-obliterator 1 68 LRRSGRQPKRTERVE  
DJC30  DnaJ (Hsp40) homolog, subfamily C, member 30 141 DPGSPRTPPPTSRTH  
DLG5  discs, large homolog 5 (Drosophila) 1195 VSSILRNPIYTVRSH  
DNLI1  ligase I, DNA, ATP-dependent 221 EEEQTKPPRRAPKTL  
DNM1L  dynamin 1-like 274 AFLQKKYPSLANRNG  
DNMBP  dynamin binding protein 1459 VARDVKQPTATPRSY  
DNS2B  deoxyribonuclease II beta 329 IGDLNRSPHQAFRSG  
DOK5  docking protein 5 72 VKNVARLPKSTKKHA  
DPOD3  polymerase (DNA-directed), delta 3, accessory subunit 428 TSSVHRPPAMTVKKE  
DPOG1  polymerase (DNA directed), gamma 507 AKKVKKEPATASKLP  
DPOLZ  REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 2494 HVLHQRFPLFTFRVL  
DPP9  dipeptidyl-peptidase 9 313 PRTGSKNPKIALKLA  
DSG2  desmoglein 2 538 FSVIDKPPGMAEKWK  
DTX4  deltex homolog 4 (Drosophila) 425 APSGYKGPQPTVKPD  
DUS2  dual specificity phosphatase 2 21 LGTLLRDPREAERTL  
DUX1  double homeobox, 1 119 AFEKDRFPGIAAREE  
DUX4  
double homeobox, 4-like; similar to double homeobox 4c; 
similar to double homeobox, 4; double homeobox, 4 
119 AFEKDRFPGIAAREE  
DUX5  double homeobox, 5 146 AFEKDRFPGIAAREE  
DVL2  dishevelled, dsh homolog 2 (Drosophila) 32 TPYLVKIPVPAERIT  
DVL3  dishevelled, dsh homolog 3 (Drosophila) 22 TPYLVKLPLPAERVT  
DYH2  dynein, axonemal, heavy chain 2 1804 RGGSPKGPAGTGKTE  
DYHC1  dynein, cytoplasmic 1, heavy chain 1 4239 NISPDKIPWSALKTL  
E2AK1  eukaryotic translation initiation factor 2-alpha kinase 1 485 NRNGKRTPTHTSRVG  
EA3L1  
transcription elongation factor B polypeptide 3C-like; 
transcription elongation factor B polypeptide 3C-like 2; 
transcription elongation factor B polypeptide 3C (elongin A3) 
459 FNSVAKTPYDASRRQ  
ECT2  epithelial cell transforming sequence 2 oncogene 816 AFSFSKTPKRALRRA  
ELOA2  transcription elongation factor B polypeptide 3B (elongin A2) 651 FKSVAKTPYDTSRRQ  
EMAL4  echinoderm microtubule associated protein like 4 175 PTKSIKRPSPAEKSH  
EME1  essential meiotic endonuclease 1 homolog 1 (S. pombe) 30 FAFLKKEPSSTKRRQ  
ENL  
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 1 
254 PKAAFKEPKMALKET  
ENPP1  ectonucleotide pyrophosphatase/phosphodiesterase 1 598 LNHLLKNPVYTPKHP  
ENPP7  ectonucleotide pyrophosphatase/phosphodiesterase 7 266 LVEFHKFPNFTFRDI  
EPHB2  EPH receptor B2 993 GQPLARRPRATGRTK  
ERCC1  
excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense 
sequence) 
178 VQVDVKDPQQALKEL  
ERI1  exoribonuclease 1 251 QLSRLKYPPFAKKWI  
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F10A1  
similar to heat shock 70kD protein binding protein; suppression 
of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting 
protein) 
43 ESMGGKVPPATQKAK  
FAKD1  FAST kinase domains 1 771 EIVGSRLPPGAERIA  
FBX21  F-box protein 21 240 RGINSRHPSLAFKAG  
FBX46  F-box protein 46 28 SQNQPRPPSAALKPS  
FBXL6  F-box and leucine-rich repeat protein 6 75 PRQPPRGPSAAAKPK  
FBXW8  F-box and WD repeat domain containing 8 29 APKKRRRPEAAERRA  
FGD2  FYVE, RhoGEF and PH domain containing 2 25 VFENSRTPEAAPRGQ  
FGD5  FYVE, RhoGEF and PH domain containing 5 881 EDSASRDPSVTHKVE  
FGD6  FYVE, RhoGEF and PH domain containing 6 10 SAAEIKKPPVAPKPK  
FGF5  fibroblast growth factor 5 248 SPIKPKIPLSAPRKN  
FHOD3  formin homology 2 domain containing 3 29 FPEPSRPPLFTFRED  
FIG4  FIG4 homolog (S. cerevisiae) 718 SPFTVRKPDETGKSV  
FMNL  formin-like 1 1032 EPPAPKSPPKARRPQ  
FND3B  fibronectin type III domain containing 3B 1011 FISIYRGPSHTYKVQ  
FOXS1  forkhead box S1 126 GAEGTRGPAKARRGP  
FREM3  FRAS1 related extracellular matrix 3 8 MAGASRHPTGTPRQL  
GAK  cyclin G associated kinase 1167 EERGVRAPSFAQKPK  
GCN1L  GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 891 FLPLLKSPLAAPRIK  
GCYB1  guanylate cyclase 1, soluble, beta 3 411 NELRHKRPVPAKRYD  
GDF5  growth differentiation factor 5 246 LRILRKKPSDTAKPA  
GMDS  GDP-mannose 4,6-dehydratase 178 TPFYPRSPYGAAKLY  
GP157  G protein-coupled receptor 157 307 SQPPTKSPAGTPKAP  
GP179  G protein-coupled receptor 179 1728 AEAIRKSPNDTGKVS  
GPI8  phosphatidylinositol glycan anchor biosynthesis, class K 140 RVLTGRIPPSTPRSK  
GPNMB  glycoprotein (transmembrane) nmb 18 LLLAARLPLDAAKRF  
GPR56  G protein-coupled receptor 56 193 LSQFLKHPQKASRRP  
H11  histone cluster 1, H1a 159 TPKKAKKPAATRKSS  
H12  histone cluster 1, H1c 131 GGTKPKKPVGAAKKP  
H13  histone cluster 1, H1d 132 GAAKPRKPAGAAKKP  
H14  histone cluster 1, H1e 131 GAAKAKKPAGAAKKP  
H15  histone cluster 1, H1b 156 KKAVKKTPKKAKKPA  
H1BP3  HCLS1 binding protein 3 216 SKKPKKHPKVAVKAK  
HAUS5  HAUS augmin-like complex, subunit 5 27 VPVAARAPESTLRRL  
HELC1  activating signal cointegrator 1 complex subunit 3 1103 IALRKRWPTMTYRLL  
HERC1  
hect (homologous to the E6-AP (UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like domain (RLD) 1 
4508 NASDLRLPSRAWKVK  
HIP1R  huntingtin interacting protein 1 related 1038 RSVTTKKPPLAQKPS  
HPLN2  hyaluronan and proteoglycan link protein 2 207 LEGSVRYPVLTARAP  
HPS1  Hermansky-Pudlak syndrome 1 137 IRKELRPPDLAQRVQ  
HRH1  histamine receptor H1 276 GGSVLKSPSQTPKEM  
HSPB8  heat shock 22kDa protein 8 73 SGMVPRGPTATARFG  
HUWE1  HECT, UBA and WWE domain containing 1 3128 LSAILRSPAFTSRLS  
HXA1  homeobox A1 214 WMKVKRNPPKTGKVG  
HXB1  homeobox B1 189 WMKVKRNPPKTAKVS  
HXK2  hexokinase 2 pseudogene; hexokinase 2 421 GSVYKKHPHFAKRLH  
HYOU1  hypoxia up-regulated 1 93 ASMAIKNPKATLRYF  
IDHC  isocitrate dehydrogenase 1 (NADP+), soluble 95 LKQMWKSPNGTIRNI  
IDHP  isocitrate dehydrogenase 2 (NADP+), mitochondrial 135 LKKMWKSPNGTIRNI  
IF140  intraflagellar transport 140 homolog (Chlamydomonas) 734 YYYFTRKPEEADRED  
IFT88  intraflagellar transport 88 homolog (Chlamydomonas) 59 RTSHGRRPPITAKIS  
IKBE  
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, epsilon 
101 PHSPGRRPPRAGRPL  
IL16  interleukin 16 (lymphocyte chemoattractant factor) 783 SSTVKKGPPVAPKPA  
IL31R  interleukin 31 receptor A 312 YNSLGKSPVATLRIP  
ILDR2  immunoglobulin-like domain containing receptor 2 518 PRLVSRTPGTAPKYD  
ILK  integrin-linked kinase 365 PEALQKKPEDTNRRS  
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IMB1  karyopherin (importin) beta 1 307 AAEQGRPPEHTSKFY  
INP5E  inositol polyphosphate-5-phosphatase, 72 kDa 552 STSKQRTPSYTDRVL  
INP5K  inositol polyphosphate-5-phosphatase K 265 TSEKKRKPAWTDRIL  
INT1  integrator complex subunit 1 12 KPTTVRRPSAAAKPS  
INVS  Inversin 688 QGTNSRRPNETAREH  
IPO9  importin 9 99 QSEKFRPPETTERAK  
IQGA3  IQ motif containing GTPase activating protein 3 635 TERVLRNPAVALRGV  
IRX3  iroquois homeobox 3 406 SAPLGKFPAWTNRPF  
ISL1  ISL LIM homeobox 1 178 RPHVHKQPEKTTRVR  
ITAD  integrin, alpha D 696 IFNETKNPTLTRRKT  
ITCH  itchy E3 ubiquitin protein ligase homolog (mouse) 260 PPRPSRPPPPTPRRP  
JAG1  jagged 1 (Alagille syndrome) 1194 NGTPTKHPNWTNKQD  
JHD2C  jumonji domain containing 1C 1646 EQRTKRQPKPTYKKK  
K1C12  keratin 12 464 STDSSKDPTKTRKIK  
KALRN  kalirin, RhoGEF kinase 2948 NGSYSKIPLDTSRLA  
KCD19  potassium channel tetramerisation domain containing 19 712 AGAKDKGPEPTFKPY  
KCNQ2  
potassium voltage-gated channel, KQT-like subfamily, member 
2 
597 DQIVGRGPAITDKDR  
KCNT1  potassium channel, subfamily T, member 1 944 LAFMFRLPFAAGRVF  
KCNT2  potassium channel, subfamily T, member 2 881 LAFMFRLPFAAGRVF  
KDM3B  lysine (K)-specific demethylase 3B 790 FSQENKAPFEAVKRF  
KDM6A  lysine (K)-specific demethylase 6A 1078 SGRRRKGPFKTIKFG  
KI18B  kinesin family member 18B 815 RSRIARLPSSTLKRP  
KI67  antigen identified by monoclonal antibody Ki-67 845 NGNVAKTPRNTYKMT  
KIF1A  kinesin family member 1A 43 TIVNPKQPKETPKSF  
KIF1B  kinesin family member 1B 43 SIINPKNPKEAPKSF  
KLF10  Kruppel-like factor 10 141 FKEEEKSPVSAPKLP  
KLH12  kelch-like 12 (Drosophila) 225 LLQYVRMPLLTPRYI  
KLH13  kelch-like 13 (Drosophila) 520 DKWIQKAPMTTVRGL  
KLH36  kelch-like 36 (Drosophila) 478 DVWEERRPMTTARGW  
KLHL9  kelch-like 9 (Drosophila) 478 DKWMQKAPMTTVRGL  
KPRA  phosphoribosyl pyrophosphate synthetase-associated protein 1 178 AVIVAKSPDAAKRAQ  
KPRB  phosphoribosyl pyrophosphate synthetase-associated protein 2 190 AVIVAKSPASAKRAQ  
KRIT1  KRIT1, ankyrin repeat containing 595 TKLKSKAPHWTNRIL  
KS6B2  ribosomal protein S6 kinase, 70kDa, polypeptide 2 467 APLPIRPPSGTKKSK  
L1CAM  L1 cell adhesion molecule 139 AEGAPKWPKETVKPV  
LAMA1  laminin, alpha 1 2227 MSSNQKSPTKTSKSP  
LAMA3  laminin, alpha 3 280 ISKAQRDPTVTRRYY  
LAMA4  laminin, alpha 4 435 EEIRSRQPFFTQREL  
LAMA5  laminin, alpha 5 281 MGKALRDPTVTRRYY  
LASS1  
growth differentiation factor 1; LAG1 homolog, ceramide 
synthase 1 
100 PRDAAKMPESAWKFL  
LEG12  lectin, galactoside-binding, soluble, 12 124 WQREARWPHLALRRG  
LHX1  LIM homeobox 1 183 LGAKRRGPRTTIKAK  
LHX5  LIM homeobox 5 183 SGTKRRGPRTTIKAK  
LIN54  lin-54 homolog (C. elegans) 315 AISPLKSPNKAVKST  
LINCR  neuralized homolog 3 (Drosophila) pseudogene 14 FEANAKAPREALRFH  
LMTK3  lemur tyrosine kinase 3 1012 ENGGLRFPRNTERPP  
LOX5  arachidonate 5-lipoxygenase 575 APPTMRAPPPTAKGV  
LT4R2  leukotriene B4 receptor 2 166 LAPRLRSPALARRLL  
LTBP2  latent transforming growth factor beta binding protein 2 10 PRTKARSPGRALRNP  
M3K11  mitogen-activated protein kinase kinase kinase 11 626 EPEEPKRPVPAERGS  
M4K1  mitogen-activated protein kinase kinase kinase kinase 1 352 RGMETRPPANTARLQ  
MADD  MAP-kinase activating death domain 1096 PQLGPRAPSATGKGP  
MAF  
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
36 KFEVKKEPVETDRII  
MAGT1  magnesium transporter 1 242 MWNHIRGPPYAHKNP  
MAP1A  microtubule-associated protein 1A 292 HLDFLRYPVATQKDL  
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MAP1B  microtubule-associated protein 1B 514 HLDFLKQPLATQKDL  
MAP9  microtubule-associated protein 9 16 TLAYTKSPKVTKRTT  
MAST2  microtubule associated serine/threonine kinase 2 868 LLEERRTPPPTKRSL  
MAST4  microtubule associated serine/threonine kinase family member 4 1906 FKRDRKGPHPTARSP  
MAZ  
MYC-associated zinc finger protein (purine-binding 
transcription factor) 
221 GAKAGRVPSGAMKMP  
MBD1  methyl-CpG binding domain protein 1 409 PYRRRKRPSSARRHH  
MED1  mediator complex subunit 1 1043 STGGSKSPGSAGRSQ  
MED26  mediator complex subunit 26 222 DKHSGKIPVNAVRPH  
METH  5-methyltetrahydrofolate-homocysteine methyltransferase 640 DLIWNKDPEATEKLL  
MGRN1  mahogunin, ring finger 1 451 GRPQSKAPDSTLRSP  
MILK2  MICAL-like 2 135 EPSGKKAPVQAAKLP  
MINT  spen homolog, transcriptional regulator (Drosophila) 1971 EENEAKEPAETLKPP  
MIS  anti-Mullerian hormone 446 RGRDPRGPGRAQRSA  
MOSC1  MOCO sulphurase C-terminal domain containing 1 290 GVMSRKEPLETLKSY  
MOSC2  MOCO sulphurase C-terminal domain containing 2 289 GVIDRKQPLDTLKSY  
MRE11  MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 300 KMNMHKIPLHTVRQF  
MRF  chromosome 11 open reading frame 9 744 VPHKKRPPKVASKSS  
MTBP  
Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) binding protein, 104kDa 
16 IWGEGKFPSAASREA  
MTCH1  mitochondrial carrier homolog 1 (C. elegans) 43 VEARARDPPPAHRAH  
MUC20  mucin 20, cell surface associated 599 MDIATKGPFPTSRDP  
MVP  major vault protein 555 EVNDRKDPQETAKLF  
MYCB2  MYC binding protein 2 3820 IKIELKGPENTLRVR  
MYT1  myelin transcription factor 1 432 KSYYSKDPSRAEKRE  
MYT1L  myelin transcription factor 1-like 496 KPYYGKDPSRTEKKE  
NAL12  NLR family, pyrin domain containing 12 125 LVTPRKDPQETYRDY  
NANG2  Nanog homeobox pseudogene 1 20 TSPKGKQPTTAEKSA  
NANOG  Nanog homeobox pseudogene 8; Nanog homeobox 77 TSPKGKQPTSAEKSV  
NAT8L  N-acetyltransferase 8-like (GCN5-related, putative) 104 DGIMERIPNTAFRGL  
NAV2  neuron navigator 2 1114 ASQVKRSPSDAGRSS  
NCAN  Neurocan 317 ADGSVRYPIQTPRRR  
NEIL1  nei endonuclease VIII-like 1 (E. coli) 321 ALPPSKAPSRTRRAK  
NEK5  NIMA (never in mitosis gene a)-related kinase 5 334 HRNEWRPPAGAQKAR  
NFE2  nuclear factor (erythroid-derived 2), 45kDa 236 RALAMKIPFPTDKIV  
NLGN2  neuroligin 2 623 FTTTTRLPPYATRWP  
NOG1  GTP binding protein 4 509 NTQGPRMPRTAKKVQ  
NOP2  NOP2 nucleolar protein homolog (yeast) 692 KAEGIREPKVTGKLK  
NPHP1  nephronophthisis 1 (juvenile) 9 LARRQRDPLQALRRR  
NRCAM  neuronal cell adhesion molecule 93 HFDIDKDPLVTMKPG  
NRX2A  neurexin 2 1699 APAAPKTPSKAKKNK  
NRX2B  
 
653 APAAPKTPSKAKKNK  
NTHL1  nth endonuclease III-like 1 (E. coli) 58 SHSPVKRPRKAQRLR  
NTRK3  neurotrophic tyrosine kinase, receptor, type 3 577 AVKALKDPTLAARKD  
NUMB  numb homolog (Drosophila) 437 QAGHRRTPSEADRWL  
NUMBL  numb homolog (Drosophila)-like 410 QPGHKRTPSEAERWL  
NUP54  nucleoporin 54kDa 249 IYVVERSPNGTSRRV  
NXF2  nuclear RNA export factor 2; nuclear RNA export factor 2B 618 LQTEGKIPAEAFKQI  
O10A3  olfactory receptor, family 10, subfamily A, member 3 229 LFAILKMPSTTGRQK  
O10A6  olfactory receptor, family 10, subfamily A, member 6 229 LFAILKMPSTTGRQK  
O10C1  olfactory receptor, family 10, subfamily C, member 1 228 LVTIFRIPSVAGRRK  
O11A1  olfactory receptor, family 11, subfamily A, member 1 230 VVAVLRVPAGASRRR  
O11G2  olfactory receptor, family 11, subfamily G, member 2 267 VRAVLRVPSAAGRRK  
OBSCN  obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 709 GLTANKPPAAAAREV  
ODB2  dihydrolipoamide branched chain transacylase E2 245 PILVSKPPVFTGKDK  
OLA1  Obg-like ATPase 1 328 IRKGTKAPQAAGKIH  
OR1B1  olfactory receptor, family 1, subfamily B, member 1 235 GAAILRLPSAAGRRR  
OR1L1  olfactory receptor, family 1, subfamily L, member 1 279 LITVLKIPSAAGKRK  
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OR1L3  olfactory receptor, family 1, subfamily L, member 3 229 LIAVLKIPSAAGKHK  
OR1L4  olfactory receptor, family 1, subfamily L, member 4 230 IVTVLRIPSAAGKWK  
OR1L6  olfactory receptor, family 1, subfamily L, member 6 266 MVTVLRIPSAAGKWK  
OR6T1  olfactory receptor, family 6, subfamily T, member 1 229 LATVLRAPTAAERRK  
OSB10  oxysterol binding protein-like 10 224 TITHHKSPAAARRAK  
OSR1  odd-skipped related 1 (Drosophila) 168 KPTRGRLPSKTKKEF  
OSR2  odd-skipped related 2 (Drosophila) 165 KPSRGRLPSKTKKEF  
P20D2  peptidase M20 domain containing 2 99 EPPEARAPSATPRPL  
P53  tumor protein p53 67 PDEAPRMPEAAPRVA  
P66B  GATA zinc finger domain containing 2B 566 GIGGHKGPSLADRQR  
PABP1  
poly(A) binding protein, cytoplasmic pseudogene 5; poly(A) 
binding protein, cytoplasmic 1 
462 RPAAPRPPFSTMRPA  
PABP3  poly(A) binding protein, cytoplasmic 3 456 RPGAPRVPFSTMRPA  
PALLD  palladin, cytoskeletal associated protein 678 QEAGARQPPPAPRSA  
PARF  chromosome 9 open reading frame 86 615 PPPPPKLPLPAFRLK  
PCD10  protocadherin 10 1032 TRAPYKPPYLTRKRI  
PCD21  protocadherin 21 744 RRVLRKRPSPAPRTI  
PCDH8  protocadherin 8 290 FAFGARTPPEARRLF  
PD1L2  programmed cell death 1 ligand 2 261 SKDTTKRPVTTTKRE  
PDE2A  phosphodiesterase 2A, cGMP-stimulated 199 QVLQQRGPREAPRAV  
PDZD2  PDZ domain containing 2 851 LGTPLKSPSLAKKDS  
PECI  peroxisomal D3,D2-enoyl-CoA isomerase 341 LKAFAKLPPNALRIS  
PERE  eosinophil peroxidise 79 LLSYFKQPVAATRTV  
PERM  Myeloperoxidase 105 LLSYFKQPVAATRTA  
PEX19  peroxisomal biogenesis factor 19 55 SGPQKRSPGDTAKDA  
PGCA  Aggrecan 212 ADQTVRYPIHTPREG  
PGCB  Brevican 216 SDQTVRYPIQTPREA  
PHX2A  paired-like homeobox 2a 275 LSSFHRKPGPALKTN  
PIAS4  protein inhibitor of activated STAT, 4 123 LNGLGRLPAKTLKPE  
PISD  phosphatidylserine decarboxylase 42 LQPLRKLPFRAFRTD  
PITM1  phosphatidylinositol transfer protein, membrane-associated 1 1213 QLLRSRGPSQAEREG  
PJA1  praja ring finger 1 71 TTKRSRSPFSTTRRS  
PK1L3  polycystic kidney disease 1-like 3 1269 INSPTKHPERTLKKK  
PKHG3  
pleckstrin homology domain containing, family G (with RhoGef 
domain) member 3 
489 RRPSGRSPTSTEKRM  
PLD1  phospholipase D1, phosphatidylcholine-specific 140 YKAFIRIPIPTRRHT  
PM2L3  postmeiotic segregation increased 2-like 3; zinc finger protein 12 35 RLDLPRSPARAPREQ  
PPIB  peptidylprolyl isomerase B (cyclophilin B) 40 ADEKKKGPKVTVKVY  
PPIC  peptidylprolyl isomerase C (cyclophilin C) 34 EGFRKRGPSVTAKVF  
PPM1D  protein phosphatase 1D magnesium-dependent, delta isoform 68 GEVSGKGPAVAAREA  
PPR3A  protein phosphatase 1, regulatory (inhibitor) subunit 3A 756 KAIIAKLPQETARSD  
PPRC1  
peroxisome proliferator-activated receptor gamma, coactivator-
related 1 
1114 TRPREKPPLPATKAV  
PRD16  PR domain containing 16 758 VKAEPKSPRDALKVG  
PRDM7  PR domain containing 7 104 PRQQVKPPWMAFRGE  
PRDM9  PR domain containing 9 104 PRQQVKPPWMALRVE  
PREX2  
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 2 
1587 LGVRDRTPQSAPRLY  
PRG4  proteoglycan 4 467 TPTTPKEPAPTTKEP  
PRLD1  
PRELI domain containing 1; similar to Px19-like protein (25 
kDa protein of relevant evolutionary and lymphoid interest) 
(PRELI) 
63 LTKTNRMPRWAERLF  
PROF4  profilin family, member 4 56 VNGFAKNPLQARREG  
PRS4  
proteasome (prosome, macropain) 26S subunit, ATPase, 1; 
similar to protease (prosome, macropain) 26S subunit, ATPase 1 
43 KKKKTKGPDAASKLP  
PTN11  
protein tyrosine phosphatase, non-receptor type 11; similar to 
protein tyrosine phosphatase, non-receptor type 11 
215 TVLQLKQPLNTTRIN  
PTN6  protein tyrosine phosphatase, non-receptor type 6 212 AFVYLRQPYYATRVN  
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PTPM1  protein tyrosine phosphatase, mitochondrial 1 30 TLFRGKVPGRAHRDW  
PUR6  
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide synthetase 
306 VTSAHKGPDETLRIK  
PUS7  pseudouridylate synthase 7 homolog (S. cerevisiae) 431 EWAKTKDPTAALRKL  
PYR1  
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, 
and dihydroorotase 
1477 VHVHLREPGGTHKED  
RAF1  v-raf-1 murine leukemia viral oncogene homolog 1 311 GWSQPKTPVPAQRER  
RAG1  recombination activating gene 1 42 VRSFEKTPEEAQKEK  
RBM15  RNA binding motif protein 15 52 MKGKERSPVKAKRSR  
RECQ5  RecQ protein-like 5 543 EASSRRIPRLTVKAR  
RELN  Reelin 1571 LPQDAKTPATAFRWW  
RFA1  replication protein A1, 70kDa 374 KFDGSRQPVLAIKGA  
RFNG  RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 39 APAPARTPAPAPRAP  
RFX6  regulatory factor X, 6 175 KTIRQKFPLLTTRRL  
RGAP1  
Rac GTPase activating protein 1 pseudogene; Rac GTPase 
activating protein 1 
432 FLRNLKEPLLTFRLN  
RGL3  ral guanine nucleotide dissociation stimulator-like 3 369 WGAVSREPLSTFRKL  
RGPD7  
RANBP2-like and GRIP domain containing 5; RANBP2-like 
and GRIP domain containing 4; RANBP2-like and GRIP domain 
containing 3; RANBP2-like and GRIP domain containing 8; 
RANBP2-like and GRIP domain containing 7; RANBP2-like 
and GRIP domain containing 6 
466 KQLFHRLPHETSRLE  
RGRF1  Ras protein-specific guanine nucleotide-releasing factor 1 731 YGEPPKSPRATRKFS  
RGS20  regulator of G-protein signaling 20 94 SHLLRRPPPEAPRRR  
RGS22  regulator of G-protein signaling 22 258 HPRTKKDPSKTNKLI  
RGS7  regulator of G-protein signaling 7 223 KSSRMRNPHKTRKSV  
RHG01  Rho GTPase activating protein 1 224 LKSTQKSPATAPKPM  
RHG05  Rho GTPase activating protein 5 1361 LLEAAKIPDKTERLH  
RHG18  Rho GTPase activating protein 18 367 TEGLLRIPGAAIRIK  
RICH2  Rho-type GTPase-activating protein RICH2 485 DPADRRQPEQARRPL  
RIF1  RAP1 interacting factor homolog (yeast) 697 IFSEQRFPVATMKTL  
RL3  ribosomal protein L3; similar to 60S ribosomal protein L3 (L4) 241 RWHTKKLPRKTHRGL  
RL3L  ribosomal protein L3-like 241 RWHTKKLPRKTHKGL  
RL9  ribosomal protein L9; ribosomal protein L9 pseudogene 25 30 RTVIVKGPRGTLRRD  
RNF17  ring finger protein 17 1540 PSHLMRYPARAIKVL  
RNPS1  
similar to ribonucleic acid binding protein S1; RNA binding 
protein S1, serine-rich domain 
26 KKSSTRAPSPTKRKD  
RPC4  polymerase (RNA) III (DNA directed) polypeptide D, 44kDa 235 EEAKMKAPPKAARKT  
RRP5  programmed cell death 11 51 RKKSQKGPAKTKKLK  
RRS1  RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 93 EAIVARLPEPTTRLP  
RS10  
ribosomal protein S10; ribosomal protein S10 pseudogene 4; 
ribosomal protein S10 pseudogene 11; ribosomal protein S10 
pseudogene 22; ribosomal protein S10 pseudogene 7; ribosomal 
protein S10 pseudogene 13 
33 DVHMPKHPELADKNV  
RS20  ribosomal protein S20 57 VKGPVRMPTKTLRIT  
RTN3  reticulon 3 1024 EKIQAKLPGIAKKKA  
RTN4  reticulon 4 982 KEAEKKLPSDTEKED  
S12A5  
solute carrier family 12 (potassium-chloride transporter), 
member 5 
114 NEGGKKKPVQAPRMG  
S15A4  solute carrier family 15, member 4 188 DQVKDRGPEATRRFF  
S1PR4  sphingosine-1-phosphate receptor 4 238 QASGQKAPRPAARRK  
S38AA  solute carrier family 38, member 10 653 SDHGGKPPLPAEKPA  
S40A1  solute carrier family 40 (iron-regulated transporter), member 1 231 WKVYQKTPALAVKAG  
SAHH2  adenosylhomocysteinase-like 1 55 MQEFTKFPTKTGRRS  
SC16A  SEC16 homolog A (S. cerevisiae) 1913 PAPETKRPGQAAKKE  
SC31B  SEC31 homolog B (S. cerevisiae) 112 ILSSGKEPVIAQKQK  
SCG2  secretogranin II (chromogranin C) 467 EKVLPRLPYGAGRSR  
SCN1A  sodium channel, voltage-gated, type I, alpha subunit 473 ASEHSREPSAAGRLS  
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SCNNB  sodium channel, nonvoltage-gated 1, beta 18 LHRLQKGPGYTYKEL  
SEC63  SEC63 homolog (S. cerevisiae) 520 WQQKSKGPKKTAKSK  
SEM7A  
semaphorin 7A, GPI membrane anchor (John Milton Hagen 
blood group) 
385 FQVADRHPEVAQRVE  
SEPT9  septin 9 143 EVLGHKTPEPAPRRT  
SET1A  SET domain containing 1A 1192 TPPQAKFPGPASRKA  
SF3B1  splicing factor 3b, subunit 1, 155kDa 110 PFAEHRPPKIADRED  
SG269  NKF3 kinase family member 69 RPPVAKKPTIAVKPT  
SGOL1  shugoshin-like 1 (S. pombe) 487 ASVNYKEPTLASKLR  
SH319  SH3 domain containing 19 35 TSGLPKKPEITPRSL  
SHAN1  SH3 and multiple ankyrin repeat domains 1 506 SPSRGRHPEDAKRQP  
SHAN3  SH3 and multiple ankyrin repeat domains 3 986 GGSFAREPSPTHRGP  
SHRM2  shroom family member 2 363 QPRGDRRPELTDRPW  
SHRM3  shroom family member 3 545 LSPVEKKPEATAKYV  
SI1L3  signal-induced proliferation-associated 1 like 3 327 EADEGRSPPEASRPW  
SIA7A  
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 
116 PEEQDKVPHTAQRAA  
SIRT2  
sirtuin (silent mating type information regulation 2 homolog) 2 
(S. cerevisiae) 
277 ASLISKAPLSTPRLL  
SIX4  SIX homeobox 4 248 LYKQNRYPSPAEKRH  
SLAF5  CD84 molecule 270 LNTFTKNPYAASKKT  
SMTN  Smoothelin 282 AQSPTRGPSDTKRAD  
SN  sialic acid binding Ig-like lectin 1, sialoadhesin 601 VLYPPRQPTFTTRLD  
SNCAP  synuclein, alpha interacting protein 860 SGDQLKRPFGAFRSI  
SNRK  SNF related kinase 471 QVVLRRKPSVTNRLT  
SOBP  sine oculis binding protein homolog (Drosophila) 682 HVKAEREPSAAERRT  
SORC1  sortilin-related VPS10 domain containing receptor 1 147 PGTRERDPDKATRFR  
SORC2  sortilin-related VPS10 domain containing receptor 2 13 PSRASKGPGPTARAP  
SORC3  sortilin-related VPS10 domain containing receptor 3 922 EHVHLRVPFVAIRNK  
SOS1  son of sevenless homolog 1 (Drosophila) 1306 SQHIPKLPPKTYKRE  
SOS2  son of sevenless homolog 2 (Drosophila) 1306 SPHLPKLPPKTYKRE  
SPT18  spermatogenesis associated 18 homolog (rat) 260 RSSRSRSPSPAPRSR  
SPT6H  suppressor of Ty 6 homolog (S. cerevisiae) 812 VTDFLRLPHFTKRRT  
SPTA1  spectrin, alpha, erythrocytic 1 (elliptocytosis 2) 781 RFEALKEPLATRKKK  
SPTA2  spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 772 RYEALKEPMVARKQK  
SPTB2  spectrin, beta, non-erythrocytic 1 354 YRTVEKPPKFTEKGN  
SPTN2  spectrin, beta, non-erythrocytic 2 357 YRTVEKPPKFTEKGN  
SPTN4  spectrin, beta, non-erythrocytic 4 1053 ALLAERFPAQAARLH  
SPTN5  spectrin, beta, non-erythrocytic 5 2502 TSPAPRSPVEARRML  
SRCAP  Snf2-related CREBBP activator protein 2437 SPARERVPRPAPRPR  
SRGP2  SLIT-ROBO Rho GTPase activating protein 3 2870 PPKKNRSPADAGRGV  
SRRM2  serine/arginine repetitive matrix 2; hypothetical LOC100132779 1928 RRSRSRTPPVTRRRS  
SSF1  PPAN-P2RY11 readthrough transcript 452 GAQARRGPRGASRDG  
SSH1  slingshot homolog 1 (Drosophila) 1025 PQGTPRDPAATSKPS  
SSH3  slingshot homolog 3 (Drosophila) 593 GQQVDRGPQPALKSR  
STAR8  StAR-related lipid transfer (START) domain containing 8 209 PVASFRHPQWTHRGD  
STEA3  STEAP family member 3 61 VVVGSRNPKRTARLF  
STIM1  stromal interaction molecule 1 645 ASRNTRIPHLAGKKA  
STIP1  stress-induced-phosphoprotein 1 525 LSEHLKNPVIAQKIQ  
STK39  serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 357 EKLLTRTPDIAQRAK  
STK6  aurora kinase A; aurora kinase A pseudogene 1 58 SNSSQRVPLQAQKLV  
STRBP  spermatid perinuclear RNA binding protein 156 IIRNTKEPTLTLKVI  
SYCP2  synaptonemal complex protein 2 184 NAMLDKMPQDARKIL  
SYDE1  synapse defective 1, Rho GTPase, homolog 1 (C. elegans) 160 KASRTKSPGPARRLS  
SYDE2  synapse defective 1, Rho GTPase, homolog 2 (C. elegans) 106 GPSFLRPPAVTVKKL  
SYEM  glutamyl-tRNA synthetase 2, mitochondrial (putative) 183 AQKLAKDPKPAIRFR  
SYG  glycyl-tRNA synthetase 479 HARATKVPLVAEKPL  
SYNJ1  synaptojanin 1 1135 PPSGARSPAPTRKEF  
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SYNJ2  synaptojanin 2 1057 LAPPSKSPALTKKKQ  
T2FA  general transcription factor IIF, polypeptide 1, 74kDa 19 TEYVVRVPKNTTKKY  
TAF2  
TAF2 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 150kDa 
673 ILALEKFPTPASRLA  
TAU  microtubule-associated protein tau 246 PAQDGRPPQTAAREA  
TB10A  TBC1 domain family, member 10A 428 SKAKPKPPKQAQKEQ  
TBL1R  transducin (beta)-like 1 X-linked receptor 1 268 TLGQHKGPIFALKWN  
TBL1X  transducin (beta)-like 1X-linked 331 TLGQHKGPIFALKWN  
TBL1Y  transducin (beta)-like 1Y-linked 278 TLGQHKGPIFALKWN  
TBX2  T-box 2 236 ANDILKLPYSTFRTY  
TBX3  T-box 3 264 ANDILKLPYSTFRTY  
TCF25  transcription factor 25 (basic helix-loop-helix) 48 RELGVRRPGGAGKEG  
TDRD7  tudor domain containing 7 407 AILYAKLPLPTDKIQ  
TITIN  Titin 
1617
3 
KMHTWRQPIETERSK  
TMPS4  transmembrane protease, serine 4 25 PLRKPRIPMETFRKV  
TNR11  
tumor necrosis factor receptor superfamily, member 11a, NFKB 
activator 
601 GPEGLREPEKASRPV  
TNR4  tumor necrosis factor receptor superfamily, member 4 247 LRRDQRLPPDAHKPP  
TNR8  tumor necrosis factor receptor superfamily, member 8 140 AGMIVKFPGTAQKNT  
TP53B  tumor protein p53 binding protein 1 1444 SRVVPRVPDSTRRTD  
TPST2  tyrosylprotein sulfotransferase 2 41 VLAGLRSPRGAMRPE  
TPX2  TPX2, microtubule-associated, homolog (Xenopus laevis) 487 PITVPKSPAFALKNR  
TREM1  triggering receptor expressed on myeloid cells 1 155 TQNVYKIPPTTTKAL  
TRIO  triple functional domain (PTPRF interacting) 1769 SSPGPKRPGNTLRKW  
TRM44  chromosome 4 open reading frame 23 748 GPAELRPPRTTPRKK  
TRPM1  
transient receptor potential cation channel, subfamily M, 
member 1 
420 TEKEKKPPMATTKGG  
TSG10  testis specific, 10 12 RSKSPRRPSPTARGA  
TUSC3  tumor suppressor candidate 3 254 MWNHIRGPPYAHKNP  
TXD16  thioredoxin domain containing 16 791 KSAVRKEPIETLRIK  
TXND6  thioredoxin domain containing 6 254 TVMGPRDPNVARREQ  
UB2E1  ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) 111 PEYPFKPPKVTFRTR  
UB2E2  ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast) 119 PDYPFKPPKVTFRTR  
UB2E3  ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) 125 SDYPFKPPKVTFRTR  
UB2L3  ubiquitin-conjugating enzyme E2L 3 66 AEYPFKPPKITFKTK  
UBP26  ubiquitin specific peptidase 26 159 TGVLQRMPLLTSKLT  
UBP31  ubiquitin specific peptidase 31 1019 PGSLAKKPESTTKRS  
UBP38  ubiquitin specific peptidase 38 515 FFEASRPPWFTPRSQ  
UBP43  ubiquitin specific peptidase 43 1074 APSSLRLPRKASRAP  
UBP49  ubiquitin specific peptidase 49 236 LPTSRRVPAATLKLR  
UBP54  ubiquitin specific peptidase 54 978 RQGLPKAPGWTEKNS  
UBR1  ubiquitin protein ligase E3 component n-recognin 1 1088 ALGPKRGPSVTEKEV  
UBR2  ubiquitin protein ligase E3 component n-recognin 2 823 AVAHFKKPGLTGRGM  
UBR4  ubiquitin protein ligase E3 component n-recognin 4 4027 LQKLIKPPAPTSKKN  
UHRF2  ubiquitin-like with PHD and ring finger domains 2 658 KGQSKKQPSGTTKRP  
UTY  ubiquitously transcribed tetratricopeptide repeat gene, Y-linked 1025 SGRRRKGPFKTIKFG  
V1AR  arginine vasopressin receptor 1A 80 LLALHRTPRKTSRMH  
VTDB  group-specific component (vitamin D binding protein) 431 ERLKAKLPDATPKEL  
WBS14  MLX interacting protein-like 836 LTDPGRIPEQATRAV  
WDR67  WD repeat domain 67 19 GKIWHRKPSPATRDG  
XIAP  X-linked inhibitor of apoptosis 360 VRTTEKTPSLTRRID  
XIRP2  xin actin-binding repeat containing 2 1847 EVNLPKAPKGTVKIV  
XRRA1  X-ray radiation resistance associated 1 592 KEKDQKKPPTAPREV  
YETS2  YEATS domain containing 2 1162 TAVVKKIPLITAKSE  
YSK4  YSK4 Sps1/Ste20-related kinase homolog (S. cerevisiae) 595 PRFQKKMPQIAKKQS  
YYAP1  YY1 associated protein 1; gon-4-like (C. elegans) 446 KPVADRFPKKAWRQK  
Z3H7B  zinc finger CCCH-type containing 7B 406 NSQDHRPPSGAQKPA  
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Z512B  zinc finger protein 512B 334 TRSENKAPRATGRNS  
ZBT12  zinc finger and BTB domain containing 12 160 LLPPARTPKPAPKPP  
ZC3H3  zinc finger CCCH-type containing 3 321 VAASSKSPRVARRAL  
ZF161  zinc finger protein 161 homolog (mouse) 191 SQEDGKSPTTTLRVQ  
ZN213  zinc finger protein 213 127 VEDLQKQPVKAWRQD  
ZN335  zinc finger protein 335 553 SRDRKKRPDPTPKLS  
ZN566  zinc finger protein 566 64 YLEQGKEPWLADREL  
ZN592  zinc finger protein 592 335 SPKSPRSPLEATRKS  
ZN624  zinc finger protein 624 112 HLENGKGPWVTVREI  
ZN727  zinc finger protein 727 62 YLEQRKEPWNARRQK  
ZN837  zinc finger protein 837 330 AERHRRGPVLARRAF  
ZN862  zinc finger protein 862 211 NALAARDPIWAARFR  
ZO1  tight junction protein 1 (zona occludens 1) 1294 DTGSFKPPEVASKPS  
ZRAN1  zinc finger, RAN-binding domain containing 1 217 GNSQRRSPPATKRDS  
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List of abbreviations 
 
AKAP A Kinase Anchoring Protein 
AMPA 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
Amph Amphiphysin 
ATP Adenosine triphosphate 
BDNF Brain-derived neurotrophic factor 
CAM  Cell adhesion molecule 
cAMP Cyclic adenosine monophosphate 
CFP Cyan fluorescent protien 
CGN Cerebellar Granule Neuron 
Chk Csk-homologous kinas 
CML Chronic myeloid leukaemia 
CMV Cytomegalovirus 
CNS Central nervous system 
CRASH Corpus callosum hypoplasia, Retardation, Adducted thumbs, Spasticity and 
Hydrocephalus 
CSF-1 Colony Stimulating Factor 1 
Csk C-terminal Src kinase 
DAVID  Database for Annotation, Visualization and IntegratedDiscovery 
DCC Deleted in Colorectal Cancer 
ECM Extracellular Martix 
ERK Extracellular-Signal-Regulated kinase 
ERM Ezrin-Radixin-Moesin 
FAK Focal Adhesion Kinase 
FGF Fibroblast Growth Factor 
FITC Fluorescein isothiocyanate 
Frs2 Fibroblast growth factor receptor substrate 2 
GABA γ-Aminobutyric acid 
GAP GTPase activating protein 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GO term Gene Ontology term 
GPS Group-based prediction System 
GST Gluathione-S-transferase 
HCN Hyperpolarization-activated cyclic nucleotide-gated 
HPK1 Hematopoietic Progenitor Kinase 1 
HPLC High-performance liquid chromatography 
Ig Immunoglobulin 
JNK c-Jun N-terminal kinase 
LRRK2 Leucine-rich repeat kinase 2 
LTP Long term potentiation 
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MAPK Mitogen activated protein kinase 
MCS Multiple Cloning Site 
MBP Maltose binding protein 
MS Mass spectrometry 
NGF Nerve growth factor 
NMDA N-Methyl-D-aspartic acid 
NT Neutotrophin 
PD  Phage Display 
PDGF Platelet-derived growth factor 
PI3K Phosphoinositide-3 kinase 
PKA Protein kinase A 
PKC Protein kinase C 
PLC Phospholipase C 
PPII Polyproline type II 
PRD Proline rich domain 
PSSM Position Site Scoring Matrix 
PTM Post-translational modification 
PTP Protein tyrosine phosphatase 
RTK Receptor tyrosine kinase 
Sema Semaphorin 
SFK Src Family Kinase 
SH2 Src homology 2 
SH3 Src homolgy 3 
SHP-1 Src homology region 2 domain-containing phosphatase-1 
shRNA short hairpin RNA 
siRNA short interfering RNA 
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